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Summary 
Fetuin-A is a liver-derived plasma protein involved in mineralized matrix metabolism. 
Biochemical studies showed that fetuin-A is essential for the formation and stabilization of 
protein-mineral complexes, called calciprotein particles (CPPs). CPP clearance from 
circulation is essential to prevent local deposition and pathological calcification. 
Consequently, calcification-prone DBA/2 mice deficient in fetuin-A suffer from severe ectopic 
calcification. In contrast, C57BL/6 fetuin-A deficient mice do not calcify spontaneously. This 
suggests that additional mechanisms must exist to prevent ectopic calcification in these 
mice. The aim of this thesis was to elucidate the role of fetuin-A stabilized CPPs in mineral 
matrix metabolism, to gain further insight into the pathomechanisms of soft tissue 
calcification in calcifying DBA/2 fetuin-A deficient mice and to identify the mechanisms 
preventing ectopic calcification in C57BL/6 mice.  
It could be shown that in mice fetuin-A containing CPPs were rapidly cleared by the 
reticuloendothelial system, namely by Kupffer cells of the liver and by marginal zone 
macrophages of the spleen. Macrophages from scavenger receptor-A (SR-A) deficient mice 
cleared CPPs less efficiently than macrophages from wildtype mice suggesting that SR-A is 
involved in CPP binding and endocytosis. The pathology of ectopic calcification in fetuin-A 
deficient DBA/2 mice was analyzed by comparative genomics. A genome wide gene 
expression analysis showed that the soft tissue calcification in fetuin-A deficient DBA/2 mice 
was associated with fibrotic tissue remodeling while mineralization associated genes were 
not differentially regulated. Furthermore, calcified lesions were found intracellularly as well as 
extracellularly within the microvasculature and contained serum proteins. These results 
suggest that ectopic calcification in fetuin-A deficient DBA/2 mice is driven by a passive, 
chemical mineral precipitation. In agreement with this, in non-calcifying fetuin-A deficient 
C57BL/6 mice prevention of calcification was not mediated by a compensatory regulation of 
mineralization associated genes. However, CPP clearance by macrophages derived from 
DBA/2 was inferior to C57BL/6 mouse macrophage clearance. This strongly suggests that 
defective CPP clearance contributed to the calcifying DBA/2 mouse phenotype.  
In conclusion, it could be demonstrated that fetuin-A containing CPPs mediate the clearance 
of mineral debris by macrophages via SR-A. Since the same receptor also contributes to the 
uptake of modified low-density lipoprotein particles in atherosclerosis, defective endocytosis 
of both types of particles may impinge on lipid as well as mineral debris clearance in 
calcifying atherosclerosis. In DBA/2 fetuin-A deficient mice defective mineral debris 
clearance, particularly the absence of fetuin-A stabilized CPPs, accelerates soft tissue 
calcification. Thus, molecular stabilization of mineral debris in the form of fetuin-A containing 
CPPs and cellular CPP clearance are both crucial in preventing pathological calcification. 
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1. Introduction 
1.1 Fetuin-A 
In 1944, fetuin-A was detected for the first time in fetal calf serum 1. The human homolog 
was discovered by Heremans 2, Schmid and Bürgi 3 in 1961. The protein, which belongs to 
the electroporetic α2-fraction of serum 4, was termed α2-Heremans-Schmid-glycoprotein 
(Ahsg) in honor to its two co-discoverers. Homologues have been described in many 
vertebrates 5 and most recently in snake 6. Fetuin-A is highly expressed during fetal life 7, 
after birth serum fetuin-A values decrease rapidly 8, 9. In the adult organism fetuin-A is 
predominantly synthesized in the liver and the physiologic serum concentration is 0.58 mg/ml 
9. During inflammation fetuin-A levels decrease, therefore fetuin-A belongs to the negative 
acute phase reactants 10-12. 
Fetuin-A belongs to the cystatin superfamily along with fetuin-B (FETUB), kininogen (KNG) 
and histidine-rich glycoprotein (HRG) 13. Fetuin-A consists of two conserved cystatin domains 
(D1 and D2), and a third (D3) proline rich domain 14. Fetuin-A undergoes several 
posttranslational modifications, including glycosylation 15, sulfation 16 and phosphorylation 17, 
its molecular weight is 56 kDa. Remarkably, an array of acidic residues in D1 was found to 
mediate the binding to basic calcium phosphate 14, 18. Due to its mineral affinity fetuin-A is an 
abundant protein in bone 19 and teeth 20.  
 
1.2 Function of Fetuin-A 
A broad array of functions of fetuin-A have been proposed mainly based on in vitro studies, 
including proteinase interaction 21-28, lipid binding 29-31, lectin binding 32-35, a role in wound 
closure 36 and promotion of keratinocyte migration 37. Furthermore, it was reported that 
fetuin-A may bind and antagonize transforming growth factor-beta (TGF-β) and bone 
morphogenic proteins (BMPs) 38. Accordingly, fetuin-A was found to regulate osteogenesis 
via TGF-β/BMP signaling 39 and fetuin-A deficient mice develop alterations in bone 
morphology 40, 41. The group of Josiah Ochieng studied the role of fetuin-A in cancer and 
reported that fetuin-A facilitates tumor growth 23, 26, 42-44. In addition, it was shown that the rat 
phosphoprotein of 63kDa (pp63) 45, later identified as rat fetuin 46, 47, and human fetuin-A 
inhibit the human insulin receptor 48. These findings prompted further research and clinical 
studies investigating the role of fetuin-A in insulin resistance and metabolic syndrome (see 
chapter 1.2.1). Furthermore, fetuin-A was associated with rheumatoid arthritis 49, long-term 
survival in patients with alcoholic liver cirrhosis 50, intrauterine growth restriction 51 and most 
recently with Alzheimer’s disease 52. 
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Another function of fetuin-A studied in great detail is the immunomodulatory activity, including 
opsonic 53 and anti-inflammatory properties 54 (see chapter 1.2.2).  
First of all, fetuin-A is a systemic inhibitor of unwanted calcification, referred to as ectopic or 
dystrophic calcification 55. The involvement of fetuin-A in pathological calcification has been 
confirmed in a knockout (KO) mouse model 56 (chapter 1.2.4) as well as in a great number of 
clinical studies on patients suffering from dystrophic calcification 57 (chapter 1.2.3). 
1.2.1 Fetuin-A in Metabolic Syndrome 
In 1983, it was described for the first time that the phosphorylated form of pp63 inhibits the 
insulin receptor tyrosine kinase as well as insulin receptor autophosphorylation 45. In 1992, 
the identity of pp63 and rat fetuin was published 46, 47, 58, 59. Low insulin receptor inhibition 
activity was reported for the human homolog of fetuin-A, the α2-HS-glycoprotein (Ahsg) in 
1993. Srinivas and coworkers showed that Ahsg purified from human serum, specifically 
inhibits insulin receptor autophosphorylation 48. Subsequently, Mathews et al. showed that 
also bovine fetuin was efficient in inhibition of the insulin receptor tyrosine kinase 60. 
However, in relevant cells with metabolic activity no classical insulin receptor inhibition could 
be detected, instead an unexplained downregulation of insulin mediated Elk1-
phosphorylation was observed 61. Furthermore, it is controversial whether the initial 
demonstrated activity of pp63 might have been attributed to a co-purified protein 46, 47. 
Analyzing fetuin-A deficient mice on a mixed genetic background of C57BL/6N (B6) and 
129Sv as well as pure B6 genetic background revealed that fetuin-A deficient mice on both 
genetic backgrounds on a high fat diet showed improved insulin sensitivity and were 
protected against obesity 62, 63. Additionally, in different patient populations serum fetuin-A 
was positively associated with metabolic syndrome (MetS) 64-67, insulin resistance 68, 69 and 
type 2 diabetes 70-73. However, Jahnen-Dechent and colleagues questioned whether the 
association of high-serum fetuin-A and MetS is a cause or consequence of high-caloric 
feeding 55.  
Recently, additional functions of fetuin-A related to obesity and MetS were shown. It was 
shown that fetuin-A induces pro-inflammatory cytokine expression and suppresses 
adiponectin production 74 and that hepatic fetuin-A expression was further increased by 
NFκB 75. These findings contradict the previous identification of fetuin-A as negative acute 
phase reactant 10-12 as well as the anti-inflammatory activity of fetuin-A discussed below (see 
1.2.2). 
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1.2.2 Immunomodulatory Functions of Fetuin-A 
1.2.2.1 Opsonic Properties of Fetuin-A 
An opsonic activity of fetuin-A was first described in 1974, when van Oss and colleagues 
found that the presence of human serum fetuin-A enhanced the phagocytosis of E.coli as 
well as of S.aureus by human neutrophils 53. In the 1980ies Lewis and coworkers showed 
that co-incubation of DNA or latex particles with fetuin-A increased their uptake in mouse 
peritoneal macrophages 76 as well as human blood monocytes 77. Strangely, opsonization 
with immunoglobulin G (IgG) did not result in an increased uptake of latex particles in these 
studies. Two decades later Thiele et al. reanalyzed the opsonic properties of fetuin-A. In 
agreement with the earlier findings, fetuin-A enhanced the uptake of most microspheres in 
dendritic cells. This effect was comparable to IgG opsonization 78. At the same time, 
Jersmann and coworkers postulated a function of fetuin-A in the clearance of apoptotic cells 
by human macrophages. They demonstrated a dose-dependent enhancement of 
endocytosis of apoptotic cells and dextran, respectively in the presence of fetuin-A 79. 
Surprisingly, co-incubation of fetuin-A and apoptotic cells during endocytosis was essential to 
increase the uptake. In contrast, pre-incubation of apoptotic cells with fetuin-A was not 
sufficient to enhance their uptake.  
In 2007, a Japanese group studied the uptake of fetuin-A opsonized negatively charged 
nanoparticles and described a receptor mediated uptake mechanism for fetuin-A opsonized 
particles. They could show that the uptake of fetuin-A coated 50 nm polystyrene particles by 
Kupffer cells was mediated by scavenger receptor A (SR-A) 80. 
1.2.2.2 Anti-Inflammatory Activity of Fetuin-A 
The first evidence of an anti-inflammatory activity of fetuin-A was provided by a study 
showing that fetuin-A inhibits neutrophil stimulation by hydroxyapatite crystals 81. The group 
of Kevin Tracey reported that fetuin-A binds spermine and mediates its anti-inflammatory 
acting. Spermine is an omnipresent biogenic amine, which was shown to inhibit the synthesis 
of pro-inflammatory cytokines in human peripheral blood mononuclear cells (PBMCs) 82. 
Later on it was demonstrated that fetuin-A is essential for the inhibition of tumor necrosis 
factor (TNF) production either by carrying spermine or the cationic drug CNI-1493. Thus, 
fetuin-A acted as an opsonin for cationic molecules and enabled their uptake by 
macrophages 54, 83. In agreement with these results, Dziegielewska and colleagues reported 
that fetuin-A reduced macrophage secretion of the pro-inflammatory compounds interleukin 
1β (Il-1β), nitric monoxide and TNFα 84. Corroborating the anti-inflammatory activity of fetuin-
A, Wang and co-workers recently have shown that fetuin-A can protect against early cerebral 
ischemic injury 85 and has a protective role in lethal systemic inflammation 12 in mice. 
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1.2.3 Inhibition of Ectopic Calcification – Formation of Soluble Calciprotein Particles 
In 1978, Triffitt and colleagues reported a strong hydroxyapatite binding ability of fetuin-A 86, 
the molecular basis of specific enrichment of fetuin-A in mineralized tissue 19, 20. This finding 
was confirmed by Terkeltaub et al. who studied fetuin-A adsorption to hydroxyapatite crystals 
81. In 1996, for the first time Schinke and colleagues demonstrated that fetuin-A was able to 
inhibit hydroxyapatite formation in mineralizing calvaria cells 14. To further elucidate the 
function of fetuin-A, fetuin-A deficient mice were generated. While fetuin-A deficient mice 
backcrossed on a mixed C57BL/6 (B6) and 129Sv genetic background developed soft tissue 
calcification only occasionally 87, fetuin-A deficient mice on DBA/2 (D2) genetic background 
suffered from severe ectopic calcification 56 (see chapter 1.2.4). Thus, it was shown that 
fetuin-A is an inhibitor of ectopic calcification in vivo. In 2003, Heiss and colleagues proposed 
a mechanism mediating calcification inhibition by fetuin-A. They could demonstrate that 
fetuin-A, in the presence of supersaturated calcium and phosphate solutions, is highly 
efficient in the formation of soluble, colloidal spheres. The so-called calciprotein particles 
(CPPs), 30-150 nm in diameter, were initially amorphous but transformed to a crystalline, 
insoluble shape with time. It was suggested that transiently soluble CPPs might provide the 
opportunity to transport and remove calcium precipitates in the body 18. This concept was 
validated by detection of fetuin-A as a major protein in protein mineral complexes in vivo. 
Price et al. identified a fetuin-A containing high molecular weight complex in the serum of rats 
treated with etidronate, an inhibitor of bone metabolism 88, 89. In 2008, Heiss and colleagues 
found particles reminiscent to CPPs in the peritoneal dialysate of a patient suffering from 
calcifying peritonitis 90. Meanwhile, detailed studies on the composition, kinetics and stability 
of CPPs were published 90-92. These studies revealed that CPP formation is a two-stage 
process, comprising spherical primary CPPs that rapidly transform into secondary CPPs 
(figure 1B, C), which are stable for at least 24h 91. Furthermore, it was shown that fetuin-A is 
essential particularly for primary CPP formation, while additional acidic proteins may 
participate in the transformation to secondary CPPs 90. Beside mineral ion stabilization by 
CPP formation, a complementary mechanism was described using small angle neutron 
scattering. It was shown that monomeric fetuin-A stabilized mineral ions in form of 
subnanometer clusters called calciprotein monomers or CPM 91. 
Another important finding was the identification of fetuin-A in serum granules formed by 
incubation of serum containing cell culture media with calcium and phosphate 93, 94. It was 
proposed that such mineralo-protein complexes are reminiscent of the highly controversial 
entity nanobacteria 93, 95-97. In 1998, the phenomenon of nanobacteria was identified in cell 
culture media for the first time 98. In the next few years it was variously described that 
nanobacteria might be associated with calcification diseases 99-102. It is now widely accepted 
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that the entity formerly described as nanobacteria is virtually identical to the protein-mineral 
complexes described above 55, 94, 96, 97. 
 
 
Figure 1. Fetuin-A mediates formation and stabilization of CPPs 55, 90.  
A. Computer-generated homology model of fetuin-A. The cystatin-like domain 1 is depicted in green, cystatin-like 
domain 2 in yellow and domain 3 in green. Hydroxapatite precursors (red) interact with acidic amino acids within 
domain 1. B. Schematic view of a CPP consisting of a crystalline mineral core coated with fetuin-A. C. 
Transmission electron microscopy of CPPs. Scale bar 100 nm. 
 
The function of fetuin-A as an inhibitor of ectopic calcification is evident since low fetuin-A 
serum levels were frequently associated with calcification diseases. A variety of clinical 
studies demonstrated that low fetuin-A concentrations were associated with vascular 
calcification and cardiovascular mortality in patients on dialysis 103, dystrophic calcification in 
patients with coronary heart disease 104, urolithiasis 105, aortic valve calcification 106, 
atherosclerosis 107 and peripheral artery disease in type 2 diabetes 108. Additionally, 
polymorphisms in the human Ahsg gene were linked to aortic stiffness 109 as well as an 
increased risk of renal calcium oxalate stone formation 110 in recent studies. These findings 
suggested an important role of fetuin-A in vascular calcification, which was studied in great 
detail by the group of Catherine Shanahan and others (see chapter 1.4.2). 
1.2.4 Fetuin-A Deficient Mice 
Originally, fetuin-A KO mice were generated on a mixed genetic background of B6 and 
129Sv for technical reasons. These mice did not develop any obvious phenotypic 
abnormalities. Occasionally, female ex-breeders showed spontaneous ectopic 
microcalcifications in soft tissues 87. When the mice were fed a mineral and vitamin D-rich 
diet calcified lesions were observed in several tissues 56. To clarify the role of fetuin-A in vivo, 
fetuin-A deficient mice were backcrossed on two defined genetic backgrounds, on pure B6 
genetic background and on the calcification sensitive D2 genetic background 111, 112. D2 
fetuin-A deficient mice suffer from severe spontaneous soft tissue calcification. The 
exacerbated calcification phenotype caused a decreased breeding performance as well as 
increased mortality of KO mice in comparison to wildtype (WT) littermates. Calcified lesions 
affected almost all major organs (figure 2). The severe calcification and consequent damage 
of the kidney caused a secondary hyperparathyroidism and an increased accumulation of 
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parathyroid hormone (see also chapter 1.4.1) 56. Myocardial calcification was associated with 
fibrosis and diastolic dysfunction 113. In contrast to D2 fetuin-A deficient mice, B6 fetuin-A KO 
mice did not suffer from spontaneous ectopic calcification. However, in a model of chronic 
kidney disease (CKD), generated by nephrectomy and feeding a high phosphate diet, B6 
fetuin-A deficient mice developed extraosseous calcification 114.  
The influence of fetuin-A on atherosclerosis has been studied in a mouse model of CKD. 
Nephrectomized B6 apolipoprotein E (ApoE) deficient mice on a high phosphate diet served 
as a model of calcifying atherosclerosis. Double deficient mice lacking ApoE and fetuin-A 
showed a worsend phenotype of vascular calcification in comparison to ApoE single KOs 115.  
 
 
Figure 2. Severe soft tissue calcification in D2 fetuin-A deficient mice 56.  
Radiological analysis of 9-month-old D2 fetuin-A KO and WT mice. KO mice develop severe ectopic calcification 
of thorax, neck, kidney, and testis. 
 
In conclusion, the generation of fetuin-A deficient mice on different genetic backgrounds has 
clearly demonstrated the calcification inhibitory potential of fetuin-A. Nevertheless, fetuin-A 
deficient mice on B6 genetic background were resistant to spontaneous pathological 
mineralization. This suggested the existence of additional inhibitors of unwanted calcification 
(see chapter 1.4.2). 
 
1.3 Fetuin-A Receptor Binding 
1.3.1 The Asialoglycoprotein Receptor 
Uptake of chemically or enzymatically desialylated fetuin-A, referred to as asialofetuin, was 
studied in great detail by Tolleshaug and co-workers. In 1977, they demonstrated that 
asialofetuin was taken up by hepatocytes in a saturable process in vitro and in vivo 116. This 
was in accordance to previous studies showing that asialoglycoproteins are taken up by liver 
parenchymal cells 117. Furthermore, Tolleshaug et al. could show that asialofetuin uptake was 
distinct from uptake of native fetuin-A as no competition occurred and native fetuin-A was not 
taken up by hepatocytes 116. While studying the fate of internalized asialofetuin Tolleshaug 
demonstrated that asialofetuin is enriched in endocytic vesicles and transported to the 
lysosmes where it is rapidly degraded 118. Starting in the 1980ies asialofetuin was used as a 
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control in diverse publications studying the uptake route via the asialoglycoprotein receptor 
(ASGP-R) 119. The ASGP-R comprises of two subunits, hepatic lectin 1 (HL1) and hepatic 
lectin 2 (HL2), forming a hetero-oligomer 120. Mice deficient in the major subunit HL1 showed 
significant impaired uptake of asialofetuin, confirming the function of the ASGP-R in vivo 121. 
1.3.2 Uptake of Fetuin-A 
Fetuin-A is a circulating serum protein. Thus, native fetuin-A is protected against hepatic 
uptake and is not able to bind the ASGP-R 116. 
Fetuin-A is critically involved in vascular calcification (122, chapter 1.4.3). This action is 
dependent on the uptake of the serum protein fetuin-A in vascular smooth muscle cells 
(VSMCs). Chen and colleagues showed that fetuin-A uptake in bovine VSMCs was calcium-
dependent and mediated by annexins. In particular, they demonstrated that fetuin-A could 
bind to annexin 2 at the cell surface. 123 
 
1.4 Calcification 
1.4.1 Maintenance of the Calcium x Phosphate Product 
The calcium x phosphate product is of critical importance in maintaining mineral 
homeostasis. Even under physiological conditions blood is considered a metastable solution 
sustaining mineral precipitation once crystals are nucleated 124. William Neuman stated that 
our bodies are constantly at risk of turning into a pillar of salt 125. Thus, inhibitors are required 
to avoid spontaneous calcification. 
In healthy man the serum total calcium concentration ranges between 2.1 and 2.6 mM. The 
ionized serum calcium level is tightly regulated by parathyroid hormone (PTH). PTH is 
secreted by the parathyroid gland at low serum calcium concentrations. It triggers calcium 
reabsorption in the kidney and indirectly induces bone resorption by osteoclasts and thus the 
mobilization of calcium from bone. Simultaneously, PTH inhibits phosphate reabsorption in 
the kidney to lower the serum phosphate level and to keep the calcium phosphate product 
constant. In case of a persistent hypocalcaemia PTH triggers calcitriol synthesis 126. Calcitriol 
is the physiologically active metabolite of vitamin D3 and induces calcium reabsorption in the 
gut as well as bone resorption 127.  
As mentioned above, the serum phosphate concentration is partially affected by serum 
calcium regulation via PTH and calcitriol. Recently, a Fibroblastic Growth Factor 23 (FGF-23) 
dependent mechanism was discovered, which directly regulates serum phosphate levels. 
FGF23 is predominantly expressed by osteocytes and osteoblasts 128, its synthesis is 
regulated by dietary phosphate and calcitriol 129-132. The main function of FGF-23 takes place 
in the kidney, therefore it was suggested that phosphate homeostasis is regulated via a 
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bone-kidney axis 133. In the kidney FGF-23 targets a complex of the FGF receptor and the 
co-receptor Klotho 134 and evokes the inhibition of phosphate uptake and calcitriol synthesis 
135, 136. Consequently, FGF-23 deficient mice suffer from hyperphospatemia, elevated 
calcitriol and soft tissue calcification 137-139. 
1.4.2 Pathologic Calcification 
Ectopic mineralization is a well-known phenomenon, occurring in many variants and 
associated with several diseases. Case reports described ectopic calcified lesions in patients 
suffering from the autoimmune disease systemic lupus erythematosus 140, different kinds of 
tumors and metastasis 141-143 and sarcoidosis, a rare granulomatous disease 144. One of the 
most severe cases of ectopic calcifications is the fibrodysplasia ossificans progressiva, 
where connective tissue is transformed into bone 145, 146. Most prominent diseases associated 
with ectopic mineralization are kidney stones, calcification associated with CKD and vascular 
calcification. In severe cases CKD is associated with calciphylaxis, also called calcific uremic 
arteriolopathy (CUA), which is a disease caused by inflammation, endovascular fibrosis and 
vascular smooth muscle cell apoptosis leading to calcification of small blood vessels 147.  
Apart from the association with various diseases, ectopic calcification is a common adverse 
event in implantation of artificial prostheses, in particular heart valve replacements 148.  
The mechanisms in ectopic calcification are diverse and not fully understood. Most studied is 
the pathology of vascular calcification as a major risk factor for cardiovascular mortality 149.  
Basically, regulation of calcification is driven by the maintenance of extracellular calcium and 
phosphate concentrations and the control by inhibitors, including low molecular weight 
inhibitors as well as proteins, proteoglycans and hyaluronans (figure 3, 124). Block and 
colleagues reported that elevated serum phosphate levels as well as an elevated calcium x 
phosphate product was associated with calcification and mortility in patients of end-stage 
renal disease (ESRD) 150, 151. Low molecular weight inhibitors include magnesium and 
pyrophosphate; bisphosphonates may also inhibit mineralization. Dietary magnesium 
supplementation was shown to be of therapeutic value in high phosphate induced aortic 
calcification 152 and connective tissue calcification in a mouse model of pseudoxanthoma 
elasticum (PXE) 153, 154. Pyrophosphate (PP) is an effective inhibitor of biological calcification 
155 and served as a lead compound for synthetic bisphosphonates 124. As PP is a potent 
inhibitor of mineralization, several proteins involved in PP metabolism are involved in 
calcification inhibition, too. Knockout of those proteins in mice resulted in various calcification 
phenotypes 156-159. A strong tissue-specific inhibitor of calcification is the matrix GLA protein 
(MGP). MGP deficient mice develop lethal mineralization of the aortic trunk 160. Another 
important modulator of unwanted calcification is osteopontin (OPN). OPN belongs to the 
fraction of non-collageneous bone proteins 161 and fulfills a multifunctional role in bone and 
the immune system 162. During inflammation OPN is secreted by macrophages and 
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stimulates cytokine synthesis 163. Originally, inhibition of ectopic calcification by OPN was 
shown in vitro 164. In vivo calcification inhibition by OPN could be shown in mice deficient in 
OPN and MGP. These mice developed an exacerbated calcification phenotype in 
comparison to MGP KO animals 165. In contrast, single deficient OPN KO mice did not show 
spontaneous calcification 166. However, OPN accumulation was also detected in calcified 
lesions 167. It was described that inhibition of calcification by OPN was mediated on the one 
hand by blocking the crystal growth and on the other hand by solubilizing mineral 
precipitates. In doing so, OPN induces expression of carbonic anhydrase 2 in monocytic 
cells, which consequently triggers dissolution of mineral by acidification of the extracellular 
milieu 168. Another interesting function of OPN was demonstrated in an in vitro study showing 
that OPN may opsonize hydroxyapatite microspheres 169. Recently, conflicting studies were 
published on the role of intact OPN and thrombin-cleaved OPN fragments in the progression 
of atherosclerosis 170, 171. 
Several more protein inhibitors of ectopic calcification have been described and confirmed in 
KO mouse models 124, 172, 173. However, none of the discussed inhibitors acts on the systemic 
level, emphasizing the important role of fetuin-A as a bona fide systemic inhibitor of ectopic 
calcification. 
 
 
Figure 3. Regulation of calcification 124.  
Elevated serum calcium and phosphate level facilitate mineralization. Apoptotic vesicle or matrix vesicle released 
by VSMCs may contain BCP and cause mineral precipitation. Presence of adequate amounts of inhibitors 
prevents ectopic calcification. 
 
1.4.3 Mechanisms of Vascular Calcification 
Chronic kidney disease is frequently associated with vascular calcification. Calcified lesions 
occur as intimal calcification of atherosclerotic plaques or within the media arteries. Media 
calcification is known as Mönckeberg sclerosis and occurs in calciphylaxis (chapter 1.4.2). 
As mentioned above prevention of unwanted calcification is a matter of accurate regulation of 
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calcification inhibitors as well as of maintenance of the calcium x phosphate product. 
Nowadays, vascular calcification is also widely considered an active process, associated with 
the transdifferentiation of VSMCs to an osteogenic/chondrocytic phenotype, which 
consequently triggers mineral formation 174. The expression of osteogenic markers by 
VSMCs was shown in numerous in vitro and in vivo studies e.g. 175-177. In particular the 
induction of the osteoblastic transription factor Cbfa-1/Runx2 178 is crucial in triggering 
transdifferentiation of VSMCs 179. Expression of Cbfa-1 may be induced by various 
conditions, including elevated inorganic phosphate levels 180, elastin degradation 181, 
oxidative stress 182, leptin accumulation 183 or glucocorticoides 175. Osteogenic VSMCs 
release vesicles reminiscent to matrix vesicles 184, which drive bone mineralization. Whether 
such basic calcium phosphate (BCP) containing vesicles 185 lead to mineral deposition 
depends on many factors. Effective phagocytosis of vesicles may prevent calcification 186. In 
addition, the presence of inhibitors like fetuin-A or γ-carboxylated MGP, which both were 
enriched in vesicles, might prevent mineral deposition 122, 185. Besides vesicles released from 
vital VSMCs apoptotic vesicle and fragments of damaged VSMCs may further drive mineral 
precipitation 187. Thus, calcification occurs also independently from osteogenic 
reprogramming. For instance calcification of heart valves was attributed to vascular 
ossification only in 13 % of all cases studied 188. So far, it is unclear whether osteogenic 
transdifferentiation is a cause or a consequence of calcification 124. 
1.4.4 Dyscalc1 – A Gene Locus Causative for Dystrophic Calcification 
While vascular calcification was extensively studied, mechanisms in soft tissue calcification 
are not well understood. Certain mouse strains are prone to dystrophic calcification. It was 
shown that D2 mice suffer from spontaneous calcifications in myocardium 111, 189 and tongue 
190, 191. Eaton and colleagues analyzed five inbred mouse strains with respect to dystrophic 
cardiac calcinosis and found cardiac lesions in D2, C3H, C3Hf and BALB/c mice, while B6 
mice never had any calcification 192. Brunnert studied cardiac calcification associated with 
skeletal muscle necrosis induced by freeze-thaw injury and found that D2 mice as well as 
C3H mice were prone to ectopic mineralization while B6 mice were resistant 112. The same 
model of dystrophic calcification was used in a genomic approach to identify a causative 
gene locus of dystrophic calcification. In this work Ivandic and coworkers identified a major 
locus on proximal chromosome 7, which was called Dyscalc1, using a linkage map approach 
and quantitative trait locus analysis (QTL) 193. The same chromosomal region was identified 
by van den Broek and colleagues studying a D2 x and D2B6F1 backcross 194. At the time the 
histidine rich calcium binding protein (Hrc) was proposed as a promising candidate gene 
causative for dystrophic calcification 194, 195. In 2001, Ivandic described 3 more gene loci on 
chromosome 4, 12 and 14 involved in dystrophic calcification 196, additionally the Dyscalc1 
locus was shortened to a 10 cM interval. Fine mapping of Dyscalc1 to a region of 0.76 Mbp 
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excluded the previous candidate Hrc, but led to the suggestion of the gene encoding the 
ATP-binding cassette C6 (Abcc6) 197. Ultrafine mapping performed by another team of 
researchers resulted in an interval of 80 Kb containing the genes EMP-3, BC013491, and 
Abcc6 (partially) and identified EMP-3 as a new candidate gene 198. However, a third 
workgroup confirmed Abcc6 as the causative gene for dystrophic calcification and reported 
on differential expression of Abbc6 in mice susceptible and resistant for dystrophic 
calcification 199. Later, a differential splice variant of Abcc6 was identified and Abcc6 protein 
deficiency in calcification prone mice was attributed to a truncated protein encoded by a 
splice variant 200. Today Abcc6 is widely considered the gene causative for dystrophic 
calcification, which was confirmed by the fact that Abcc6 deficient mice suffer from ectopic 
calcification associated with pseudoxanthoma elasticum (PXE) 201. Abcc6 deficient mice 
developed a mild calcification phenotype, where calcified lesions were detected in elastic 
fibers of blood vessels, Bruch’s membrane in the eye 201 and strikingly in vibrissae 202. In 
agreement with the phenotype of Abcc6 KO mice, mutations of Abcc6 were likewise 
associated with PXE 203.  
In the current thesis, fetuin-A deficient mice on D2 genetic background were used as a model 
of ectopic calcification. The dramatic calcification phenotype in this particular genetic 
background mice may be attributed to differential expression of Abcc6 or rather a truncated 
protein product of Abcc6. 
 
1.5 Mononuclear Phagocyte System 
Many efforts were made to group phagocytic active cells into subpopulations or a system. 
Two categories of phagocytes, namely mononuclear and polymorphonuclear phagocytes 
may be easily distinguished by the morphology of their nuclei. In 1924, Ludwig Aschoff 
defined the term reticulo-endothelial system (RES). He proposed that reticular cells of spleen 
and lymph nods, reticular cells of lymph and blood sinusoids, Kupfer cells, histiocytes, 
splenocytes and monocytes should fall into this category, while he excluded endothelial cells 
and fibrocytes because of their poor phagocytic activity 204. The term RES has been 
frequently criticized, consequently during a conference on mononuclear phagocytes in 1969 
a new classification was adopted 205. Highly phagocytic active mononuclear cells were 
grouped to the mononuclear phagocyte system (MPS). These cells originate from bone 
marrow, are transported into the bloodstream and are localized in tissues as resident 
macrophages 206. Depending on their localization resident macrophages display a 
characteristic morphology. Resident macrophages were identified in spleen, lymph nodes, 
bone marrow, liver (Kupfer cells), pleural and peritoneal fluids, brain (microglia), bone 
(osteoclasts), lung (alveolar macrophages), skin, gut and endocrine organs 206, 207. 
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1.5.1 Macrophages 
Macrophages show a high level of heterogeneity depending on their localization as well as 
their activation state. Four different states of macrophage activation were described, namely 
innate activation, classical activation, alternative activation and deactivation. The activation 
pathway is regulated by the particular stimulus of activation, e.g. lipopolysaccharide (LPS) 
triggers innate or classical activation, while presence of IL-4 leads to alternative activation. In 
each case a specific program of cytokine release and modification of surface receptors is 
initiated 208.  
Cells of the innate immune system recognize pathogen-associated molecular patterns 
(PAMPs) through highly conserved pattern recognition receptors (PRRs). Macrophages 
express a broad range of receptors involved in immune recognition of PAMPs, apoptotic cells 
as well as particular matter. These receptors include scavenger receptors (chapter 1.5.2), 
glycosylphosphatidylinositol (GPI)-anchored receptors, integrins, receptors belonging to the 
immunoglobulin (Ig) superfamily, seven transmembrane receptors, natural killer (NK)-like C-
type lectin-like receptors, C-type lectins, toll-like receptors and the mannose receptor. In 
particular, complement mediated phagocytosis is mediated by the complement receptor 3 
(CR3) grouped with the integrins, antibody-dependent phagocytosis is mediated by Fc 
receptors and fungal antigens are mainly endocytosed in a dectin-1 dependent manner 209. 
Each macrophage subpopulation expresses a distinct pattern of receptors. This specific 
profile of surface receptors should be considered when macrophage model systems, either 
primary macrophages or macrophage cell lines, are studied.  
1.5.2 Scavenger Receptors 
The growing family of scavenger receptors (SRs) is characterized by scavenging modified 
forms of LDL 210. In 1987, scavenger receptor ligands were identified in vivo for the first time, 
when the clearance of oxidized forms of LDL was studied 211. In 1990, the first scavenger 
receptors were purified, the bovine scavenger receptors SR-AI and SR-AII 212. Both subtypes 
have a very similar structure (figure 4), where SR-AII is lacking a c-terminal cysteine-rich 
domain as consequence of alternative splicing 213. Macrophages from mice deficient in the 
murine scavenger receptor-A (MSR-A) gene showed a significantly decreased uptake of 
acetylated LDL (acLDL) in vitro. In vivo clearance of acLDL was normal suggesting the 
existence of additional scavenger receptors 214. Later it was shown that SR-AI/II may 
recognize several PAMPs and are essential for immune recognition of various pathogens, 
e.g. S. pyogenes 215, 216. 
Today, about 15 SRs have been described, most of them have a dual role in the recognition 
of modified self and pathogenic patterns 217. Redundancy of SRs was demonstrated in 
macrophages from SR-A/CD36 double deficient mice, which showed significantly less 
efficient endocytosis of modified LDLs than corresponding single KO mice 218.  
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With respect to the role of SRs in the clearance of modified LDLs, their role in atherogenesis 
was studied in ApoE deficient mice. While decreased formation of atherosclerotic lesions 
was observed in ApoE/CD36 double deficient mice in comparison to ApoE single KO mice, 
no improvement in the atherosclerotic phenotype of ApoE/SR-AI/II deficient mice was seen 
219. These findings confirmed a pro-atherogenic role for CD36, whereas the function of SR-
AI/II in atherogenesis remained unclear.  
 
 
Figure 4. Scavenger receptor family 209. 
Schematic view of a selection of scavenger receptors espressed by macrophages. MARCO, macrophage 
receptor with collagenous structure, a scavenger receptor type A; LOX-1, lectin-like oxidized low density 
lipoprotein receptor 1; SRCR, scavenger receptor cysteine-rich domain; CTDL, C-type lectin carbohydrate-binding 
domain; GPI, glycosylphosphatidylinositol. 
 
1.6 Clearance of Particular Matter 
Micro- and nanoparticles have been intensively studied in relation to targeted delivery of 
drugs and antigens. The uptake route of particular matter strongly depends on particle size, 
geometry, charge as well as on protein absorption. Studies in beagle dogs demonstrated that 
intravenously injected polystyrene spheres accumulated in liver, spleen and lung tissue. 
Increasing particle diameters (up to 12 µM) directed the spheres to the lung, while smaller 
microspheres (5-7 µM) were detected predominantly in liver and spleen 220. A similar 
biodistribution was obtained with polystyrene particle of nanometer size 221. Particle size 
influences not only the target organ but also the target cell type. For instance, Ogawara and 
colleagues showed a size dependent intrahepatic distribution of polystyrene particles. 500 
nm particles were exclusively taken up by non-parenchymal cells, whereas 50 nm particles 
were also taken up by liver hepatocytes 222. Moghimi and colleagues showed that hydrophilic 
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coating reduced liver particle uptake in rats but facilitated their uptake in spleen 223. These 
data suggested an impact of particle surface characteristics on their biodistribution. 
Apart from the targeting of particles to specific tissues and cells, the efficiency of their uptake 
is of particular interest. Interestingly, mechanical properties regulate phagocytosis. It was 
shown, that Fc-receptor mediated uptake of rigid particles was much more efficient than 
uptake of soft particles of identical chemical properties 224. Thiele et al. studied the influence 
of plasma protein absorption to polystyrene spheres in dendritic cells in vitro. In particular the 
effects of serum albumin, immunoglobulins and fetuin-A applied as single proteins or 
mixtures were examined. In agreement with earlier findings (chapter 1.2.2), they showed that 
fetuin-A enhanced the uptake of most of the particles, the effect was comparable to IgG 
opsonization. In contrast albumin coating inhibited phagocytosis 78. Champion and Mitragotri 
studied the influence of particle geometry on endocytosis. They pointed out that the influence 
of particle shape overruled particle size. This was attributed to the fact that local shape 
determines the complexity of the actin structure 225. 
Finally, targeting of particulate matter depends on receptor recognition. Particles may be 
opsonized by immunoglobulins, complement or plasma proteins. Endocytosis of 
immunoglobulin opsonized particles is mediated by Fc receptors and complement opsonized 
particles are taken up via complement receptor. Furthermore, two proteins of the pentraxin 
family have been shown to have opsonic properties, namely serum amyloid P (SAP) and C-
reactive protein (CRP). Also endocytosis of SAP and CRP-coated particles is mediated by Fc 
receptors 226, 227. As described before, there is strong evidence that fetuin-A has likewise 
opsonic properties 78, 79. However, no receptor responsible for fetuin-A binding was identified 
in these studies. Nagayama and colleagues proposed a SR-A mediated uptake of fetuin-A 
opsonized particles 80. It is reasonable to assume that unopsonized particles might bind to 
PRRs, which have a broad ligand specifity. For instance, silica particles were taken up by 
macrophage receptor with collagenous structure (MARCO), a class A scavenger receptor 228. 
1.6.1 Endocytosis and Immune Response of Hydroxyapatite Particles 
Hydroxyapatite (HAP) crystals are associated with various inflammatory diseases, e.g. 
rheumatoid arthritis 229. Endocytosis by cells of the MPS 230 and inflammatory properties of 
HAP have been shown in vitro 81 and by injection of HAPs into the foot pads of rats 231. 
However, neither an uptake mechanism nor a specific signaling pathway has been 
discovered to this date. In 2004, Kandori and colleagues demonstrated absorption of IgG to 
HAP 232, which might have an impact on the immunomodulatory function of HAP. IgG 
opsonization of HAP was confirmed in another study. In addition to these studies OPN was 
suggested as an opsonin for HAP 169. 
Nadra and coworkers showed uptake of BCP crystals, consisting mainly of HAP by 
macrophages. In addition, induction of pro-inflammatory cytokine secretion in particular of 
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TNFα was detected 233. Subsequently, participation of toll-like receptor 4 (TLR4) in the pro-
inflammatory response was reported 234. Fellah et al. showed a pro-inflammatory reaction 
following BCP injection in vivo 235. In 2008, Nadra and colleagues refined their previous 
analysis. They found that TNFα induction was mediated by NFκB and was critically 
dependent on particle size, where the smallest HAP particles were most reactive 236. 
Recently, induction of IL-1β through NLRP3 inflammasome activation was shown 237. 
 
1.7 Experimental Aims 
Ectopic calcification is a common pathological event associated with chronic kidney disease 
as well as atherosclerosis. To this date in particular soft tissue calcification is poorly 
understood. D2 fetuin-A deficient mice suffer from severe soft tissue calcification and provide 
a suitable model for calcification diseases like calciphylaxis 56. In the current thesis, D2 
fetuin-A deficient mice were studied to investigate mechanisms involved in the formation of 
calcified lesions, which might serve as a basis for new therapeutic strategies of calcification 
diseases. Moreover, additional principles of calcification inhibition should be identified. To 
this end, calcification resistant B6 fetuin-A deficient mice and calcification prone D2 fetuin-A 
deficient mice were compared regarding their gene expression profiles and endocytic 
properties. Uptake of protein-mineral particles might be critically involved in the clearance of 
mineral debris and thus in the prevention of calcification. 
The molecular basis of calcification inhibition by fetuin-A was studied in great detail by Heiss 
and colleagues 18, 90, 92. In brief, fetuin-A mediates the formation and stabilization of CPPs. 
CPPs may form spontaneously in body fluids, in particular in situations with elevated calcium 
and phosphate levels. To prevent mineral precipitation removal of CPPs from circulation is of 
critical value. In the current thesis, the fate of CPPs was examined in vivo. Furthermore, the 
target organs, cell types and the uptake mechanism of CPPs were analyzed.  
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2. Methods 
2.1 Animals  
Wildtype and fetuin-A deficient mice on either C57BL/6N or DBA/2N genetic background 
were maintained in a temperature-controlled room on a 12-hour light/dark cycle. Standard 
diet (Ssniff, Soest, Germany) and water were given ad libitum. Mice were kept at the animal 
facility of Universitätsklinikum Aachen, Pauwelsstr. 30. All animal experiments were 
conducted in agreement with German animal protection law and were approved by the state 
animal welfare committee. 
 
2.2 Necropsy 
Mice were sacrificed with an overdose of isofluran (Forene, Abbott, Wiesbaden, Germany). 
The abdomen was opened and the skin was removed. Organs were subsequently harvested. 
Photomicrographs were taken using a Canon EOS D1000 XS SLR digital camera and a 
Canon EF 100 mm 2,8 L IS USM macro objective (Canon, Tokyo, Japan). 
 
2.3 Immunofluorescence Staining 
Mice were sacrificed with isofluran, exsanguinated, perfused with 20 ml ice-cold PBS (PBS 
Dulbecco, Biochrom AG, Berlin, Germany) and organs were collected. The tissues were 
embedded in Tissue-Tek O.C.T. compound (Sakura, Alphen aan den Rijn, Netherlands) 
frozen in liquid nitrogen and kept at -20 °C until usage. Cryosections 6 µm thick were cut and 
fixed with Bouin’s fixative if not stated otherwise. Calcified tissue was decalcified with 0.5 M 
EDTA over night. PBS washed sections were blocked with 3 – 10 % goat serum (Dako, 
Hamburg, Germany) prior to primary antibody incubation. Dilution factors as well as 
incubation time of all primary antibodies are summarized in table 1. In case of double 
staining primary antibodies derived from different species were used and applied 
simultaneously. Primary antibodies were detected by secondary antibodies coupled with 
Alexa Fluor 488 or Alexa Fluor 546 (all secondary antibodies were purchased from Molecular 
Probes, Life Technologies, Carlsbad, CA, USA). DAPI (Sigma, Taufkirchen, Germany) was 
adopted as nuclear stain. Stained sections were examined using a Leica DMRX fluorescence 
microscope (Leica Microsystems GmbH, Wetzlar, Germany) and DISKUS software (Carl H. 
Hilgers, Technisches Büro, Königswinter, Germany). Pictures were processed with Adobe 
Photoshop (Adobe Systems GmbH, München, Germany).  
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2.4 Fetuin-A Imaging 
Fetuin-A was used to image calcified lesions 238. Purified bovine fetuin-A was prepared as 
previously described 18 and injected intraperitoneal one day before dissection of mice, a dose 
of 100 µl of a 7 mg/ml protein solution was applied. Fetuin-A was detected on Bouin’s 
stabilized cryosections using a homemade rabbit polyclonal anti-fetuin-A antibody (AS 237) 
and a secondary Alexa Fluor 546 goat anti rabbit antibody (Molecular Probes). 
 
Table 1. Antibodies for immunofluorescence staining.  
antigen company (ordering number) dilution factor incubation time 
CD31 BD Pharmingen (550274) 10 1 h 
CD68 AbD Serotec (MCA 1957) 500 1 h 
F4/80 Abcam (ab6640) 1000 1 h 
bovine fetuin-A homemade, AS 237 1000 over night 
Lyve-1 Acris Antibodies GmbH ( DP3513P) 1000 1 h 
Madcam BD Pharmingen (550556) 10 over night 
MARCO AbD Serotec (MCA 1849) 10 over night 
Moma-1 BMA Biomedicals (T-2011) 10 1 h 
OPN Assay Designs, Inc. (915-021) 100 1 h 
OPN R&D Systems (AF808) 1000 1 h 
The table summarizes all primary antibodies used within this thesis. For each antibody the ordering information as 
well as the experimental conditions are given. Antibodies were purchased from Acris Antibodies GmbH (Herford, 
Germany), BD Pharmingen (Franklin Lakes, NJ, USA), Serotec (Düsseldorf, Germany), Abcam (Cambridge, UK), 
BMA Biomedicals (Augst, Switzerland), Assay Designs (belongs to Enzo Life Science, Lörrach, Germany). 
 
2.5 Electron Microscopy  
Evaluation of calcified lesions in young mice was performed in collaboration with Marc D. 
McKee, McGill University, Montreal, Canada. Mice were sacrificed with an overdose of 
isofluran, exsanguinated, perfused with 20 ml cold PBS and organs were collected. Tissues 
were fixed in 4% paraformaldehyd and sent to Canada for tissue embedding, sectioning and 
electron microscopy. 
For examination of injected CPPs mice were sacrificed with an overdose of isofluran, 
exsanguinated, and perfused with 20 ml cold PBS at 30 min after injection of fluorescence 
labeled CPPs. Tissue samples were fixed in 3 % glutaraldehyde (in 0.1 M Soerensen's 
phosphate buffer (pH 7.4, 13 mM NaH2PO4 x H2O, 87 mM Na2HPO4 x 2H2O)) for 24 hours 
and handed over to Jörg Bornemann, Electron Microscopy Facility, RWTH Aachen 
University, Germany for further sample preparation and evaluation. 
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2.6 Gene Expression Analysis 
2.6.1 Sample Preparation 
2.6.1.1 Microarray Analysis of Calcified Brown Adipose Tissue  
Wildtype and fetuin-A deficient DBA/2 mice at 6 week of age were used, 3 female and 3 male 
mice. Mice were sacrificed with an overdose of isofluran, exsanguinated and perfused with 
20 ml cold PBS. Brown adipose tissue was dissected from the kidney pelvis region. Tissue 
samples were homogenized and stored in peqGOLD RNAPure reagent (PEQLAB 
Biotechnologie GMBH, Erlangen, Germany). RNA extraction was performed using the 
RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
protocol. Gene expression profile was analyzed with Affymetrix Mouse Genome 430 2.0 
Arrays (Affymetrix, Santa Clara, CA, USA). RNA preparation and microarray handling was 
performed by Beate Kratz, Chip Facility, IZKF Aachen, Germany. 
2.6.1.2 Microarray Analysis of Kidney and Liver 
Wildtype and fetuin-A deficient DBA/2 mice and C57BL/6 mice were 36 days of age, 6 mice 
of each genotype were used, whereof 3 were female and 3 were male (except DBA/2 
wildtype mice where 4 mice, 2 of each sex, were used). Mice were sacrificed with an 
overdose of isofluran, exsanguinated and perfused with 20 ml cold PBS. Liver and kidneys 
were collected. Tissue samples were homogenized and stored in peqGOLD RNAPure 
reagent (PEQLAB Biotechnologie GMBH, Erlangen, Germany). Phenol-Chloroform 
extraction was applied to purify RNA. Gene expression profile was analyzed with Affymetrix 
Mouse Genome 430 2.0 Arrays (Affymetrix, Santa Clara, CA, USA). RNA preparation and 
microarray handling was performed by Beate Kratz, Chip Facility, IZKF Aachen, Germany. 
2.6.2 Microarray Data Analysis 
Gene data analysis was carried out using Bioconductor 239 packages under R1. Differential 
expression between groups was examined following the workflow shown in figure 5. 
2.6.2.1 Import of Files in Bioconductor and Introduction of Phenotype Information 
Cel files were read into Bioconductor using the Affy package 240. Phenotype information for 
each file was introduced as a table. Phenotype information included gender and genotype of 
the mice corresponding to the arrays. 
2.6.2.2 Quality Assessment 
Quality of microarrays was assessed using the ArrayQualityMetrics package 241. The arrays 
were analyzed with the outlier detection algorithm within the package. Arrays with two or 
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more outlier calls were considered insufficient quality and were excluded from further 
normalization and data analysis.  
 
 
 
Figure 5. Microarray data analysis.  
Hierarchical scheme of the microarray data analysis using Bioconductor under R1. A general work flow of data 
analysis is given (central column), the left column contains information about the applied Bioconductor package, 
the right column summarizes the type of files which can be obtained at the different stages of the analysis. 
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2.6.2.3 Normalization and Nonspecific Filtering 
Background adjustment, normalization and summarization were applied using the RMA 
algorithm within the Affy package under Bioconductor 239, 240. Afterwards the processed data 
was stored in a so-called expression set containing a value for each probe sets proportional 
to its expression strength. Next probe sets, which could not be annotated to any gene were 
removed from the expression set, e.g. technical controls. Finally, a mean standard deviation 
of all probe sets was calculated. All probe sets, which had a lower standard deviation than 
the mean standard deviation were excluded. Both filtering methods were performed using the 
Genefilter package 242. 
2.6.2.4 Detection and Visualization of Differential Expression 
Differential expression was probed using Bayesian statistics and Limma package 233. 
Differences between genotype, sex as well as a possible interaction of both were calculated. 
Multiple testing correction was performed using the procedure of Benjamini Hochberg 
implemented in the Multtest package 243. Probe sets with a p-value below 0.05 were 
considered as differentially expressed. Annotation of probe sets was applied with Annaffy, 
Annotate and Mouse4302.db packages 244-246 under Bioconductor. Volcano plot 
representation was used to visualize differential expression. 
2.6.2.5 Pathway Analysis 
Differential expressed probe sets were tested for overrepresentation of KEGG gene sets. 
The analysis was performed using the GSEABase package 247 under Bioconductor. 
2.6.3 Quantitative PCR 
RNA was prepared as described before (chapter 2.6.1.2). Reverse transcription was 
performed with the Reverse Transcription Core Kit (Eurogentec, Köln, Germany) according 
to the manufacturer’s protocol. Primers were synthesized by Eurofins MWG Operon 
(Ebersberg, Germany). Primer sequences were chosen with the Primer-Blast tool (NCBI, 
Bethesda, MD, USA), primer sequences are given in table 2. Quantitative PCR was 
performed with the Maxima SYBR Green/Rox qPCR Master Mix (Fermentas GmbH, St. 
Leon-Rot, Germany). Eukaryotic 18S rRNA Endogenous Control (Applied Biosystems, Life 
Technologies) was used for standardization. PCRs were performed using an ABI 7500 
System (Applied Biosystems) and a 3-step program (according to the master mix protocol). 
PCR amplicons were resolved on 2 % agarose gels using the Bio-Rad Sub-Cell system (Bio-
Rad Laboratories GmbH, München, Germany). As size marker Gene RulerTM 100 bp DNA 
Ladder (Fermentas) was used. 
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Table 2. Primer sequences. 
name forward primer reverse primer product size [bp] 
1453145_at TGCACCAGGTCTGTTTCTGT GGTGGCTGTTTCTCAGAAGG 196 
1429452_x_at GAAGCTTCTCGATTGGAAGC CACTGCTCCAGTTGTTGGTG 257 
 
2.6.4 Blast 
Nucleotide sequences of probe sets corresponding to the transcribed sequence of 
4933439C20Rik were obtained from the NettAffx Analysis Center (Affymerix). Sequences 
were blasted against the mouse genomic and transcript database using the nucleotide blast 
tool on http://www.ncbi.nlm.nih.gov/ (NCBI). 
 
2.7 Protein Analysis 
Mice were sacrificed with an overdose of isofluran, exsanguinated and perfused with 20 ml 
cold PBS. Interscapular brown adipose tissue, skin (interscapular region) and heart were 
dissected. Calcified lesions were scraped out under a dissection microscope (Leica MZ6). 
Calcification-free tissue was collected as control tissue. Samples were frozen in liquid 
nitrogen and stored at -70 °C. Samples were thawed, transferred to 2 ml reaction tubes and 
incubated with SDS sample buffer (0.25 M TRIS (AppliChem GmbH, Darmstadt, Germany), 
8.2 % SDS (AppliChem GmbH), 20 % glycerin (Fluka, St. Louis, MO, USA), 10 % β-
mercaptoethanol (AppliChem GmbH), bromophenol blue (SERVA, Heidelberg, Germany)) 
containing 40 mM EDTA (ICN Biomedicals, Frankfurt, Germany) at 96 °C for 5 min. 
Approximately 10 µl of SDS sample buffer per 1 mg sample weight were used. The 
supernatant was removed and tissue pellets were homogenized for 2.5 min at 25 Hz in a 
mixer mill (Tissue Lyser II, Qiagen, Hilden, Germany). Afterwards samples were boiled 5 
minutes in SDS sample buffer containing EDTA. 
2.7.1 SDS-PAGE  
Protein extracts were separated in 12.5 % polyacrylamid gels using SDS-PAGE 248. Gels 
were washed in ultra-pure water and proteins were stained with Imperial Protein Stain 
(Thermo Fisher Scientific, Rockford, IL, USA) for 2 hours. Excessive stain was removed by 
washing in ultra-pure water over night. Pictures of gels were taken using a Canon DS126191 
EOS Rebel XS SLR digital camera (Canon, Tokyo, Japan). 
2.7.2 Mass Spectrometry Analysis 
Protein bands of interest were cut out and vacuum dried in a Savant DNA SpeedVac 
DNA110 concentrator (Thermo Fisher Scientific). Tandem mass spectrometry analysis 
including sample digestion was performed by Ulrike Kusebauch, Institute For System 
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Biology, Seattle, WA, USA. Data analysis was conducted using Mascot algorithms 249. The 
ion score cut-off was set to 30, representing a probability of 10-3. Major proteins within a 
protein band were determined according to the exponentially modified protein abundance 
index (emPAI) 250.  
 
2.8 CPP Preparation 
2.8.1 Protein Purification  
Bovine fetuin-A, asialofetuin and albumin (Sigma, Taufkirchen, Germany), respectively, were 
purified by gel filtration using a TRIS buffered HiLoad 16/60 Superdex 200 column (GE 
Healthcare, Freiburg, Germany) equilibrated in PBS and pumped at 1 ml/min according to a 
protein purification standard operation procedure (SOP) (supplemental protocol 1). The 
concentration of the pooled fetuin-A monomer and asialofetuin fractions was assessed 
photometrically (E1% = 5.3 at 280 nm 115). The concentration of the pooled albumin fractions 
was assessed using a Bradford-Assay (Roti-Nanoquant from Roth, Karlsruhe, Germany). 
Proteins were labeled with Alexa488 carboxylic acid, succinimidyl ester according to the 
labeling kit protocol (Invitrogen). Free label was removed using Zeba spin desalting columns 
(Thermo Scientific, Dreieich, Germany). Protein fractions were snap-frozen in liquid nitrogen 
and stored at –20 °C until use. 
2.8.2 CPP Formation 
Protein solutions were cleared by centrifugation (10,000 g, 10 min, 4 °C). CPPs were 
prepared by mixing stock solutions filtered through a 0.22 µm filter, to give a final 
concentration of 1.0 mg/ml fetuin-A, 10 mM CaCl2, 6mM Na2HPO4, 140 mM NaCl, 50 mM 
Tris-HCl pH7.4 14, 18. CPP formation was performed according to a SOP (supplemental 
protocol 2). The precipitation mix was incubated for one hour at 37 °C and CPPs were 
separated from the monomer and concentrated by membrane filtration cartridges with a 300 
kDa cut-off (Centrisart, Sartorius Stedim Biotech GmbH, Goettingen, Germany). Protein 
concentration in preparations was determined using a BCA-Assay (Thermo Scientific). 
 
2.9 In Vivo Clearance of CPPs 
Mice were injected i.v. with a maximum of 200 µl phosphate buffer solutions containing 160 
µg fetuin-A, asialofetuin in form of monomeric protein or complexed as CPPs, respectively, 
with bovine serum albumin or with fluorescence labeled polystyrene beads of 0.17 µm or 
0.055 µm diameter (Bangs Laboratories, Inc., Fishers, USA). Mice were sacrificed at 2, 10, 
30, 60 and 180 minutes after injection to establish the serum clearing and organ distribution 
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of the different preparations. Serum samples taken immediately after injection (< 1 min) were 
assigned 100 % injected dose. To prepare organ extracts, mice were sacrificed with an 
overdose of isoflurane, exsanguinated, perfused with 20 ml cold PBS and tissues were 
collected. 
2.9.1 Preparation of Serum and Tissue Samples 
Tissues (liver, spleen, kidney, lung, heart, aorta, muscle, thymus, pancreas, gonads, skin, 
bone marrow, bone and brain) were split in half. One part was used for protein extraction. 
Organ pieces were weighed and washed in cold buffer A (50 mM TRIS/HCl (pH 7.4), 2 mM 
EDTA, 150 mM NaCl). Afterwards the tissue samples were homogenized in 10 parts (v/w) 
cold buffer B (50 mM Tris/HCl (pH 7.4), 10 % v/v glycerol, 5 mM magnesium acetate, 50 mM 
EDTA, 0.5 mM DTT (AppliChem GmbH), protease inhibitor cocktail (Complete (Roche, 
Mannheim, Germany)) in a Retsch MM300 Mixer Mill (for liver, kidney and pancreas samples 
20 parts (v/w) were used). Samples were cleared by centrifugation at 10,000 g, 4 °C for 10 
min. The supernatant was transferred into a fresh tube and the protein concentration was 
determined with a dye assay (Roti-Quant, Roth, Karlsruhe, Germany). Equal amounts of 
diluted tissue extracts as well as from diluted serum samples were separated using SDS-
PAGE and the fluorescence signal was scanned with a Typhoon 9410 imager (GE 
Healthcare). The images were quantified by densitometry with the ImageJ software 251. The 
remaining tissue was used for immunofluorescence staining (see chapter 2.3).  
 
2.10 Cell Culture 
All cells were cultured at 37 °C and 5 Vol.-% CO2 in a humidified atmosphere (MCO-2OAIC 
CO2 incubator, Sanyo Biomedical, Bad Nenndorf, Germany). All cell handling was performed 
in a flow hood (Herasafe KSP 15, Thermo Fisher Scientific).  
2.10.1 Cell Lines 
Raw and J774A.1 macrophages, Hela cells, Cos1 and Cos7 cells and L929 cells were grown 
on tissue grade cell culture plates (Sarstedt, Nümbrecht, Germany) in Dulbecco´s Modified 
Eagle´s Medium (DMEM, Gibco, Life Technologies) or Roswell Park Memorial Institute 
(RPMI-1640, Gibco, Life Technologies) each containing 10 % FBS (Gibco, Life 
Technologies) and antibiotics, respectively. Detachment of cells was achieved by trypsin 
(Gibco, Life Technologies) treatment or by scraping with a rubber policeman (macrophages).  
2.10.2 Production of M-CSF containing L929-Cell Conditioned Medium (LCM) 
L929 cells were grown in DMEM medium containing 4.5 g/l glucose, 10 % fetal bovine serum 
(FBS), 29.2 mg/ml L-glutamin, 100 U penicillin and 100 µg streptomycin (media as well as 
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supplements were purchased from Gibco) on T-75 cell culture plates (Sartstedt) until 80-90% 
confluency. Cells were detached and transferred to T-175 flasks (Sarstedt) and grown for two 
more days. After that, cells were kept in media containing 5 % FBS and supernatant was 
harvested after day 2 and day 4. Collected supernatant was centrifuged at 3000 rpm, filtered 
through a 0.22 µm filter and aliquots were frozen at -20 °C. 
2.10.3 Bone Marrow Derived Macrophage (BMM) Differentiation and Culture 
Mice were sacrificed with an overdose of isofluran. Femur and tibiae of adult mice were 
dissected. The epiphyses were removed and bones were flushed with 20 ml of RPMI-1640 
medium. The cell suspension was centrifuged at 250 x g for 5 min and resuspended in 2 ml 
of RPMI-1640 medium containing 10 % FBS, 20 % LCM, 29.2 mg/ml L-glutamin, 100 U 
penicillin and 100 µg streptomycin. Cells were seeded on two bacterial plastic dishes with a 
diameter of 15 cm (BD Pharmingen) containing 24 ml culture media each. At day 3 after 
seeding, cells were fed with 15 ml culture media. After 6 days cells were adherent and a 
medium change was performed. After that, medium was changed every three days. As cells 
were fully differentiated at this stage medium without LCM supplement was used. 
Experiments were carried out between day 9 and day 13 post bone marrow harvesting. 
 
2.11 Binding Assay 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic demonstration of CPP binding assays.  
A. Binding assays performed on WT and KO macrophages (see table 3). Cells were incubated on ice with 
different concentrations of fetuin-A monomer or fetuin-A containing CPPs ranging from 0.01 mg/ml to 0.175 
mg/ml. B. Competitive binding with acLDL. Macrophages were incubated on ice with CPPs in varying 
concentrations, ranging from 0.05 to 0.2 mg/ml fetuin-A contained in the medium in the presence or absence of 
10 µg/ml acetylated LDL (acLDL). 
 
Receptor binding was studied in cell lines or bone marrow derived macrophages harvested 
from mice deficient in different kind of clearing receptors. Table 3 lists all used mouse strains. 
BMMs were harvested and differentiated as described in chapter 2.10.3. Cell lines were used 
at approximately 80 % confluency and cells were detached as described in chapter 2.10.1, 
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BMMs were pre-treated with 10 mM EDTA for 10 min and scraped with a rubber policeman. 
Receptor binding assays were performed in reaction tubes with 500,000 cells (in 500 µl) + 
500 µl dil-labeled acLDL (Molecular Probes), Alexa488-labeled CPPs or fetuin-A monomer 
containing serum-free medium for 45 minutes on ice. Cells were washed twice with medium 
and PBS at 4 °C, fixed with para-formaldehyde and cell-associated fluorescence was 
measured by flow cytometry (chapter 2.13). 
2.12 Endocytosis Assay 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic demonstration of CPP endocytosis assays.  
A. Endocytosis assays performed on WT and KO macrophages (see table 3). Cells were incubated at 37 °C with 
different concentrations of fetuin-A containing CPPs ranging from 0.01 mg/ml to 0.175 mg/ml. B. Inhibition 
assays: Macrophages were pre-incubated with different endocytosis inhibitors. After that cells were incubated at 
37 °C with CPPs in varying concentrations, ranging from 0.01 to 0.2 mg/ml fetuin-A contained in the medium. 
 
2.12.1 Endocytosis Assay 
The murine macrophage cell line Raw 246.7 or BMMs harvested from mice deficient in 
specific clearing receptors were used to study cellular uptake of fetuin-A and CPPs. Cells 
were seeded on 24-well cell culture plates (TPP, Trasadingen, Switzerland) with 250,000 
cells per well over night. The cells were incubated for up to three hours with fluorescence 
labeled fetuin-A monomer or CPPs in fresh serum-free RPMI at different protein 
concentrations. In blocking experiment (all inhibitors were purchased from Sigma) cells were 
incubated for 30 min in the presence of cytochalasin D (10 - 40 µM), Ly294002 (10 – 100 
µM) or polyinosinic acid (1 – 5 ng/µl, polyinosinic acid was removed for addition of CPPs) 
before 10 min incubation with CPPs. Cells were washed twice with PBS, fixed with para-
formaldehyde and cell-associated fluorescence was measured by flow cytometry (chapter 
2.13). 
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2.12.2 Modified Endocytosis Assay to Analyze the Role of Galectins 
BMMs harvested from Galectin 1 or Galectin 3 deficient mice and wildtype mice were used to 
study cellular uptake of fetuin-A and CPPs in presence and absence of galectins. Cells were 
seeded on 24-well cell culture plates (TPP, Trasadingen, Switzerland) with 250,000 cells per 
well over night. Half of the wells were incubated with 1 µg/ml LPS (Sigma). For endocytosis 
assays the one half of the supernatant was removed and replaced by fresh serum-free RPMI 
containing fluorescence labeled fetuin-A monomer or CPPs at different protein 
concentrations. Macrophages were incubated 10 min at 37 °C. After that, cells were washed 
twice with PBS, fixed with para-formaldehyde and cell-associated fluorescence was 
measured by flow cytometry (chapter 2.13). 
 
Table 3. Overview of clearance receptor-deficient bone-marrow derived macrophages studied in binding- 
and endocytosis assays.  
Note that CD36 macrophages were studied in collaboration with Laura Helming (München, Germany). 
79, 218, 227, 252-256 
2.13 Flow Cytometry 
Cell-associated fluorescence was measured by flow cytometry using a FACSCalibur system 
(Becton Dickinson, Heidelberg, Germany), excitation optics: 15 mW 488 nm argon-ion laser; 
emission optics: photomultiplier with band-pass filter: 530/30 nm; detection channel: green 
deficiency function in endocytosis source 
C57BL/6    
Annexin 5 phagocytosis of dead cells  Martin Herrmann (Erlangen, Germany) 
Annexin 6 stimulation of LDL particle endocytosis Martin Herrmann (Erlangen, Germany) 
CD36 clearing of modified LDL particle  Peter Voshol  (Leiden, Netherlands) 
Dectin-1 binding of β-glucan and various unidentified bacterial and endogenous ligands  
Gordon Brown 
(Aberdeen, UK) 
FcγR clearing of immune complexes and of SAP- and CRP- opsonized particles 
Falk Nimmerjahn 
(Erlangen, Germany) 
Galectin 1 inhibition of phagocytosis via FcγR Martin Herrmann (Erlangen, Germany) 
Galectin 3 enhancing clearance of apoptotic neutrophils Martin Herrmann (Erlangen, Germany) 
SR-A clearing of modified LDL particle Siamon Gordon (Oxford, UK) 
Fetuin-A enhancing clearance of apoptotic neutrophils own breeding 
WT - corresponding to KO or own breeding 
   
DBA/2   
Fetuin-A enhancing clearance of apoptotic neutrophils own breeding 
WT - own breeding 
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channel (FL-1H). 5,000 – 10,000 cells were evaluated per sample. The analysis was 
performed using CellQuestPro software (Becton Dickinson). 
 
2.14 Statistics 
Statistical analysis was performed using Prism 4 software (Graphpad, La Jolla, CA, USA). 
One-way ANOVA with Tukey’s multiple comparison test was used to test for overall 
differences in non-size matched experimental groups. Experiments containing two factors 
were analyzed with two-way ANOVA with Bonferroni post test. Curve fitting was performed 
assuming linear or nonlinear regression. 
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3. Results 
3.1 The Pathology of Ectopic Calcification in Fetuin-A Deficient Mice 
Fetuin-A is a well-studied systemic inhibitor of ectopic calcification 55. Consequently, fetuin-A 
deficient mice develop pathological mineralization. Whereas fetuin-A deficient mice 
backcrossed on the calcification sensitive genetic background DBA/2 (D2) showed 
widespread soft tissue calcifications 56, mice combined with C57BL/6 (B6) background were 
resistant to spontaneous ectopic mineralization. Nonetheless, uremic B6 fetuin-A deficient 
mice on a high phosphate diet also developed extraosseous calcification 114.  
In this thesis, soft tissue calcification in D2 fetuin-A deficient mice was examined. A detailed 
analysis of the pathology of ectopic calcification should contribute to a better understanding 
of the underlying mechanism leading to the severe phenotype in D2 fetuin-A deficient mice. 
3.1.1 Severe Soft Tissue Calcification in Adult D2 Fetuin-A Deficient Mice 
The phenotype of D2 fetuin-A deficient mice was studied before by Schäfer et al. It was 
shown that mice develop soft tissue calcification in heart, lung, testis, skin, tongue and 
kidney 56. Here the severe ectopic calcification is demonstrated by photographs of a 
representative necropsy (figure 8). The observed mouse was a female ex-breeder and 42 
weeks of age. Soft tissue calcification was observed in interscapular brown adipose tissue 
(figure 8D-E), heart (figure 8B, F), lung (figure 8G), spleen (figure 8H), pancreas (figure 8I), 
kidneys (figure 8C, J), ovaries (figure 8C, K) and skin (not shown). Calcification in 
interscapular brown adipose tissue appeared as macroscopically visible spherical lesions 
(arrowheads in figure 8D, E). The heart had a heavily enlarged left atrium (figure 8B, F), 
calcified lesions spread throughout the myocardium and were of millimeter size (exemplary 
lesions are marked by arrowheads in figure 8F). Lesions in lung were spherical but 
considerably smaller than lesions in brown adipose tissue; in the photomicrograph they are 
observable as evenly distributed white spheres (figure 8G). In spleen lesions were randomly 
spread through the red pulp. The lesions appeared as white spheres, the size of the lesions 
was diverse. In average spleen lesions exceeded the size of lesions found in lung (figure 
8H). Lesions in pancreas were reminiscent of those in interscapular brown adipose tissue 
(figure 8E, I). The kidneys showed severe ectopic calcification: a great number of white 
spherical lesions occurred in the cortex (figure 8J).  
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Figure 8. Necropsy of a female D2 fetuin-A deficient mouse.  
The abdomen was opened and organs were subsequently removed (A-C). Severe ectopic calcification was 
observed in interscapular brown adipose tissue (D-E), heart (B, F), lung (G), spleen (H), pancreas (I), kidneys (C, 
J) and ovaries (C, K). The left ovary showed a cystoid shape. Arrowheads indicate exemplary calcified lesions (B-
K) and the enlarged sternum (A). 
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Finally, gonads were observed. The uterus horns appeared normal, ovaries showed severe 
calcification (the arrowhead in figure 8K indicates an exemplary calcification). The left ovary 
was cystic (figure 8K). Beside the ectopic calcification the mouse had a heavily enlarged 
sternum (figure 8A). 
In conclusion, several month old D2 fetuin-A deficient mice showed severe soft tissue 
calcification. Lesion morphology was dependent on the affected tissue. However, in most 
tissues lesions were spherical and appeared transparent to white. In all organs observed 
lesions were detectable macroscopically. Eventually, abnormalities including formation of 
cysts in ovaries (figure 8K) and kidneys (not shown) were observed. 
 
3.1.2 Early-stage Calcified Lesions Colocalize with the Microvasculature  
Formation of calcified lesions was studied in young D2 fetuin-A deficient mice. First a 
technique suitable to detect early stage lesions of micrometer scale even in 
immunofluorescence staining had to be developed. On the one hand a recently patented 
method was used 238. It was shown that fetuin-A injected intraperitoneal into fetuin-A deficient 
mice accumulated at calcification sites 257. Thus, immunofluorescence staining on 
cryosections from fetuin-A injected mice with a fetuin-A specific antibody was performed to 
detect calcified lesions. It was also previously published that osteopontin (OPN) accumulates 
in calcified lesions 258. Therefore, antibody staining of OPN was used to identify calcified 
lesions. Both fetuin-A and OPN detected calcified lesions with high sensitivity even at early 
small stages (2 weeks age, figures 9A, E) that were invisible in histology and X-ray analysis. 
To draw a conclusion on the mechanisms of lesion formation it was of great interest to study 
whether the lesion formation occurred intra- or extracellular and whether lesion formation 
might take place within the vasculature. Consequently, double staining of OPN or fetuin-A 
stained calcified lesions and either an endothelial marker, namely CD31, or the lymph duct 
marker lyve-1 was performed. Figure 9A and 9E shows early-stage lesions clearly localized 
inside capillaries. Even at late stage lesions CD31-positive vessels were found in tight 
proximity to the lesions (figures 9B, D, F). In contrast, double staining with lyve-1 revealed 
that there was no colocalization with lymphatic vessels (figures 9C, D).  
In summary, early-stage calcified lesions in lung and brown adipose tissue could be identified 
and readily stained by fetuin-A and OPN, respectively. These lesions as well as late-stage 
lesions in myocardium were in tight association with the microvasculature, but not with lymph 
ducts. 
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Figure 9. Colocalization of early stage calcified lesions and vascular markers.  
Immunohistochemistry of cryosections prepared from brown adipose tissue (E), lung (A) or myocard (B-D, F) of 
D2 fetuin-A deficient mice. Calcified lesions stained positive for OPN (A, B) and were demarcated by CD31, an 
endothelial marker (B, D) but not by Lyve-1 a lymph duct marker (C, D). Injected fetuin-A bound to calcified 
lesions and was readily detected using fetuin-A antibody (E, F). Even at early small stages (2 weeks age A, E) 
fetuin-A like OPN staining detected calcified lesions with high sensitivity that were invisible in histology and X-ray 
analysis. The fetuin-A stained lesion in E was enclosed by CD31-positive endothelial cells. Asterisks and 
arrowheads indicate calcified lesions. Scale bars 50 µm. 
 
 
3.1.3 Transmission Electron Microscopy of Calcified Lesions 
Transmission Electron Microscopy (TEM) was applied to study the micro-architecture of 
calcified lesions in 2-week-old D2 fetuin-A deficient mice. Ectopic calcification in D2 fetuin-A 
deficient mice occurred in most soft tissue types 56. However, as shown before (chapter 
3.1.1) the morphology of soft tissue calcification was tissue dependent. Here, interscapular 
brown adipose tissue was studied because in this tissue (i) recent findings suggested that 
calcification is initiated very early and (ii) soft tissue calcification is severe.  
In fact, TEM of early-stage calcified lesions in interscapular brown adipose tissue 
demonstrated a broad spectrum of lesion morphologies. Nonetheless, it was possible to 
classify the lesions into three categories:  
 Type 1:  Lesions with concentric rings of alternating high and low electron density 
  (figure 10). 
 Type 2:  Diffuse lesions within the microvasculature (figure 11).  
 Type 3:  Electron dense lesions (figure 12).  
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Figure 10. Lesions with concentric rings of alternating high and low electron density.  
TEM of calcified lesions in brown adipose tissue dissected from a 2-week-old D2 fetuin-A deficient mice suffering 
from severe soft tissue calcification. Various spherical mineral precipitates with alternating layers of high and low 
electron densities were observed. Three different morphologies of calcified lesions are shown. Spheres had a 
diameter ranging from 6 to 9 µm. A: Calcified lesion embedded in brown adipose tissue, rich in lipid vacuoles. B: 
Inset of A. Calcified lesion built of two spheres attached to each other. Spheres displayed “tree-aging-ring-like” 
structures of layers with varying electron density. The outer layer of lesions was not clearly defined and included 
several roundish extensions. C, D: Inset of B. E: Round calcified lesion built of multiple concentric layers. F: 
Lesion consisting of an electron dense core surrounded by a broad layer with lower electron density. This core is 
enclosed by a diffuse layer consisting of several electron dense spots. Scale bars: 20 µm (A); 2 µm (B, E, F); 1 
µm (C, D). 
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Figure 11. Difuse lesions within the microvasculature.  
TEM of calcified lesions in brown adipose tissue dissected from a 2-week-old D2 fetuin-A deficient mice suffering 
from severe soft tissue calcification. Lesions were observed within the microvasculature. All lesions consisted of 
electron dense filamentous mineral debris and organic and cellular conglomerate with less electron density. A-C: 
Calcified lesion surrounded by endothelium, the arrowheads indicate nuclei of endothelial cells. B: Inset of A. D-F: 
Calcified lesion within an arteriole, clearly identified by the characteristic composition of its vessel wall: i = tunica 
intima; m = tunica media; e = tunica externa. E, F: Magnification of D. Scale bars: 10 µm (D-E); 5 µm (A, B); 2 µm 
(C, F). 
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Figure 12. Electron dense lesions.  
TEM of calcified lesions in brown adipose tissue dissected from a 2-week-old D2 fetuin-A deficient mice suffering 
from severe soft tissue calcification. A: Electron dense lesions embedded in brown adipose tissue rich in lipid 
vacuoles. B: Inset of A. Electron dense lesion, which might have developed by aggregation of several roundish 
lesions. Each of these round building blocks had a diameter of approximately 2 µm. The lesion was enclosed by 
membranous structures. C: A diffuse conglomerate of electron dense material was visible. The lesion was 
surrounded by membranous structures. D: Intracellular electron dense lesions. Lipid loaded vacuoles were found 
in proximity to the lesions indicating a brown adipocyte. m = mitochondria; lv = lipid vacuole; arrowheads indicate 
membranous structures. Scale bars: 5 µm (A); 2 µm (B); 1 µm (C, D). 
 
Type 1 lesions were spherical and had a diameter ranging from 6 µm to 9 µm. They occurred 
either as single spheres (figure 10E-F) or as cluster of two spheres (figure 10A-B). The lesion 
shown in figure 10A-D was built of rings with alternating electron density resembling tree-
aging-rings. This highly organized structure was found in particular in the core of the lesion 
whereas the outer layer was mostly unorganized and diffuse. In contrast, the lesion shown in 
figure 10E was not perfectly spherical, but was built of several layer with varying electron 
density. In this case, the “tree-aging-ring-like” structure was found as well in the outer layer of 
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the lesion. A third example of a type 1 lesion is shown in figure 10F. The lesion consisted of 
an electron dense core surrounded by a broad layer of lower electron density. The following 
layer was less organized and diffuse, it contained several single spots of high electron 
density. Type 2 lesions were found within the microvasculature. The lesions shown in figure 
11A-C were surrounded by a single layer of endothelium. Nuclei of endothelial cells are 
indicated by arrowheads. The diameter of the vessels was about 19 µm (figure 11A) and 17 
µm, respectively (figure 11C). The lesion shown in figure 11D-E was located within a small 
arteriole, it was surrounded by an endothelium (tunica intima) enclosed by a single layer of 
smooth muscle cells (tunica media) and the tunica externa. The arteriole had a diameter of 
approximately 35 µm (figure 11D). All type 2 lesions were composed of fibrous, electron 
dense mineral precipitate and organic conglomerate with less electron density. Type 3 
lesions were the most diverse lesions observed, their morphologies ranged from clusters of 
electron dense spheres (figure 12A-B) to electron dense diffuse precipitates (figure 12D). 
Lesions shown in figure 12B, D were detected in tight proximity to lipid vacuoles and 
mitochondria, both characteristics of brown adipocytes. To some extent membranous 
structures enclosed the lesions (see arrowheads in figure 12B, D).  
In summary, calcified lesions in D2 fetuin-A deficient mice showed diverse form, structure 
and localization. Despite this diverging morphology, lesions could be divided into three 
subtypes: lesions with concentric rings of alternating high and low electron density (type 1 
lesions), diffuse lesions within the microvasculature (type 2 lesions) and electron dense 
lesions (type 3 lesions).  
3.1.4 Gene Expression Analysis 
3.1.4.1 Differential Gene Expression in Calcified Brown Adipose Tissue 
In newborn mice brown adipose tissue is mainly localized between the scapulae 259, another 
deposit is found in the kidney pelvis region. Brown adipose tissue can be considered 
homogeneous with a limited number of cell types. Therefore, brown adipose tissue dissected 
from the kidney pelvis was chosen to compare the gene expression profile of calcified D2 
fetuin-A deficient mice and wildtype controls. The quality of microarrays was assessed using 
the ArrayQualityMetrics package 241 under Bioconductor 239. Figure 13 illustrates the analysis. 
Arrays, which scored as outliers in two or more tests were considered poor quality and were 
excluded from further analysis. 
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Figure 13. Quality assessment of brown adipose tissue microarrays. 
Quality of microarrays was assessed using arrayQualityMetrics package under Bioconductor. A: Boxplot 
demonstration of array intensity distribution. Each box corresponds to one array. The plot summarizes the 
distribution of probe intensities (log2 Intensities are plotted on the y-axis) across all arrays. Boxes should have 
similar size and y position (median). Sizes of boxes were in the same range, whereas the comparison of medians 
revealed that array ko5, wt2 and wt6 were outliers, particularly medians of wt2 and wt6 were remarkably low. B: 
Density plot illustrates the density of a given intensity within an array; one would expect a similar pattern for all 
arrays. The arrays wt2 and wt6 were biased towards low intensity probes, which qualified those arrays as outliers. 
C: Affymetrix quality control (QC) stats report. The percentage of “present” calls is given for each array in the left 
row in blue, the red numbers indicate the average background value for each array. The percentage of present 
calls is similar in all arrays. The background level is remarkably low for arrays wt2 and wt6 as already seen in A 
and B. The relation between 3’ probe sets and 5’ probe sets of the control genes β-actin (triangles) and GAPDH 
(circles) was within the recommended range (light blue box) for all arrays. D: Heatmap representation of the 
distance between arrays. The false colour heatmap indicates the mean absolute distance of the M-values for 
each pair of arrays, with M = log2(intensity1) - log2(intensity2), where intensity1 is the intensity of the array studied 
and intensity2 is the intensity of a "pseudo"-array, which has the median values of all the arrays. This plot 
confirmed wt2 and wt6 as outliers. Note that ko1-3, wt1-2 and wt7 were females and ko4-6, wt4-6 were males. 
 
Figure 13A shows a boxplot of array intensity distribution. The mean intensity of the arrays 
ko5, wt2 and wt6 diverged remarkably from the other arrays. This difference of wt2 and wt6 
was also observed in the density plot (figure 13B). The ratio of 3 prime and 5 prime probe 
sets of the constitutively expressed control genes β-Actin and Gapdh is commonly used to 
judge RNA quality according to an Affymetrix recommendation. The RNA quality of all arrays 
was good as the ratio of both control genes matched the recommended range (figure 13C). 
However, the Affymetrix quality control report identified the arrays wt2 and wt6 to have 
Results 
38 
remarkably low overall background intensity values. These arrays were likewise reported as 
outliers by distance measuring (figure 13D). Therefore, the arrays wt2 and wt6, 
corresponding to one female and one male wildtype animal, were removed from the data set, 
whereas the array ko5 was retained as it had only one outlier call. The data from the 
remaining ten arrays were normalized and tested for differential expression among KO and 
WT animals using Bayesian statistics. Volcano plot demonstration shown in figure 14 
showed several genes significantly upregulated and a lower number of genes significantly 
downregulated in KO mice. 
 
 
Figure 14. Gene expression in adipose tissue of D2 wildtype and knockout mice. 
Volcano plot representatation of gene expression in brown adipose tissue dissected from the region of kidney 
pelvis. Examined mice had D2 genetic background and were 6 weeks old. Differential expression between fetuin-
A deficient and wildtype mice is shown as log-ratio on the x-axis, negative values represent higher expression in 
KO mice, positive values represent higher expression in wildtype mice. The y-axis encodes the probability for 
differential regulation calculated by Bayesian statistics in the Limma package under Bioconductor. Each dot 
denotes a probe set, probe sets with highest probability score are depicted in blue and probe sets with highest 
log-ratio are depicted in red, marked probe sets are labeled with the appropriate gene name. 
 
 
In total 395 probe sets (supplemental table 1) were found to be significantly differentially 
regulated (genes with a p-value < 0.05 after multiple testing correction were considered as 
significant). Most significant probe sets (red label) and probe sets with highest fold change 
(blue label) were annotated with the corresponding abbreviation of the gene name. All 
significant genes with a fold change above four (log-ratio >2) are summarized in table 4.  
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Table 4. Differential expression in adipose tissue.  
probe set symbol p-value log-ratio 
upregulation    
RIKEN cDNA 1110032A04 gene 1110032A04Rik 0.004 -6.977 
small proline-rich protein 1A Sprr1a 0.005 -6.021 
small proline-rich protein 2A Sprr2a 0.005 -5.495 
small proline-rich protein 2A Sprr2a 0.009 -4.683 
RIKEN cDNA 1110032A04 gene 1110032A04Rik 0.003 -4.369 
myelin and lymphocyte protein, T-cell differentiation protein Mal 0.001 -4.316 
matrix metallopeptidase 12 Mmp12 0.001 -4.315 
transmembrane protease, serine 2 Tmprss2 0.008 -4.157 
secreted phosphoprotein 1 Spp1 0.024 -4.116 
uroplakin 3A Upk3a 0.014 -3.949 
lymphocyte antigen 6 complex, locus D Ly6d 0.002 -3.845 
sorting nexin 31 Snx31 0.008 -3.728 
forkhead box A1 Foxa1 0.001 -3.628 
myelin protein zero Mpz 0.001 -3.525 
Purkinje cell protein 4 Pcp4 0.001 -3.493 
prostate stem cell antigen Psca 0.008 -3.436 
carnitine palmitoyltransferase 1b, muscle Cpt1b 0.006 -3.390 
WAP four-disulfide core domain 2 Wfdc2 0.022 -3.351 
cadherin 1 Cdh1 0.007 -3.256 
claudin 4 Cldn4 0.002 -3.185 
pyridoxal-dependent decarboxylase domain containing 1 Pdxdc1 < 0.001 -3.159 
myelin basic protein Mbp 0.001 -3.148 
forkhead box Q1 Foxq1 0.001 -3.137 
involucrin Ivl 0.005 -3.078 
transmembrane protease, serine 2 Tmprss2 0.016 -3.063 
FXYD domain-containing ion transport regulator 3 Fxyd3 0.001 -3.056 
keratin 18 Krt18 0.002 -3.046 
chloride channel calcium activated 2 Clca2 0.001 -2.976 
small proline-rich protein 2F Sprr2f 0.001 -2.969 
myelin basic protein Mbp 0.001 -2.943 
gasdermin C2 Gsdmc2 0.028 -2.917 
chloride channel calcium activated 2 Clca2 0.010 -2.904 
regulator of G-protein signaling 1 Rgs1 0.043 -2.862 
grainyhead-like 2 (Drosophila) Grhl2 0.001 -2.799 
transmembrane protease, serine 2 Tmprss2 0.008 -2.798 
ring finger protein 128 Rnf128 0.020 -2.792 
myelin basic protein Mbp 0.003 -2.785 
otopetrin 1 Otop1 0.043 -2.784 
keratin 20 Krt20 0.001 -2.775 
ring finger protein 128 Rnf128 0.011 -2.772 
GATA binding protein 3 Gata3 < 0.001 -2.743 
myelin basic protein Mbp 0.001 -2.702 
cytochrome c oxidase, subunit VIIa 1 Cox7a1 0.030 -2.699 
myelin basic protein Mbp 0.003 -2.654 
keratin 7 Krt7 0.027 -2.652 
uroplakin 1A Upk1a 0.010 -2.623 
sonic hedgehog Shh 0.012 -2.619 
epiphycan Epyc 0.001 -2.600 
pyruvate dehydrogenase kinase, isoenzyme 4 Pdk4 0.005 -2.597 
calponin 1 Cnn1 0.005 -2.535 
RIKEN cDNA 1600029D21 gene 1600029D21Rik 0.047 -2.506 
keratin 5 Krt5 0.001 -2.504 
steroid 5 alpha-reductase 1 Srd5a1 0.002 -2.504 
forkhead box Q1 Foxq1 0.005 -2.497 
SH3-binding domain glutamic acid-rich protein Sh3bgr 0.007 -2.492 
SH3-domain GRB2-like 2 Sh3gl2 0.001 -2.454 
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The table shows probe sets, which were significant (p-value < 0.05) differentially expressed in adipose tissue dissected 
from 6 weeks old D2 wildtype and fetuin-A deficient mice. Bayesian statistics was used for calculation of probabilities 
(p-value) and log-ratio, negative log-ratio encode upregulation of the particular probe-set in fetuin-A deficient mice, 
positive values denote downregulation. The table shows most highly differentially regulated genes with a log-ratio 
above 2. Note that gene names are given for each probe set, double entries may occur in case of genes which are 
represented by several probe sets encoding different regions or splice variants of the gene. 
 
 
In total 93 probe sets matched those criteria, 84 probe sets were upregulated in KO mice and 
nine were downregulated. Among the ten most highly upregulated probe sets, two members 
of the small proline rich (sprr) protein family were found, a protein family previously 
associated with various inflammatory diseases 260-262 and cellular stress response 263. Sprr1a 
was 64.9 fold increased, Sprr2a was represented by two probe sets with 45.1 and 25.7 fold 
upregulation in KO mice respectively. The two probe sets corresponding to the transcribed 
sequence 1110032A05Rik with fold changes of 126 and 20.7 were further highly upregulated 
probe sets. They encode the small subunit of serine palmitoyltransferase B with unknown 
RIKEN cDNA 1600029D21 gene 1600029D21Rik 0.006 -2.451 
myosin, heavy polypeptide 11, smooth muscle Myh11 0.003 -2.416 
aquaporin 3 Aqp3 0.009 -2.409 
SH3-domain GRB2-like 2 Sh3gl2 0.001 -2.406 
PERP, TP53 apoptosis effector Perp 0.029 -2.340 
shisa homolog 3 (Xenopus laevis) Shisa3 0.001 -2.324 
aquaporin 3 Aqp3 0.010 -2.311 
aquaporin 3 Aqp3 0.008 -2.290 
interleukin 1 receptor antagonist Il1rn 0.033 -2.255 
RIKEN cDNA 2200001I15 gene 2200001I15Rik 0.007 -2.222 
cathepsin E Ctse 0.001 -2.203 
tetraspanin 8 Tspan8 0.011 -2.185 
claudin 7 Cldn7 0.005 -2.178 
interferon regulatory factor 6 Irf6 0.044 -2.177 
apolipoprotein D Apod 0.005 -2.159 
transmembrane protein 30B Tmem30b 0.012 -2.158 
myelin basic protein Mbp 0.005 -2.140 
vesicle amine transport protein 1 homolog-like (T. californica) Vat1l 0.001 -2.137 
serine protease inhibitor, Kunitz type 1 Spint1 0.033 -2.132 
myocardin Myocd 0.010 -2.110 
regulating synaptic membrane exocytosis 1 Rims1 0.003 -2.087 
steroid 5 alpha-reductase 1 Srd5a1 0.002 -2.070 
actin, gamma 2, smooth muscle, enteric Actg2 0.009 -2.057 
claudin 23 Cldn23 0.005 -2.044 
flavin containing monooxygenase 5 Fmo5 0.013 -2.030 
cell death-inducing DNA fragmentation factor, alpha subunit-like effector A Cidea 0.009 -2.022 
deiodinase, iodothyronine, type II Dio2 0.022 -2.015 
RIKEN cDNA 4930550L11 gene 4930550L11Rik 0.006 -2.011 
    
downregulation    
pyridoxal-dependent decarboxylase domain containing 1 Pdxdc1 < 0.001 4.111 
cytochrome b reductase 1 Cybrd1 < 0.001 3.119 
penta-EF hand domain containing 1 Pef1 < 0.001 3.108 
basonuclin 1 Bnc1 0.004 2.587 
glycoprotein m6a Gpm6a 0.005 2.483 
mesothelin Msln 0.008 2.460 
glycoprotein m6a Gpm6a 0.023 2.355 
fibroblast growth factor 1 Fgf1 0.007 2.091 
plakophilin 2 Pkp2 0.028 2.011 
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function. The myelin and lymphocyte protein (Mal) had a fold change of 19.9. The matrix 
metallopeptidase 12 (Mmp12), involved in extracellular remodeling, showed a fold change of 
19.9. The transmembrane protease, serin 2 (Tmprss2) had a fold change of 17.8. Uroplakin 
3A showed a fold change of 15.4. Finally, the secreted phosphoprotein 1 (Spp1), with a fold 
change of 17.3 was detected as another highly upregulated probe set. Spp1 is also known as 
osteopontin, a protein with various biological functions, which was previously histologically 
detected at calcified deposits 258, 264, 265. 
All significant probe sets, in total 395, were screened for biological function using the KEGG 
gene set. Table 5 lists ten gene sets, which were significantly overrepresented among the 
tested probe sets. Several pathways related to tissue remodeling, namely focal adhesion, 
ECM-receptor interaction, cell cycle, p53 signaling, cell adhesion molecules and notch 
signaling pathway were amongst the differentially regulated pathways.  
This part of the thesis aimed to analyze changes in gene expression of calcifying brown 
adipose tissue in the kidney pelvis region. In summary, the gene expression analysis of 
brown adipose tissue revealed a strong change in gene expression pattern in response to 
soft tissue calcification. A program of tissue reorganization was initiated by upregulation of 
several genes. Most of them were found to be members of KEGG gene sets related to tissue 
remodeling. However, no probe sets associated with the process of deposition of calcium 
phosphate were found to be differentially regulated. Thus, all identified changes were likely 
secondary to the soft tissue calcification.  
 
Table 5. Pathway analysis of significant regulated genes.  
KEGG pathway size exp. count count p-value 
Focal adhesion 174 4 11 0.001 
ECM-receptor interaction 74 2 6 0.004 
Cell cycle 100 2 7 0.005 
p53 signaling pathway  54 1 5 0.005 
Small cell lung cancer 79 6 2 0.006 
Selenoamino acid metabolism 25 1 3 0.015 
Aminophosphonate metabolism 13 1 3 0.03 
Cell adhesion molecules (CAMs) 115 2 6 0.034 
Notch signaling pathway 37 1 3 0.043 
Bladder cancer 37 1 3 0.043 
Differentially expressed probe sets in adipose tissue were tested of overrepresentation of KEGG gene sets. For 
each gene set the name of the pathway and the corresponding size is given. The expected count (exp. count) 
estimates the count of random hits, which depends on the size of the pathway and the number of tested probe 
sets. The count gives the actual number of significant probe sets matching the specific pathway. The probability of 
overrepresentation of the gene set is assumed by the p-value. 
 
3.1.4.2 Differential Gene Expression in Kidney 
Gene expression profile of kidneys was examined in 5-week-old D2 Ahsg -/- and Ahsg +/+ 
mice. Previously it was shown that ectopic calcification in D2 fetuin-A deficient mice in most 
tissues was detectable from an age of approximately 2 weeks, whereas soft tissue 
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calcification in kidneys started considerably later 264. Therefore, in kidneys of 5-week-old 
mice the calcification should not exceed a few early stage calcified lesions. Thus evaluation 
of the gene expression pattern in these mice may provide insights into the mechanisms 
preceding the formation of calcified lesions.  
 
 
 
Figure 15. Quality assessment of kidney microarrays. 
Quality of microarrays was assessed using arrayQualityMetrics package under bioconductor. A. Boxplot 
demonstration of array intensity distribution. Each box corresponds to one array. The plot summarizes the 
distribution of probe intensities (log2 intensities are plotted on the y-axis) across all arrays. Boxes had similar size 
and y position (median) did not show any outliers. B. Density plot illustrates the density of a given intensity within 
an array; as expected a similar pattern was found for all arrays. C. Affymetrix quality control (QC) stats report. The 
percentages of “present” calls are given for each array in the left row, upper number, the lower numbers give the 
average background value for the corresponding array. Both values were within the same range throughout all 
arrays. The relation between 3’ probe sets and 5’ probe sets of the control genes β-actin (triangles) and GAPDH 
(circles) was inside the recommended threshold (light blue box) for all arrays. D. Heatmap representation of the 
distance between arrays. The false colour heatmap depicts the mean absolute distance of the M-values for each 
pair of arrays, with M = log2(intensity1) - log2(intensity2), where intensity1 is the intensity of the array studied and 
intensity2 is the intensity of a "pseudo"-array, which has the median values of all the arrays. The plot demonstrats 
a good quality of arrays by a low distance. Note that arrays ko1-3 and wt1-2 correspond to male mice, arrays ko4-
6 and wt3-4 correspond to female mice. 
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The quality of microarrays was evaluated using the ArrayQualityMetrics package 241 under 
Bioconductor 239. Exemplary results from the quality analysis are illustrated in figure 15. All 
arrays were of good quality. The mean intensity of all arrays was within the same range 
(figure 15A-B). Moreover, the Affymetrix quality control (figure 15C) report including the 
measurement of the relation between 3’ probe sets and 5’ probe sets of the control genes β-
actin and GAPDH did not identify any outlier. Last, the distance between arrays was 
determined confirming that array quality was homogenous (figure 15D). Thus, all arrays were 
retained for the analysis of differential expression among WT and KO mice. The gene 
expression pattern is demonstrated in a Volcano plot (figure 16), each probe set is depicted 
as a dot according to its p-value and ratio between WT and KO mice. The most interesting 
candidate genes, those with smallest p-value (red label) and highest log-ratio (blue label), 
are found in the upper right and upper left corner of the plot. Only few genes were found in 
these regions.  
 
 
Figure 16. Gene expression in kidney of D2 wildtype and knockout mice. 
Volcano plot demonstration of gene expression in kidney. Examined mice had D2 genetic background and were 5 
weeks old. Differential expression between fetuin-A deficient and wildtype mice is shown as log-ratio on the x-
axis, negative values represent higher expression in KO mice, positive values represent higher expression in 
wildtype mice. The y-axis encodes the probability for differential regulation calculated by Bayesian statistics in the 
limma package under bioconductor. Each dot denotes a probe set, probe sets with highest probability score are 
depicted in blue and probe sets with highest log-ratio are depicted in red, marked probe sets are labeled with the 
appropriate gene name. 
 
In table 6 all 16 significantly differentially regulated genes are listed (genes with a p-value < 
0.05 after multiple testing correction were considered as significant). Note that one gene may 
be represented by several probe sets, this particularly accounts to genes with long 
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transcripts. The two most highly upregulated probe sets encoded for solute carrier family 15 
(H+/peptide transporter), member 2 (Slc15a2) and were 14.1 and 6.2 fold increased in fetuin-
A deficient kidneys. Slc15a2, also known as peptide transporter 2 (PEPT2), belongs to the 
superfamily of proton oligopeptide transporter (POT) 266. PEPT2 is expressed predominantly 
in the kidney and was shown to be a proton-dependent transporter of di- and tripeptides as 
well as of a variety of peptidomimetics 267, 268. Next, three probe sets encoding the pyridoxal-
dependent decarboxylase containing 1, a protein with unknown function, appeared among 
the differentially regulated candidates. Two of them, matching exon 14-16 and exon 24, were 
upregulated in D2 fetuin-A deficient mice with a fold change of 5.8 and 1.9, respectively. A 
third probe set matching a sequence outside the coding sequence (CDS) was 14.4 fold 
decreased in fetuin-A deficient animals. In total three isoforms of pyridoxal-dependent 
decarboxylase containing 1 are mapped in NCBI, the exons 14 to 16 are contained in all of 
them whereas exon 24 is uniquely expressed in isoform 3. The same differential expression 
pattern of the three probe sets was found in adipose tissue (see chapter 3.1.4.1) and liver of 
5-week-old D2 fetuin-A deficient mice (see chapter 3.1.4.3). Further differentially upregulated 
probe sets were: Angiotensin I converting enzyme (peptidyl-dipeptidase A) 2, a key factor of 
the renin-angiotensin pathway, with a fold change of 2.2; ubiquitin specific peptidase 1 with a 
fold change of 2.1 and sulfotransferase family 3A, member 1 with a fold change of 1.9.  
Downregulated genes were: Major urinary protein 1 with a fold change of 12.1; aldo-keto 
reductase family 1, member C18 with a fold change of 6.2; catechol-O-methyltransferase 1 
with a fold change of 4.4; GRAM domain containing 3, represented by 2 probe sets with fold 
changes of 4.3 and 2.9 respectively; alpha-2-HS glycoprotein / fetuin-A with a fold change of 
3.9; ribosomal protein L17 with a fold change of 3.6 and ring finger protein 41 with a fold 
change of 2. Given the fact that the fetuin-A gene is absent in fetuin-A deficient mice and 
fetuin-A is naturally expressed at very low level in wildtype kidney 269 the 3.9 fold 
downregulation must be interpreted as down-regulation from very low expression (< 1% of 
liver expression) to zero. Nevertheless, this finding demonstrated the high sensitivity of 
microarray based expression studies. 
In summary, only few differentially regulated genes were identified in kidneys of 5-week-old 
D2 fetuin-A deficient and wildtype mice. 
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Table 6. Differential expression in kidneys from fetuin-A deficient D2 mice.  
probe set symbol p-value log-ratio 
upregulation    
solute carrier family 15 (H+/peptide transporter), member 2 Slc15a2 < 0.001 -3.821 
solute carrier family 15 (H+/peptide transporter), member 2 Slc15a2 < 0.001 -2.624 
pyridoxal-dependent decarboxylase domain containing 1 Pdxdc1 < 0.001 -2.532 
angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 Ace2 0.030 -1.117 
ubiquitin specific peptidase 1 Usp1 0.011 -1.079 
pyridoxal-dependent decarboxylase domain containing 1 Pdxdc1 0.038 -0.929 
sulfotransferase family 3A, member 1 Sult3a1 0.049 -0.913 
    
downregulation    
pyridoxal-dependent decarboxylase domain containing 1 Pdxdc1 < 0.001 3.849 
major urinary protein 1 Mup1 < 0.001 3.601 
aldo-keto reductase family 1, member C18 Akr1c18 0.001 2.625 
catechol-O-methyltransferase 1 Comt1 < 0.001 2.141 
GRAM domain containing 3 Gramd3 < 0.001 2.109 
alpha-2-HS-glycoprotein Ahsg < 0.001 1.973 
ribosomal protein L17 Rpl17 < 0.001 1.854 
GRAM domain containing 3 Gramd3 < 0.001 1.517 
ring finger protein 41 Rnf41 0.012 1.022 
The table shows probe sets, which were significantly (p-value < 0.05) differentially expressed in kidneys dissected 
from 5-week-old D2 wildtype and fetuin-A deficient mice. Bayesian statistics was used for calculation of 
probabilities (p-value) and log-ratio, negative log-ratio encode upregulation of the particular probe-set in fetuin-A 
deficient mice, positive values denote downregulation. Note that gene names are given for each probe set, double 
entries may occur in case of genes which are represented by several probe sets encoding different regions or 
splice variants of the gene. 
 
3.1.4.3 Differential Gene Expression in Liver 
In adult mammals fetuin-A is predominantly expressed in the liver 19, 269. Consequently, gene 
expression in liver of D2 fetuin-A deficient mice and wildtype controls was studied to identify 
causalities of the fetuin-A deficiency in calcifying mice. Genome-wide expression was 
analyzed in 5-week-old D2 fetuin-A deficient mice of both sexes and matching wildtype 
controls using Affymetrix microarrays.  
Quality of microarrays was analyzed using the ArrayQualityMetrics package 241 under 
bioconductor 239. Arrays, which scored as outliers in two or more tests were considered poor 
quality and were excluded from further analysis. Figure 17 illustrates the analysis. Figures 
17A, B point out that the mean intensity of the arrays ko4 and wt1 diverged remarkably from 
the other arrays. The Affymetrix quality control shown in figure 17C confirmed this finding in 
reporting high background levels for those two arrays. The RNA quality measured by judging 
the ratio of 3’ and 5’ probe sets of two houskeeping genes was good in all arrays. Finally, 
distance measuring (figure 17D) confirmed the arrays ko4 and wt1 as outliers and suggested 
to exclude these arrays from the data set. The remaining data was normalized and 
differential expression was calculated using Bayesian statistics. The gene expression profile 
is illustrated in a Volcano plot (figure 18), each probe set is depicted as a dot according to its 
p-value and ratio between WT and KO mice. 
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Figure 17. Quality assessment of liver microarrays. 
Quality of microarrays was assessed using arrayQualityMetrics package under bioconductor. A: Boxplot 
demonstration of array intensity distribution. Each box corresponds to one array. The plot summarizes the 
distribution of probe intensities (log2 intensities are plotted on the y-axis) across all arrays. The boxes of the 
arrays ko4 and wt1 were slightly smaller in comparison to all other arrays. Along with this the median intensity of 
those arrays was remarkably high. B: Density plot illustrates the density of a given intensity within an array; one 
would expect a similar pattern for all arrays. The arrays ko4 and wt1 were biased towards high intensity probes, 
which denoted those arrays as outliers. C: Affymetrix quality control (QC) stats report. The percentages of 
“present” calls are given for each array in the left row, upper number, the lower numbers give the average 
background value for the corresponding array. The percentage of present calls was clearly lower for ko4 and wt1. 
Furthermore, the background level was remarkably high for those arrays as already seen in A and B. The relation 
between 3’ probe sets and 5’ probe sets of the control genes β-actin (triangles) and GAPDH (circles) was inside 
the recommended threshold (light blue box) for all arrays. D: Heatmap representation of the distance between 
arrays. The false colour heatmap depicts the mean absolute distance of the M-values for each pair of arrays, with 
M = log2(intensity1) - log2(intensity2), where intensity1 is the intensity of the array studied and intensity2 is the 
intensity of a "pseudo"-array, which has the median values of all the arrays. This plot confirmed ko4 and wt1 as 
outliers. Note that arrays ko1-3 and wt1-2 correspond to male mice, arrays ko4-7 and wt3-4 correspond to female 
mice. 
 
 
In total, 142 probe sets (supplemental table 2) were significantly differentially regulated 
(probe sets with a p-value < 0.05 after multiple testing correction were considered as 
significant). Differentially regulated probe sets with a fold change above 4 (log-ratio >2) are 
summarized in table 7.  
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Figure 18. Gene expression in liver of D2 wildtype and fetuin-A knockout mice. 
Volcano plot demonstration of gene expression in liver. Examined mice had D2 genetic background and were 5 
weeks old. Differential expression between fetuin-A deficient and wildtype mice is shown as log-ratio on the x-
axis, negative values represent higher expression in KO mice, positive values represent higher expression in 
wildtype mice. The y-axis encodes the probability for differential regulation calculated by Bayesian statistics in the 
limma package under bioconductor. Each dot denotes one probe set, probe sets with highest probability score are 
depicted in blue and probe sets with highest log-ratio are depicted in red, marked probe sets are labeled with the 
appropriate gene name. 
 
Most highly upregulated genes in fetuin-A deficient liver were three sulfotransferases, 
enzymes of the phase II metabolism. Sulfotransferase family 3A, member1 (Sult3a1) was 
103.6-fold increased in D2 fetuin-A deficient mice, sulfotransferase family 2A, member 2 
(Sult2a2) was 50.7-fold upregulated and expression of sulfotransferase family 1E, member 1 
(Sult1e1) was 16-fold higher in fetuin-A deficient animals than in wildtype littermates. Another 
highly upregulated probe set matched lipocalin 2, a carrier protein involved in the innate 
immune response 270, and was 14.1-fold increased in D2 fetuin-A deficient mice. 
Furthermore, the acute-phase reactants 271 serum amyloid A 2 (SAA-2) and serum amyloid 
A1 (SAA-1) were increased 7.4-fold and 6-fold, respectively. Likewise, the scavenger 
receptor CD36, which recently was identified as a receptor of serum amyloid A proteins 272, 
was upregulated 4.2-fold. Additionally, two genes already identified in the kidney expression 
analysis appeared among the differentially regulated genes:  the probe sets of pyridoxal-
dependent decarboxylase containing 1 and the peptide transporter PEPT2 showed the same 
expression pattern as in the kidney (compare chapter 3.1.4.2).  
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Table 7. Differential Expression in liver from fetuin-A deficient D2 mice.  
probe set symbol p-value log-ratio 
upregulation    
sulfotransferase family 3A, member 1 Sult3a1 0.012 -6.695 
RIKEN cDNA C730007P19 gene C730007P19Rik 0.032 -5.665 
sulfotransferase family 1E, member 1 Sult1e1 0.009 -4.002 
lipocalin 2 Lcn2 0.004 -3.820 
serum amyloid A 2 Saa2 0.042 -2.890 
solute carrier family 15 (H+/peptide transporter), member 2 Slc15a2 < 0.001 -2.817 
ribonucleotide reductase M2 Rrm2 0.005 -2.810 
DNA segment, Chr 17, human D6S56E 5 D17H6S56E-5 0.024 -2.744 
baculoviral IAP repeat-containing 5 Birc5 0.014 -2.721 
cyclin B2 Ccnb2 0.038 -2.670 
serum amyloid A 1 Saa1 0.043 -2.575 
pyridoxal-dependent decarboxylase domain containing 1 Pdxdc1 < 0.001 -2.551 
cDNA sequence AB056442 AB056442 0.008 -2.517 
minichromosome maintenance deficient 6 (MIS5 homolog, S. 
pombe) (S. cerevisiae) Mcm6 0.007 -2.516 
minichromosome maintenance deficient 6 (MIS5 homolog, S. 
pombe) (S. cerevisiae) Mcm6 0.016 -2.474 
regulator of calcineurin 2 Rcan2 0.002 -2.470 
ribonucleotide reductase M2 Rrm2 0.017 -2.411 
SPARC related modular calcium binding 2 Smoc2 0.004 -2.247 
PDZ binding kinase Pbk 0.046 -2.204 
SPARC related modular calcium binding 2 Smoc2 0.008 -2.148 
cell division cycle associated 8 Cdca8 0.025 -2.131 
CD36 antigen Cd36 0.015 -2.059 
minichromosome maintenance deficient 5, cell division cycle 46   
(S. cerevisiae) Mcm5 0.013 -2.043 
histone cluster 1, H2ae Hist1h2ae 0.016 -2.039 
    
downregulation    
alpha-2-HS-glycoprotein Ahsg < 0.001 8.631 
pyridoxal-dependent decarboxylase domain containing 1 Pdxdc1 < 0.001 4.762 
cytochrome P450, family 4, subfamily a, polypeptide 12a Cyp4a12a 0.041 4.635 
solute carrier organic anion transporter family, member 1a1 Slco1a1 0.017 3.712 
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, 
yeast)-like 3 Elovl3 0.016 3.522 
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 5 Hsd3b5 0.008 3.275 
kidney androgen regulated protein Kap 0.001 3.193 
RIKEN cDNA 2610016E04 gene 2610016E04Rik 0.011 3.181 
GRAM domain containing 3 Gramd3 < 0.001 2.651 
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 2 Hsd3b2 0.002 2.593 
cytochrome P450, family 7, subfamily b, polypeptide 1 Cyp7b1 0.001 2.252 
cytochrome P450, family 7, subfamily b, polypeptide 1 Cyp7b1 0.002 2.244 
GRAM domain containing 3 Gramd3 < 0.001 2.190 
major urinary protein 3 Mup3 0.001 2.125 
NADPH oxidase 4 Nox4 0.006 2.039 
The table shows probe sets, which were significant (p-value < 0.05) differentially expressed in liver dissected from 
5-weeks-old D2 wildtype (n=3) and fetuin-A deficient mice (n=5). Bayesian statistics was used for calculation of 
probabilities (p-value) and log-ratio, negative log-ratio encode upregulation of the particular probe-set in fetuin-A 
deficient mice, positive values denote downregulation. The table shows most highly differentially regulated genes 
with a log-ratio above 2. Note that gene names are given for each probe set, double entries may occur in case of 
genes which are represented by several probe sets encoding different regions or splice variants of the gene. 
 
 
As expected fetuin-A / Ahsg was identified as the most strongly downregulated gene in the 
liver of D2 fetuin-A deficient mice (this finding was confirmed in B6 fetuin-A deficient mice, 
Results 
49 
see 3.3.1.2), a fold change of 396.5 was observed, indicating absence of fetuin-A expression 
in D2 fetuin-A deficient livers. Further highly downregulated genes in the liver of D2 fetuin-A 
deficient mice were: Cytochrome P450, family 4, subfamily a, polypeptide 12a with a 24.9-
fold decrease; solute carrier organic anion transporter family, member 1a1 with a 13.1-fold 
decrease and elongation of very long chain fatty acids /FEN1/Elo2, SUR4/Elo3, yeast-like 3 
with a 11.5 fold change.  
Interestingly, none of the upregulated genes mentioned above was significantly differentially 
regulated in the liver of non-calcifying B6 fetuin-A deficient mice, pointing to a role of these 
genes in the pathology of ectopic calcification. In contrast, all mentioned downregulated 
probe sets showed a similar expression pattern on B6 genetic background, therefore the 
downregulation was not linked to the calcification phenotype. 
3.1.5 Protein Content of Calcified Lesions 
Soft tissue calcification in D2 fetuin-A deficient mice was detected from an age of 10 days 264. 
Early calcified lesions were nodular and of micrometer size. In the course of time the lesions 
grew consecutively. The lesions reached millimeter size, and progress of lesions was 
associated with intensive tissue remodelling. Here late stage calcified lesions were dissected 
and analyzed with regard to their protein content. Figure 19B demonstrates millimeter sized 
lesions isolated from interscapular brown adipose tissue (BAT). Proteins were extracted from 
calcified lesions and intact tissue and separated using SDS-PAGE. Comparison of the 
protein band pattern in calcified and non-calcified tissue revealed several differentially 
expressed bands (figure 19A). The protein content of these bands was determined with mass 
spectrometry (MS). The table in figure 19C lists the major proteins of each band ranked by 
their emPAI score. This score measures the quantitative contribution of each identified 
protein to the sum of proteins detected in the individual band. In skin lesions five bands were 
enriched or shifted in comparison to intact tissue. Band 1 and 2 were at the same height as 
the serum albumin band, which was also present in intact skin. Consequently, serum albumin 
was identified in both bands. Interestingly, band 1 also contained complement component 9 
and hemoglobin subunit beta-1. Fibrinogen beta chain was also highly enriched in calcified 
skin tissue (figure 19A, C band 3). In band 4 carbonic anhydrase 3, Ig kappa chain C region, 
histone H2B type 1-C/E/G and serum amyloid P-component (SAP) were detected. 
Apolipoprotein A-I (ApoA1) was identified in band 5 as well as in protein extracts from 
calcified lesions in the heart and BAT (band 6 and 7).  
In summary, MS could identify several serum proteins tightly associated or bound to calcified 
lesions. The enzyme carbonic anhydrase 3, which catalyzes the formation of bicarbonate 
was also enriched in calcified lesions of the skin. The most proteins were found in skin 
lesions, whereas in lesions of heart and BAT exclusively ApoA1 was identified. 
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Figure 19. Proteomic analysis of calcified lesions.  
Calcified lesions as well as non-calcified tissue samples were dissected from D2 fetuin-A deficient mice with 
severe ectopic calcification. Proteins were extracted using SDS sample buffer containing EDTA and homogenized 
using a mixer mill. A: SDS-PAGE of samples prepared from serum, intact tissue and calcified lesions of skin, 
heart and brown adipose tissue (BAT). Numbered protein bands were enriched in calcified lesions. M = marker. 
B: Millimeter-sized nodular calcified lesions scraped from interscapular BAT. C: Proteins identified by LC-MS in 
bands marked in A. Proteins that were most frequently detected in the MS-based peptide fragment analysis are 
shown. Analysis of MS results was performed under Mascot 249, the ion score cut-off was set to 30 and 
exponentially modified protein abundance index (emPAI) was used to identify the major proteins. EmPAI score for 
each identified protein is given. Proteins which contributed at least 50% to the entity of proteins within the 
examined band are shown. 
 
 
3.2 Clearance of Calciprotein Particles 
Various biochemical studies have shown that fetuin-A is essential for the formation of high 
molecular weight protein-mineral complexes, called calciprotein particles (CPPs) 18, 90-92. To 
prevent local deposition and pathological calcification CPPs must be cleared from circulation 
once they have formed. Thus, the in vivo clearance of CPPs was studied to identify the target 
skin lesion    heart lesion    
1 Serum albumin 19.93  6 Apolipoprotein A-I 21.24 
 Complement component 9 7.39     
  Hemoglobin subunit beta-1 7.3     
2 Serum albumin 20.9  BAT lesion   
3 Fibrinogen beta chain 24.36  7 Apolipoprotein A-I 36.3 
4 Carbonic anhydrase 3 11.86     
 Ig kappa chain C region 6.51     
 Histone H2B type 1-C/E/G 6.23     
  Serum amyloid P-component 5.71     
5 Apolipoprotein A-I 36.3     
A 
B    C 
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organ and cell type responsible for CPP uptake. Finally, the specific uptake route and a 
candidate receptor will be examined. 
3.2.1 Clearance of Protein-Mineral Complexes from the Circulation is Fast and Efficient 
To study the clearance of CPPs in vivo, CPPs were generated as described before 18 and 
injected intravenously into mice. All protein and particle preparations were purified before 
use. For comparison labeled monomeric fetuin-A (F-A), asialofetuin (AsF) and bovine serum 
albumin (BSA) were injected. It is known that AsF is rapidly cleared by the asialoglycoprotein 
receptor (ASGP-R), which binds terminal galactose residues on desialylated plasma proteins 
273, 274. BSA has a long half-life in serum 275.  
Figure 20 illustrates the clearance of various fluorescence-labeled proteins and CPP 
preparations from blood. Blood was collected at different time points and clearance 
calculated from densitometry of the fluorescence signal of serum samples separated in SDS-
PAGE.  
 
 
Figure 20. Clearance of fluorescence-labeled protein from mouse serum.  
Fluorescence-labeled proteins (160 µg) were injected intravenously into mice and blood was drawn at indicated 
time points to determine the amount of remaining circulating protein. Shown are the fluorescence signals as 
percentage of the value measured one minute after injection. BSA had the longest half-life (t1/2) of all proteins 
tested, and in descending order: t1/2 fetuin-A monomer > t1/2 CPPs > t1/2 asialofetuin. a, statistically significant 
different from fetuin-A monomer at the same time point, p < 0.01; b, statistically significant different from CPP, p < 
0.01. n ≥ 4 
 
 
Figure 1 shows that the clearance of fetuin-A CPPs was faster than the clearance of fetuin-A 
monomer with serum half-lifes t1/2 of 45 and 149 minutes, respectively. CPP clearance was 
also clearly faster than BSA clearance (t1/2 247 min) and AsF monomer was cleared even 
faster than both fetuin-A monomer and CPPs with t1/2 43 minutes. This finding corroborated 
the presence of a high-affinity asialoglycoprotein receptor, strongly discriminating between 
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fully glycosylated fetuin-A and asialofetuin (half-life 149 min vs. 43 min, respectively). In 
summary, faster clearance of fetuin-A containing CPPs vs. fetuin-A monomer suggested that 
clearance was greatly enhanced by mineral complex formation of fetuin-A and possibly by 
fetuin-A clustering. 
3.2.2 CPPs Are Taken up by Liver Kupffer Cells 
The CPP clearance from blood should be reflected by their organ accumulation. Figure 21 
illustrates CPP clearance and accumulation in the liver, a major organ of the 
reticuloendothelial system (RES). Figure 21 shows fluorescence micrographs of liver 
sections and localization of fluorescent CPPs in defined cells scattered throughout the liver 
sinusoids (figure 21A-E). Antibody staining showed that CPPs were taken up by F4/80 and 
CD68 positive liver macrophages or Kupffer cells (figure 21F, G), while F4/80-negative liver 
sinusoidal endothelial cells did not accumulate CPPs. CD68 or macrosialin is a 
transmembrane glycoprotein belonging to the lysosomal-associated membrane protein 
(LAMP) family and is expressed specifically by tissue macrophages 276. F4/80 antigen is a 
cell surface glycoprotein expressed on a wide range of mature tissue macrophages including 
Kupffer cells and macrophages in the red pulp of the spleen 209.  
A similar distribution was observed when fluorescent polystyrene beads were injected into 
mice. These beads had a diameter of 170 nm and thus resembled CPP size. Like CPPs 
beads colocalized with F4/80 and CD68 (figure 22). 
 
 
Figure 21: Localization and degradation of labeled CPPs in the liver.  
A-E. The green fluorescence signal of the CPPs in liver sections diminished rapidly from 2 to 180 minutes 
suggesting maximum clearing within 10 min and degradation thereafter. F., G. Immunostaining with macrophage 
specific antibodies CD68 and F4/80 (red) showed colocalization (yellow) with CPPs (green) inside the 
macrophages. H. Decrease in fluorescence of liver sections measured by histomorphometry (black line, n ≥ 4 for 
each time point) as shown in A-E. Shown are the mean values ± SEM. Bars in A-G: 50 µm. 
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Taking fluorescence of Kupffer cells as a proxy of cellular clearance, uptake of fluorescence-
labeled CPPs peaked at two minutes and decreased thereafter (figure 21A-E). Densitometry 
of fluorescence micrographs showed that 55 % of the fluorescent material present 2 minutes 
after injection had disappeared 8 minutes later indicating fast clearance and degradation of 
CPPs in Kupffer cells (figure 21H). The half-life of CPPs in Kupffer cells was 3 minutes. 
Thus, the clearance rate for CPPs was considerably faster than that determined from serum 
disappearance (t1/2 45 min) shown above (see 3.2.1). This may be attributed to the fact that 
CPP preparations also contain monomeric fetuin-A 92 greatly distorting the apparent serum 
clearance rate, but not the CPP accumulation rate in Kupffer cells. 
In accordance to published data asialofetuin monomer was predominantly cleared by 
hepatocytes, not by macrophages (not shown) 121, 274. Fetuin-A monomer was cleared by 
unspecified cells with slow kinetics typical for long circulating plasma proteins like albumin 
(not shown). Of note, quantification of the more or less homogenous fluorescence-signal of 
both monomer types was disturbed by tissue auto-fluorescence of the liver. In summary, no 
cell-type specific accumulation was observed in fetuin-A monomer, whereas a rapid 
macrophage specific uptake and clearance was observed for CPPs. 
 
 
Figure 22. Localization of beads in the liver.  
Beads were injected i.v. into mice and the liver was harvested 30 min thereafter. Shown are different 
magnifications of frozen sections with green fluorescent beads (diameter 170 nm) and cellular antigens detected 
with a secondary antibody labeled in red. Immunostaining with macrophage specific antibodies F4/80 (A, B) and 
CD68 (C, D) showed co-localization (yellow) with beads inside the macrophages. Size bars in A, C 200 µm; B, D 
50 µm. 
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3.2.3 Uptake of CPPs – TEM Analysis 
Next, we determined the fate of CPPs after uptake by liver macrophages. We therefore 
studied transmission electron micrographs of liver samples taken 30 minutes after injection of 
CPPs. Figure 23 shows that CPPs formed electron dense, dark small needle like crystals 
with a size of approximately 60 to 160 nm along the long axis, which were densely packed in 
vesicles in Kupffer cells. These vesicles differed in size (approximately 0.5-2 µm diameter, 
see figure 23C-E) and were surrounded by membranes suggesting endosomal uptake and 
degradation of CPPs. Lysosomes were found next to CPP containing endosomes. 
Eventually, endosomes and lysosomes fused and formed heterolysosomes (see figure 23D-
E). 
 
 
Figure 23. Intracellular localization of CPPs following Kupffer cell endocytosis.  
In bright field transmission electron microscopy (TEM) of liver sections, injected CPPs appeared as electron 
dense, dark, nanosized crystals. A., B. CPPs accumulated in vesicles (B inset of A). In the immediate vicinity of 
the CPP-containing vesicles, lysosomes (Ly) were observed. C. A small vesicle with a well defined double layer 
membrane surrounding a dense package of CPPs is assessable. Generally, all membranes appeared intact and 
therefore no signs of apoptosis or cell stress could be detected by TEM. D. Several CPP-containing vesicles were 
located near to each other, lysosomes were tightly associated with the vesicles. A heterolysosom (HLy) was 
formed by fusion of a CPP-containing vesicle and a lysosome. E., F. Successive magnifications of D showing 
calciumphosphate crystals with a size of about 50 to 150 nm. N: nucleus; Arrowheads: CPP containing vesicles. 
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3.2.4 Organ Distribution of Fetuin-A, Asialofetuin and CPPs 
To quantify the organ distribution of fluorescence-labeled CPPs and monomeric proteins, 
individual perfused organs of mice were analyzed. The amount of intact (high molecular 
weight) and degraded (low molecular weight) labeled fetuin-A was measured in cellular 
extracts by SDS-PAGE and quantified by fluorescence imaging (figure 24). The background 
fluorescence was arbitrarily set to the average fluorescence signal observed in extracts from 
those organs that scored negative by immunofluorescence (figure 25, the background level is 
indicated by dashed lines in each case). Any residual signal in these organs was attributed to 
insufficient blood removal despite organ perfusion.  
 
 
Figure 24. Densitometry of organ extracts.  
Representative analysis of organ extracts 30 min after i.v. injection of fluorescence-labeled fetuin-A containing 
CPPs. A. Coomassie staining of organ extracts separated by SDS-PAGE. B. Fluorescence scan revealed 
accumulation of CPPs predominantly in liver and spleen. 10 ng of purified fluorescence-labeled fetuin-A served as 
internal standard (first lane). Intact fetuin-A was detected in high molecular weight bands, degraded fetuin-A was 
detected in two low molecular weight bands. C. Densitometry of fluorescent protein bands. Intact and degraded 
fetuin-A in organ extracts were measured relative to the internal protein standard. In brain no signal for intact 
protein was detected, therefore signals of low molecular bands were set as background and subtracted from all 
other samples. St, standard; L, liver; K, kidney; Mu, muscle tissue; T, thymus; H, heart; Lu, lung; P, pancreas; S, 
spleen; A, aorta; G, gonads; Sk, skin; Br, brain; Bm, bone marrow; B, bone. 
 
Fetuin-A monomer accumulated to 1.5-fold background level in liver, kidney and bone 
marrow (figure 25A) suggesting that these organs may be involved in clearance, excretion 
and deposition of monomeric fetuin-A, which is highly enriched in bone mineral matrix 
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compared to other serum proteins 19. This slight fluorescence accumulation was not caused 
by free fluorescence dye that might have dissociated from fetuin-A, because injected Alexa-
488 dye was immediately excreted through the kidney and appeared in the urine within 
seconds without any detectable accumulation in organ extracts (not shown).  
The AsF monomer showed a specific accumulation in the liver so that the hepatic content 
was up to 8.6-fold higher than the background (figure 25B). The AsF content in the liver 
peaked at 60 minutes reaching a maximum of 2.75 µg/100 mg fresh organ weight and 
declined thereafter. The second highest signal (up to 2.9-fold over background) was detected 
in kidneys showing mostly degraded asialofetuin. This suggests elimination of AsF protein 
from circulation in the liver and subsequent excretion through the kidney. 
 
 
Figure 25. Organ distribution and kinetics of fluorescence-labeled proteins.  
Fluorescence-labeled proteins were injected i.v. in mice. Mice sacrificed 10, 30, 60 and 180 minutes afterwards 
and organs were harvested. The tissue protein extracts were analyzed by SDS-PAGE and the content of the 
fluorescence-label in the tissues was evaluated by densitometry. The values shown were quantified relative to an 
internal standard of 10 ng labeled fetuin-A co-separated on each gel. The protein content is given as the absolute 
protein amount per 100 mg fresh organ weight. The dotted lines indicate the mean signal of all organs after the 
subtraction of the brain values considered as negative control because of the blood-brain barrier and excluding 
bone because of the considerably lower values. Note the significantly increased levels of labeled protein in the 
liver of AsF monomer and CPP compared to the mean protein content of the other organs as well as the higher 
levels observed in the spleen of CPP injected mice. (At least three animals per group were investigated at each 
time point). 
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Figure 25B shows that the distribution of CPPs differed strongly from fetuin-A monomer. 
Strong fluorescence signals were detected in liver extracts immediately after injection of 
CPPs (figure 25, see also figure 21A-E, H) and decreased continuously between 10 min and 
3 hours. The highest amount was present at 30 minutes post injection and attained 8-fold 
background level. At this time CPP liver content corresponded to 31 % of the total injected 
dose of CPP. A decrease over time was seen for both, the intact as well as the degraded 
portion of CPP associated fetuin-A. A comparable pattern was seen in the spleen revealing 
up to 5-fold increase over background yet lower content than the liver (range 5 - 2.5-fold in 
spleen and 8 - 4.6-fold in liver). The initially high fluorescence continuously decreased at 60 
and 180 min post injection. All other tissues showed comparatively constant fluorescence 
values over time and thus did not contribute to clearance and excretion of CPPs. Fluorescent 
protein content was also consistently low in myocardium, axillary lymph nodes, pancreas, 
gonads and skeletal muscle (all not shown). 
In summary, the quantification of organ extracts showed that CPPs were predominantly 
cleared by liver and spleen. Both organs also degraded CPPs as shown by the initial rapid 
increase and the following steady decline in signal intensity compared to other tissues.  
3.2.5 Marginal Zone Macrophages of the Spleen Clear Protein Mineral Particles 
Besides the specific uptake of CPPs by Kupffer cells of the liver, quantification of organ 
extracts suggested the spleen as the second major organ clearing CPPs from circulation. 
Next to the liver, spleen is a major organ of the reticuloendothelial system involved in 
clearance of particles from circulation. The clearance of fluorescent CPPs in spleen was 
analyzed using fluorescence microscopy. The spleen comprises two compartments, the red 
pulp and the white pulp. The red pulp filters aged erythrocytes, the white pulp has an 
important role in antigen recognition and immune cell maturation. The spleen marginal zone 
separates these two compartments. Figure 26 demonstrates clearly that CPPs accumulated 
within the marginal zone. Cell-type specific markers were employed to determine the cell 
type responsible for CPP clearance in spleen. The spleen harbors several types of 
macrophages, localized in the red pulp or the marginal zone. The white pulp is mostly free of 
macrophages, but contains dendritic cells (DC).  
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Red pulp macrophages were identified by immunostaining using F4/80 antibody (figure 27), 
marginal metallophilic macrophages (MMM) were stained with MOMA-1/sialoadhesin 
antibody (figure 27A, B) and marginal zone macrophages (MZM) were stained with antibody 
against MARCO (macrophage receptor with collagenous structure, a scavenger receptor 
type A) (figure 27E, F) 277. MMM and MZM macrophage populations in the marginal zone are 
separated by a layer of sinus lining cells, which stain positive for the cell adhesion molecule 
MAdCAM-1 (figure 27C, D). MZM are located exclusively in the outer side of the sinus lining 
cell layer of the marginal zone (pointing to the red pulp), the MMM are localized mainly on 
the inner side of the marginal sinus pointing to the white pulp and a fraction of weakly 
MOMA-1 positive cells is also found on the outer side pointing to the red pulp. Figure 26 
shows that CPP (green color) accumulated in the marginal zone, but were absent in white 
pulp and red pulp. The sinus lining cell marker MAdCAM-1 (figure 27C, D) separated a few 
CPPlo/MOMApos macrophages from CPPhi/MARCOpos macrophages (figure 27E, F) 
suggesting that most CPPs were taken up by MARCOpos MZM whereas the contribution of 
MOMA-1pos MMM was clearly lower. The same MARCO-positive cell population was shown 
to take up also fluorescent polystyrene beads of 170 nm diameter (figure 28E, F). In contrast, 
using beads of smaller size (diameter 55 nm) we could not detect a similar distribution in the 
marginal zone (not shown). No specific accumulation of this kind of particle could be 
visualized in vesicles of macrophages as seen with the CPPs or with larger beads. 
 
 
Figure 26. CPPs accumulate in the marginal zone of the spleen. 
Spleen was harvested 30 min after CPP injection. Shown are different stains of spleen sections. A. Dapi, nuclear 
staining and B. Alexa-488 labeled CPPs in green and F4/80 staining of red pulp (rp) macrophages with a 
secondary antibody in red. CPPs accumulated in the marginal zone (m), which confines the white pulp (wp). 
Asterisks indicate white pulp segments. Scale bars 200 µm. 
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Figure 27. Colocalization of CPPs with cell-type specific markers in the marginal zone.  
Spleens were harvested 30 min after CPP injection. Shown are different magnifications of spleen sections with 
Alexa-488 labeled CPPs in green and cell-type specific surface markers detected with a secondary antibody in 
red. CPPs showed partial co-localization (yellow) with the MOMA-1 antigen of the MMM (A, B), no co-localization 
with MAdCAM-1 as a marker for sinus lining cells (C,D), and almost complete colocalization with MARCO-positive 
marginal zone macrophages. WP, indicates white pulp; MZ, marginal zone and RP, red pulp. Scale bars in A, C 
and E: 200 µm, bars in B, D and F: 50 µm. 
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Figure 28. Colocalization of polysytrene beads with cell-type specific markers in the spleen marginal 
zone.  
Beads were injected i.v. into mice and spleens were harvested 30 min thereafter. Shown are different 
magnifications of frozen sections with green fluorescent beads (diameter 170 nm) and cellular antigens detected 
with a secondary antibody labeled in red. The beads showed a similar distribution as the CPPs before: only a 
weak co-localization with the MOMA-1 marker for MMM (A, B), no overlap with MAdCAM-1 as a marker for sinus 
lining cells (C, D) but a strong colocalization with MARCO-positive marginal zone macrophages (E, F). WP, white 
pulp; MZ, marginal zone and RP, red pulp. Scale bars in A, C and E: 200 µm, bars in B, D and F: 50 µm. 
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3.2.6 Deposition of Injected Calciprotein Particles in Lung Tissue 
Occasionally, spotty fluorescent aggregates were noticed in lung tissue. They were detected 
in nearly all samples taken from mice injected with CPPs, but were never seen in lung tissue 
of mice injected with fluorescent fetuin-A (figure 29) or AsF monomer (not shown).  
 
 
Figure 29. CPP accumulation in the lung microvasculature.  
Fluorescent deposits were observed in lung tissue of mice injected with CPPs after a circulation time of 60 
minutes. A: Distribution of green-fluorescent CPPs in lung tissue. B, C: Colocalization studies with the CD68 
specific macrophage antibody revealed no overlap of the CPP signal with alveolar macrophages. Shown are the 
overlays of the DAPI nuclei staining (blue), the green fluorescence of Alexa 488 labeled fetuin-A incorporated in 
the injected CPPs and the red fluorescence of the CD68 staining, respectively. Scale bars: 200 µm (A, B); 50 µm 
(C). 
 
The large size of these fluorescent deposits and their distribution indicated aggregation or 
precipitation of CPPs at predilection sites (figure 29A). Unlike the fluorescence signal of 
CPPs in liver sections (figure 29A), the signal in lung tissue did not decrease significantly 
during the observation period of 3 h (not shown). This points to continued deposition without 
degradation of CPPs in lung tissue. Indeed, immunohistological staining of alveolar 
macrophages showed that there was no colocalization of CPP aggregates with CD68-
positive macrophages (figure 29B, C). The CPP deposits found were often too large to be 
endocytosed by a phagocytic active cell (figure 29A). Furthermore, lung alveolar 
macrophages are specialized to take up antigens from the alveolar space rather than from 
circulation. 
3.2.7 In Vitro Clearance of CPPs by Macrophages 
Liver and spleen are both part of the RES or mononuclear phagocytic system. The RES 
comprises phagocytes that clear endogenous cell debris, fibrin clots and particulate matter 
including colloidal particles and bacteria. Foremost among these phagocytes are Kupffer 
cells in the liver and tissue-resident macrophages in the spleen and stromal tissues 
(histiocytes). The immunohistological staining with macrophage-specific antibodies (figure 
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21, 27) showed that CPPs were cleared by macrophages. To study the clearance in detail 
endocytosis assays using the macrophage-like murine cell line RAW 246.7 were performed.  
 
 
Figure 30. Raw 246.7 cells endocytose CPPs rapidly.  
A. Adherent cells were incubated with fetuin-A monomer or CPPs both containing 0.1 mg/ml fluorescent fetuin-A 
and fluorescence was measured by flow cytometry. Cell count was plotted against cell-associated fluorescence. 
Each curve represents a different incubation time as indicated in the legend, the filled grey curve represents 
untreated cells. B. Uptake of fetuin-A monomer (squares) and CPPs (triangles) demonstrates highly increased 
uptake of CPPs in comparison to monomeric fetuin-A.  
 
Figure 30 shows the results of a typical experiment testing endocytosis of fetuin-A monomer 
and CPPs at 37°C. Uptake was measured by evaluating cell-associated fluorescence using 
flow cytometry. Figure 29A illustrates the flow cytometry results for cell-specific fluorescence 
after incubation with fluorescence-labeled fetuin-A monomer (F-A monomer) or CPPs (F-A 
CPP), respectively. Despite similar amounts of labeled fetuin-A present in both monomer and 
CPP preparations offered to RAW 246.7 cells (figure 30B squares and triangles, 
respectively), much more CPPs than fetuin-A monomer were endocytosed. The cell-
associated fluorescence signal of fetuin-A monomer ranged between 2 – 6% of the signal 
detected for CPPs (p < 0.001 for all time points). These results are in full agreement with the 
in vivo clearance shown in figures 20, 21, 25 and 27 that consistently showed much more 
efficient uptake of fetuin-A containing CPPs than monomeric fetuin-A resulting in 
colocalization of CPPs but not of fetuin-A monomer with macrophages.  
To determine the uptake mechanism for CPPs RAW 246.7 macrophages were pre-incubated 
with different inhibitors of endocytosis (table 8) for 30 min. Pre-incubation of RAW 246.7 
macrophages with cytochalasin D an inhibitor of actin polymerization reduced the uptake of 
CPPs. This effect was most prominent at the highest CPP concentration (0.1 mg/ml). The 
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cell-associated fluorescence of internalized CPPs decreased from 1282 to 253 and 151 
when 20 µM or 40 µM cytochalasin D were added (ns for 20 µM and p < 0.01 for 40 µM, 
figure 31, table 8). Additionally, binding of CPPs to RAW macrophages in the presence of 
Cytochalasin D was studied at 4°C. A decrease in cell-associated fluorescence was 
observed for 0.1 mg/ml CPPs from 184.5 to 93.9 (p < 0.05) and 125.3 (n.s.) for 20 µM or 40 
µM cytochalasin D, respectively. Theoretically, CPP binding should not be dependent on the 
cytoskeleton. Thus, the small effect of cytochalasin D at 4°C may be attributed to residual 
uptake activity of macrophages under these conditions. 
 
 
Figure 31. CPP uptake requires the cytoskeleton.  
Raw macrophages were incubated with CPPs containing 0.01 or 0.1 mg/ml fluorescent labeled fetuin-A, 
respectively, for (A) 60min at 4°C or (B) 10 min at 37°C. Cells were pre-treated with the indicated dosage of 
Cytochalasin D, an inhibitor of actin polymerization, 30 min before addition of CPPs (except controls). Cell-
associated fluorescence was measured by flow cytometry. Cytochalasin D slightly reduced CPP binding to 
macrophages and strongly inhibited the uptake of CPPs. * p < 0.05; ** p < 0.01. 
 
3.2.8 Inhibition of the Spleen Tyrosine Kinase 
The spleen tyrosine kinase (SYK) belongs to the family of non-receptor tyrosine kinases. 
SYK is a crucial mediator in the signal transduction cascade mediated by transmembrane 
proteins containing immunoreceptor tyrosine-based activation motifs (ITAMs). ITAM motifs 
are found associated to a broad range of immunoreceptors 278. The influence of SYK in 
binding and uptake of CPPs was evaluated using Piceatannol a known inhibitor of SYK 279. 
Figures 32A, B show a dose-dependent inhibition of CPP uptake in both RAW macrophages 
and bone marrow derived macrophages (BMMs) by pre-treatment of cells with Piceatannol. 
The CPP uptake was reduced to 19% and 11% of the initial cell-associated fluorescence in 
RAW macrophages and BMMs, respectively, when 100 µM Piceatannol were applied (p < 
0.001). Uptake of fetuin-A monomer was low as described before (see chapter 3.2.7) and not 
affected by Piceatannol treatment. Binding of CPPs, evaluated by incubation of RAW 
macrophages at 4°C was also not affected by Piceatannol treatment (figure 32C).  
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Figure 32. Influence of Piceatannol-treatment on CPP uptake and viability of cells.  
A.-C. BMMs (A) or Raw Macrophages (B, C) were pre-treated with Piceatannol an inhibitor of the spleen tyrosin 
kinase (syk) for 30 min in serum-free medium. Cells were incubated with either fetuin-A monomer or CPPs both 
containing 0.1 mg/ml fluorescent fetuin-A for 10 min at 37°C (uptake, A-C) or for 60 min at 4°C (binding, C). Cell-
specific fluorescence was measured by flow cytometry. D., E. Viability of cells after Piceatannol-treatment was 
evaluated. Adherent cells were incubated with Piceatannol for 30 min. Live/dead staining was performed 1h after 
removal of Piceatannol. Living cells were stained with FDA (green fluorescence), dead cells stained positive for PI 
(red fluorescence). (D) Representative picture of control cells (left) and cells treated with 100 µM Piceatannol 
(right). (E) Quantitative analysis of PI/FDA staining showing increased cell death of Piceatannol-treated cells.      
** p < 0.01.  
 
Piceatannol was used in various studies to inhibit SYK 226, 280, 281. Nevertheless, specificity of 
this inhibitor is questionable, and inhibition of other kinases was also described 281, 282. 
Therefore, the influence of Piceatannol on the uptake of additional ligands including 
acetylated lipoproteins (acLDLs) and polystyrene beads was evaluated. Although uptake of 
acLDL is mediated predominantly by a SYK independent route via scavenger receptors 216, 
endocytosis of acLDL as well as of polystyrene beads was strongly inhibited by Piceatannol 
treatment (data not shown). Therefore, a live/dead staining was performed to test if reduced 
particle uptake was attributed to an effect of Piceatannol on cell viability. To address this 
question viability of Piceatannol-treated cells was evaluated one hour after the treatment. 
Figure 32D shows a representative fluorescence micrograph of untreated cells and cells 
incubated with 100 µM Piceatannol clearly demonstrating increased numbers of dead cells. 
The quantitative analysis shown in figure 31E revealed a doubling in dead cells count at 100 
µM Piceatannol compared to untreated cells (p < 0.01). 
In summary, a severe reduction in CPP endocytosis following Piceatannol treatment was 
observed. However, it remains unclear whether this effect was attributed to specific SYK 
inhibition, to an unspecific inhibition of other kinases involved in signal-transduction or to 
cytotoxicity. 
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3.2.9 Fcγ Receptor Does not Participate in CPP Binding and Uptake 
Even though a high number of dead cells was seen after Piceatannol treatment it could not 
be excluded that SYK may participate in CPP endocytosis as the inhibitory effect of CPP 
uptake overruled the cell mortality. Therefore, Fcγ receptor (FcγR) mediated endocytosis, the 
most prominent SYK-dependent pathway 280 was further studied. Thus, the role of the 
endocytosis pathway used by the classical opsonins, immunoglobulins, as well as by the 
opsonic serum proteins C-reactive protein and serum amyloid P 226, 283 was elucidated. 
Downstream of SYK phosphatidylinositol 3-kinase (PI3K) acts as a key molecule in the signal 
transduction pathway of the FcγR. Inhibition of PI3K was studied in RAW macrophages using 
Ly294002 hydrochloride. Inhibition of PI3K resulted only in a weak reduction of CPP uptake 
at both CPP concentrations tested (figure 33A). In addition, the role of FcγR in CPP 
endocytosis was studied in BMMs from FcγR deficient mice in comparison to wildtype BMMs. 
Cells were incubated with CPPs at 4 °C or 37 °C to study binding and endocytosis, 
respectively. Figures 33B, C show that neither binding nor endocytosis of CPPs was affected 
by FcγR deficiency.  
In summary, it could be shown that CPP uptake was not mediated by FcγR. Furthermore, a 
participation of PI3K-dependent pathways was excluded. 
 
 
Figure 33. Fcγ receptor does not participate in CPP binding and uptake.  
A. Adherent Raw macrophages were pre-treated with Ly294002, an inhibitor of the phosphoinositol-3-kinase, for 
30 min in serum-free medium. After that, cells were incubated with CPPs containing 0.01 mg/ml or 0.1 mg/ml 
fluorescent fetuin-A, respectively, for 10 min at 37°C. Cell-specific fluorescence was measured by flow cytometry. 
CPP uptake was slightly diminished at the highest inhibitor concentration. ** p < 0.01. B,C. Bone marrow derived 
macrophages of wildtype (WT) FcγR- deficient mice were studied. B. Binding assay: Cells were seeded (500,000 
cells per sample) and incubated on ice for 45 minutes with CPPs. Cell-associated fluorescence was measured by 
flow cytometry. C. Adherent cells (250,000 cells per sample) were incubated at 37°C for 10 minutes with 0.01 
mg/ml or 0.1 mg/ml CPPs. Cell-associated fluorescence was measured by flow cytometry. FcγR deficiency did not 
influence CPP binding and uptake. 
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Table 8. Summary of CPP binding- and phagocytosis assays.  
Binding or uptake of fluorescently labeled CPPs (values in brackets refer to CPPs pre-incubated with mouse 
serum) was analyzed using flow cytometry. Median fluorescence of macrophages was compared to untreated or 
wildtype control cells with two way ANOVA statistics. Each comparison was repeated at least three times. ↓ 
reduced binding/uptake of CPPs; ↑ enhanced binding/uptake of CPPs; = no significant change in binding/uptake 
of CPPs; * only one inhibitor dose tested; n.d. not determined. 
 
3.2.10 Scavenger Receptor-A is Involved in CPP Clearance 
It was stated that CPPs resemble lipoprotein particles in many ways 55. Therefore, the role of 
scavenger receptors a growing family of receptors known for scavenging modified forms of 
LDL 216 was studied. First, polyinosinic acid (Poly-I) a well-known ligand of these receptors 
was used as competitive ligand. Indeed, CPP uptake by RAW macrophages was inhibited 
when cells were pre-incubated with Poly-I (figure 34D). The cell-associated fluorescence was 
reduced from 172 to 124 (p < 0.01) and 100 (p < 0.001) when macrophages were pre-
incubated with 2 ng/µl or 10 ng/µl Poly-I, respectively (figure 34D). These results confirmed a 
major role of scavenger receptors in the uptake of CPPs. Here SR-AI/II and the class B 
scavenger receptor CD36 were studied further. BMMs were prepared from CD36 and SR-
AI/II knock-out mice to investigate the role of these receptors in CPP endocytosis. Figure 
34A shows CPP uptake in WT (green) and SR-AI/II KO macrophages (pink). Indeed, 
wildtype macrophages showed higher uptake of fluorescence-labeled CPPs than 
macrophages from the SR-AI/II deficient mice. The cell-specific fluorescence was reduced in 
SR-AI/II deficient macrophages at all examined CPP concentrations and ranged from 57% to 
73% of the fluorescence signal detected in wildtype macrophages (p < 0.01 for all CPP 
concentrations tested). To mimic in vivo uptake we pre-incubated CPPs with mouse serum 
before addition to cells. Using this approach, the role of additional serum proteins which may 
 binding uptake 
KO BMM:   
C57BL/6 SR-A KO (n=3) ↓ p < 0.001 ↓ p < 0.001 (↓ p < 0.001) 
C57/BL6 SR-A/MARCO KO (n=3) ↓ p < 0.001 n.d. 
C57BL/6 CD36 KO (n=2) = n.d. 
C57BL/6 Fcγ KO (n=3) = = 
C57BL/6 AnnexinA5 KO (n=2) n.d. = 
C57BL/6 AnnexinA6 KO (n=2) n.d. = 
C57BL/6 Dectin KO (n=2) n.d. = 
C57BL/6 Galectin 1 KO (n=2) n.d. = 
C57BL/6 Galectin 3 KO (n=2) n.d. = 
   
Inhibitors Raw Mφ:   
Cytochalasin D (20µM, 40 µM) = ↓ p < 0.01 
Piceatannol (10-100 µM) ↓ p < 0.05* ↓ p < 0.001 (↓ p < 0.001*) 
Ly294002 (10-100 µM) n.d. = 
Poly-I (2-40 ng/µl) n.d. ↓ p < 0.001 (↓ p < 0.001) 
   
Competition BMM:   
acLDL (n=3) ↓ p < 0.01 n.d. 
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adhere to CPPs and consequently may influence their uptake, was examined. In fact, 
studying SR-AI/II-KO BMMs compared to wildtype BMMs the difference in CPP uptake was 
even more pronounced when CPPs were pre-incubated with mouse serum (figure 34B). 
Here the fluorescence signal was reduced to 44-49% (p < 0.001 for all CPP concentrations 
tested). Remarkably, CPP uptake in SR-AI/II deficient BMMs was as low as fetuin-A 
monomer uptake (dashed line figure 34B).  
The effect of serum pre-treatment on endocytosis in RAW macrophages incubated with Poly-
I was in agreement with these results. While 10 ng/µl Poly-I reduced endocytosis of uncoated 
CPPs to 52%, uptake of CPPs pre-incubated with serum was reduced to 37%, 32% and 
29%, respectively employing mouse, human or fetal calf serum (figure 34D). Remarkably, 
endocytosis of serum-coated CPPs per se was also reduced in comparison to uncoated 
CPPs (figure 34D).  
In addition to uptake CPP binding to cells was investigated. In agreement with the results 
from endocytosis assays SR-AI/II deficient BMMs showed diminished CPP binding, the 
fluorescence signal was reduced to 63-78% compared to wildtype BMMs (p < 0.05 for 0.05 
mg/ml and 0.175 mg/ml CPPs). The difference in binding was less pronounced than the 
difference in uptake. This may be explained by the general tendency of CPPs to adhere to 
the cell membrane, as CPPs also bound to various cell lines including non-professional 
phagocytic cells, HeLa, Cos1 and Cos7 cells (data not shown). Of note, under the same 
conditions only negligible binding of fetuin-A monomer was observed in all four macrophage 
types (dashed lines in figure 34C). 
To support the role of SR-AI/II in CPP binding we conducted a competitive binding assay and 
incubated wildtype BMMs with CPPs in the presence or absence of acetylated low-density 
lipoprotein particles (acLDL), a known ligand of SR-AI/II. Figure 35 shows that binding of 
CPPs to macrophages was decreased in the presence of acLDL. The observed cell-
associated fluorescence was diminished to 43-71% dependent on CPP concentrations 
studied (p < 0.001). 
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Figure 34. Scavenger receptors are involved in binding and uptake of CPPs.  
A-C. BMMs of WT and SR-A KO mice were studied. A, B. Uptake assay: Adherent cells were incubated at 37 °C 
for 10 minutes with CPPs (A) or with fetuin-A monomer or with CPPs pre-treated with serum (B). Cell-associated 
fluorescence was measured by flow cytometry. Uptake of uncoated CPPs and serum-coated CPPs was 
concentration dependent and saturable. SR-A KO BMM uptake of CPPs was reduced (p < 0.001). Uptake of 
serum pre-treated fetuin-A monomer was low and did not show any difference between WT and KO. Remarkably 
SR-A KO macrophage uptake of serum pre-treated CPPs was as low as uptake of fetuin-A monomer. C. Binding 
assay: Cells were seeded and incubated on ice for 45 minutes with CPPs or fetuin-A monomer ranging from 0.01 
to 0.175 mg/ml fetuin-A contained in the medium. Cell-associated fluorescence was measured by flow cytometry. 
The binding of CPPs was concentration dependent saturable. Macrophages from SR-A KO mice showed reduced 
binding compared to wildtype (p < 0.001). Binding of fetuin-A monomer to macrophages of all cell sources was 
minimal. D. Adherent raw macrophages were incubated with CPPs or CPPs pre-incubated with serum in a 
concentration of 0.1 mg/ml fluorescent labeled fetuin-A for 10 minutes. Cells were treated with the SR-A ligand 
polyinosinic acid (Poly-I) 30 min before addition of CPPs. Cell-associated fluorescence was measured by flow 
cytometry. Poly-I dose-dependently reduced CPP uptake. Serum absorption to CPPs slightly diminished the 
overall uptake of CPPs, yet caused an even greater inhibition of uptake by Poly-I. ** p < 0.01; *** p < 0.001 
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Figure 35. Competitive binding of CPPs and acetylated LDL.  
Bone marrow derived macrophages from wildtype mice were seeded and incubated on ice for 45 minutes with 
CPPs in the presence or absence of 10 µg/ml acetylated LDL (acLDL). Cell-associated fluorescence was 
measured by flow cytometry. Added acLDL decreased CPP binding at all concentrations of fetuin-A. *** p < 0.001 
 
While SR-AI/II was essential for CPP binding and endocytosis, the acLDL receptor CD36 284, 
had no impact on CPP binding. Binding of CPPs to CD36 deficient BMMs was at the same 
level as to wildtype BMMs (data not shown, table 8). Although endocytosis of CPPs particles 
was strongly decreased in SR-AI/II deficient BMMs, a small proportion of CPPs was still 
taken up. Thus, other receptors may contribute to CPP uptake. Annexins 2, 5, and 6 have 
been reported to mediate fetuin-A endocytosis 123, 285, apoptotic cell clearance 252 and 
enhanced lipoprotein particle endocytosis 253, respectively. However, the endocytosis of 
CPPs either in the absence or the presence of serum was not affected by annexin A5 or 
annexin A6 deficiency (figure 36B, C).  
Finally, the influence of the C-type lectin dectin-1 on CPP endocytosis was studied. Dectin-1 
is involved in antifungal immunity and recognizes β-glucan as well as unidentified bacterial 
and endogenous ligands 254. Importantly, dectin-1 signaling includes SYK 278. Since a 
contribution of SYK in CPP endocytosis could not be excluded (see chapter 3.2.8), SYK-
dependent receptors, e.g. dectin-1 may be critically involved in CPP uptake. This possibility 
was studied using the well established endocytosis assay comparing BMMs from KO mice 
with wildtype BMMs. Figure 36A shows that dectin-1 deficiency had no influence on CPP 
uptake.  
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Figure 36. CPP uptake in Dectin- Annexin A5- and Annexin A6- deficient macrophages.  
Bone marrow derived macrophages of wildtype (WT) and Dectin- (A), Annexin A5-(B) and Annexin A6- (C) 
deficient mice were studied. Adherent cells were incubated at 37°C for 10 minutes with 0.1 mg/ml CPPs or fetuin-
A monomer with or without serum pre-treatment (see legend). Cell-associated fluorescence was measured by 
flow cytometry. Observed fluorescence was dependent on the ligand presented but none of the studied receptor 
deficiencies (KO) caused reduced CPP uptake. 
 
In summary, the results suggest that CPPs are bound and taken up by macrophages via 
receptor-mediated endocytosis and that tissue macrophages such as marginal zone 
macrophages in the spleen and Kupffer cells in the liver participate in this uptake. The uptake 
mechanism is restricted to the fetuin-A containing CPPs, because fetuin-A monomer 
circulates much longer in vivo and distributes differently in the body when compared to 
CPPs. Binding and uptake of CPPs by macrophages is predominantly mediated by SR-AI/II 
while CD36, Fcγ, dectin-1, annexin A5 or annexin A6 are not involved. 
3.2.11 Does a Galectin-Fetuin Interaction Influence CPP Uptake? 
The galectin family of proteins shares an affinity for β-galactosides. In addition, all galectins 
contain a homologous carbohydrate recognition domain (CRD) 286. Various functions of 
galectins have been described in immune cells 287. In macrophages, it was shown that 
galectin-1 inhibited phagocytosis via FcγR 255 while galectin-3 was effective in enhancing 
clearance of apoptotic neutrophils 256. To elucidate the role of these galectins in CPP uptake, 
CPP endocytosis was studied in galectin-1 and galectin-3 deficient BMMs in comparison to 
wildtype BMMs. Since a lipopolysaccharide (LPS)-galectin interaction was reported in 
particular for galectin-3 288, the influence of LPS stimulation was examined as well. Figure 37 
shows that neither galectin-1 nor galectin-3 deficiency affected endocytosis of uncoated or 
serum-coated CPPs or fetuin-A monomer. Even following LPS stimulation no differences 
among galectin genotypes were observed (figure 37B).  
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Figure 37. Does a galectin – fetuin-A interaction influence CPP uptake?  
Bone marrow derived macrophages of wildtype (WT), Galectin 1 and Galectin 3 deficient mice were studied. Cells 
were seeded and incubated in presence of 1 µg/ml LPS (except controls), after 24h 0.1 mg/ml CPPs or fetuin-A 
monomer (serum-coated or serum-free, as indicated) were added and cells were incubated for 10 minutes at 
37°C. Cell-associated fluorescence was measured by flow cytometry. LPS treatment increased the uptake of 
serum-free CPPs (p < 0.05) but not of the other ligands, the galectin genotype had no influence on CPP uptake. 
 
Thus, for the first time it could be shown that fetuin-A stabilized calciprotein particles, CPPs 
were removed from circulation fast and efficient in vivo. Cells of the reticuloendothelial 
system, namely hepatic Kupffer cells and splenic marginal zone macrophages contributed to 
the clearance of CPPs but not of fetuin-A monomer. It could be shown that macrophage 
uptake of CPP is receptor mediated and that in particular scavenger receptor AI/II is 
essential for CPP endocytosis. 
 
3.3 Prevention of Ectopic Calcification in B6 Fetuin-A Deficient Mice 
While fetuin-A deficiency combined with DBA/2 (D2) genetic background led to severe soft 
tissue calcification (see 3.1), C57BL/6 (B6) fetuin-A deficient mice were resistant to 
spontaneous ectopic calcification. In this part of the thesis, mechanisms involved in the 
prevention of ectopic calcification in resistant B6 mice were studied.  
3.3.1 Gene Expression Analysis 
To identify putative candidate genes involved in the inhibition of dystrophic calcification in 
fetuin-A deficient B6 mice, differential gene expression in liver and kidney of fetuin-A 
deficient and wildtype mice was studied. The genome wide expression pattern of non-
calcifying B6 mice and calcifying D2 mice were analyzed by comparative genomic and 
bioinformatics tools to identify compensatory genes. Gene expression in kidney was 
evaluated to identify local changes in gene expression induced by calcification, while gene 
expression in liver was examined to identify systemic changes in gene expression induced 
by calcification. 
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3.3.1.1 Gene Expression Profile of Kidney of B6 Fetuin-A Deficient Mice 
Gene expression profiles of kidneys were examined in 5-week-old B6 fetuin-A deficient and 
wildtype mice using genome wide gene expression microarrays. The quality of microarrays 
was evaluated using the ArrayQualityMetrics package 241 and Bioconductor software 239. 
Exemplary results from the quality analysis are illustrated in figure 38.  
 
 
 
Figure 38. Quality assessment of B6 kidney microarrays. 
Quality of microarrays was assessed using arrayQualityMetrics package under bioconductor. A: Boxplot 
demonstration of array intensity distribution. Each box corresponds to one array. The plot summarizes the 
distribution of probe intensities (log2 intensities are plotted on the y-axis) across all arrays. Sizes of boxes were in 
the same range, whereas the comparison of medians revealed fluctuation between arrays. B: Density plot 
illustrates the density of a given intensity within an array; as expected a comparable pattern was found for all 
arrays. C: Affymetrix quality control (QC) stats report. The percentages of “present” calls are given for each array 
in the left row, upper number, the lower numbers give the average background value for the corresponding 
arrays. The number of present calls was within the same range for all arrays. The background value confirmed 
the fluctuations seen in A. The relation between 3’ probe sets and 5’ probe sets of the control genes β-actin 
(triangles) and GAPDH (circles) was inside the recommended threshold (light blue box) for all arrays. D: Heatmap 
representation of the distance between arrays. The false color heatmap depicts the mean absolute distance of the 
M-values for each pair of arrays, with M = log2(intensity1) - log2(intensity2), where intensity1 is the intensity of the 
array studied and intensity2 is the intensity of a "pseudo"-array, which has the median value of all arrays. This plot 
confirmed the variability between arrays. Note that arrays ko1-3 and wt4-6 correspond to female mice, arrays ko4-
6 and wt1-3 correspond to male mice. 
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The mean intensity of arrays showed slight fluctuations, but no outlier was detected (figure 
38A-B). This could be confirmed via the Affymetrix quality control report (figure 38C) 
including the measurement of the relation between 3’ probe sets and 5’ probe sets of the 
control genes β-actin and GAPDH. The low amount of variation in mean intensities likewise 
suggested a good method reproducibility (figure 38D). Therefore, all arrays were included in 
the analysis of differential expression of WT and KO mice. The gene expression patterns are 
represented in a Volcano plot (figure 39). Each probe set is depicted as one dot according to 
its p-value and expression ratio between WT and KO mice. The most interesting candidate 
genes have the lowest p-value (red label) and the highest log-ratio (blue label). They are 
found in the upper right and upper left corner of the plot. Only few genes were found in these 
regions. In total, 74 probe sets (supplemental table 3) were significantly differentially 
regulated (probe sets with a p-value < 0.05 after multiple testing correction were considered 
significant). 
 
 
Figure 39. Gene expression in kidney of B6 wildtype and knockout mice. 
Volcano plot demonstration of gene expression in kidney. Examined mice had B6 genetic background and were 
5-week-old. Differential expression between fetuin-A deficient and wildtype mice is shown as log-ratio on the x-
axis, negative values represent higher expression in KO mice, positive values represent higher expression in 
wildtype mice. The y-axis encodes the probability for differential regulation calculated by Bayesian statistics in the 
Limma package under Bioconductor. Each dot denotes a probe set, probe sets with highest probability score are 
depicted in blue and probe sets with highest log-ratio are depicted in red, marked probe sets are labeled with the 
appropriate gene name. 
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Table 9. Differential expression in kidney of B6 fetuin-A deficient mice.  
probe set symbol p-value log-ratio 
upregulation    
D site albumin promoter binding protein Dbp < 0.001 -3.169 
cytochrome P450, family 24, subfamily a, polypeptide 1 Cyp24a1 0.003 -2.987 
D site albumin promoter binding protein Dbp < 0.001 -2.890 
RIKEN cDNA 4933439C20 gene 4933439C20Rik 0.001 -2.366 
RIKEN cDNA 4933439C20 gene 4933439C20Rik < 0.001 -2.010 
    
downregulation    
aldo-keto reductase family 1, member C14 Akr1c14 < 0.001 2.928 
aldo-keto reductase family 1, member C18 Akr1c18 0.001 2.519 
alpha-2-HS-glycoprotein Ahsg < 0.001 2.466 
lymphocyte antigen 6 complex, locus F Ly6f < 0.001 2.387 
RIKEN cDNA 9130221J18 gene 9130221J18Rik 0.001 2.017 
The table shows probe sets, which were significant (p-value < 0.05) differentially expressed in kidney dissected 
from 5-week-old B6 wildtype (n=4) and fetuin-A deficient mice (n=6). Bayesian statistic was used for calculation of 
probabilities (p-value) and log-ratio, negative log-ratio encodes upregulation of the particular probe-set in fetuin-A 
deficient mice, positive values denote downregulation. The table shows most highly differentially regulated genes 
with a log-ratio above 2. Note that gene names are given for each probe set, double entries may occur in case of 
genes which are represented by several probe sets encoding different regions or splice variants of the gene. 
 
 
Differentially regulated probe sets with a fold change above 4 (log-ratio > 2) are summarized 
in table 9. Five probe sets matching these criteria were differentially upregulated. They 
correspond to the genes D site albumin promoter binding protein (Dbp), cytochrome P450, 
family 24, subfamily a, polypeptide 1 (Cyp24a1) and the RIKEN cDNA 4933439C20 gene 
(4933439C20Rik). Dbp, a transcription factor under circadian control 289, was represented by 
two probe sets showing 9- and 7.4-fold upregulation. Cyp24a1, encoding the 25-
hydroxyvitamin D-24-hydroxylase enzyme (24-OHase), was 7.9-fold increased in KO mice. 
24-OHase is responsible for the catabolic breakdown of 1,25-dihydroxyvitamin D, the active 
form of vitamin D 290. Further highly upregulated probe sets were the two probe sets 
corresponding to the transcribed sequence 4933439C20Rik showing 5.2- and 4-fold 
upregulation, respectively. Five probe sets were strongly downregulated (table 9, log-ratio > 
2). Aldo-keto reductase family 1, member C14 was 7.6-fold decreased and expression of 
aldo-keto reductase family 1, member C18 was 5.7-fold reduced in fetuin-A deficient mice. 
Both enzymes belong to the family of hydroxysteroid dehydrogenases 291. Fetuin-A 
deficiency could be detected in that the Ahsg gene was 5.5-fold downregulated. Further 
decreased probe sets were lymphocyte antigen 6 complex, locus F, showing 5.2-fold 
downregulation and the transcribed sequence RIKEN cDNA 9130221J18 gene showing 4.1-
fold downregulation. 
The following part of the thesis focused on the identification of genes having a compensatory 
function and thus contributing to prevention of ectopic mineralization. To detect candidate 
genes, differentially expressed genes in fetuin-A deficient B6 mice were chosen. Expression 
of these candidates was analyzed in calcifying D2 fetuin-A deficient mice as well, and genes 
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showing differential regulation (log-ratio > 1) were excluded. Exclusion was decided based 
on the fact that these genes obviously were not efficient in inhibition of pathological 
calcification as severe soft tissue mineralization occurred in D2 fetuin-A deficient mice. The 
resulting candidates are illustrated in a heatmap (figure 40).  
 
 
Figure 40. Heatmap representation of differentially expressed genes in kidney of B6 mice.  
Differential expression in kidneys of 5-week-old fetuin-A deficient and wildtype mice was calculated using 
Bayesian statistics under Bioconductor. Probe sets shown were significantly (p < 0.05) differentially expressed in 
B6 mice; probe sets, which were altered in kidneys of D2 mice (log-ratio > 1) were excluded. Each column 
corresponds to one DNA array; each row represents a probe set. The color encodes the expression intensity of 
individual probe sets, ranging from highest expression values in dark red, medium expression values in white to 
lowest expression values in dark blue. Probe sets, which were altered in B6 knockout animals in comparison to all 
other genotypes are encircled (black boxes) as candidate genes for a compensatory effect. Hierarchical clustering 
of arrays according to the shown subset of genes revealed that B6 genotypes were differentiated by this subset 
while D2 genoytpes were partially unassigned. 
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Expression values in B6 fetuin-A deficient and wildtype mice as well as in mice with D2 
genetic background are color-coded, lowest expression values are depicted in dark blue, 
medium expression values in white and highest expression values in dark red. The arrays 
were assigned to columns according to a hierarchical clustering algorithm of this subset of 
genes. Assignment of arrays matched the fetuin-A genotype in the B6 samples, whereas D2 
arrays clustered only partially according to the Ahsg genotype. This finding confirmed the 
specific importance of this gene subset in fetuin-A deficient B6 mice but not in D2 mice.  
Seven candidate probe sets could be identified using this heatmap representation. These 
candidates were of special interest because they showed (i) high expression values in B6 
fetuin-A deficient mice along with low expression values in B6 and D2 wildtype and in D2 
fetuin-A deficient mice or (ii) they showed remarkably low expression values in B6 fetuin-A 
deficient mice and high expression values in all other genotypes. Probe sets with high 
expression values encode for 4933439C20Rik. Probe sets showing low expression in B6 
fetuin-A deficient mice correspond to dipeptidyltransferase 4 (Dpp4), glycosyltransferase 25 
domain containing 2 (Glt25d2) and the transcribed sequence RIKEN cDNA 1700112E06 
gene (1700112E06Rik). It seems unlikely that a compensatory mechanism based on 
downregulation of genes prevented ectopic mineralization in B6 fetuin-A deficient mice. If 
such a mechanism existed the candidate gene would be inhibited in non-calcifying wildtype 
mice. Therefore, it was assumed that prevention of calcification in B6 fetuin-A deficient mice 
might be due to compensatory upregulation of candidate genes. Thus, the expression profile 
and function of the uniquely upregulated probe sets corresponding to 4933439C20Rik was 
further studied (see chapter 3.3.1.3).  
3.3.1.2 Gene Expression Profile in Liver of B6 Fetuin-A Deficient Mice 
Gene expression profile of liver was examined in 5-week-old B6 Ahsg -/- and Ahsg +/+ mice 
using genome wide gene expression microarrays. The quality of microarrays was evaluated 
using the ArrayQualityMetrics package 241 under Bioconductor 239. Exemplary results from the 
quality analysis are illustrated in figure 41. The mean intensity of arrays showed slight 
fluctuations (figure 41A-B). No outlier could be identified, which could be confirmed by the 
Affymetrix quality control report (figure 41C) including the measurement of the relation 
between 3’ probe sets and 5’ probe sets of the control genes β-actin and GAPDH. Last not 
least the distance in mean intensities between arrays was evaluated showing again that only 
little variability occurred (figure 41D). Therefore, all arrays were included in the analysis of 
differential expression among WT and KO mice. The gene expression pattern is illustrated in 
a Volcano plot (figure 42). Each probe set is depicted as a single dot according to its p-value 
and the ratio between WT and KO mice. The most interesting candidates have the lowest p-
values (red label) and the highest log-ratios (blue label). They can be found in the upper right 
and upper left corner of the plot. Only few genes were found in these regions.  
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Figure 41. Quality assessment of B6 liver microarrays. 
Quality of microarrays was assessed using ArrayQualityMetrics package under Bioconductor. A: Boxplot 
demonstration of array intensity distribution. Each box corresponds to one array. The plot summarizes the 
distribution of probe intensities (log2 intensities are plotted on the y-axis) across all arrays. Sizes of boxes were in 
the same range, comparison of medians revealed slight variations between arrays. B: Density plot illustrates the 
density of a given intensity within an array; as expected a comparable pattern was found for all arrays. C: 
Affymetrix quality control (QC) stats report. The number of present calls (left row, upper number) was within the 
same range for all arrays. The background value (left row, lower numbers) confirmed slight fluctuations as seen in 
A. The relation between 3’ probe sets and 5’ probe sets of the control genes β-actin (triangles) and GAPDH 
(circles) was inside the recommended threshold (light blue box) for all arrays. D: Heatmap representation of 
distance between arrays. The false color heatmap depicts the mean absolute distance of M-values for each pair 
of arrays, with M = log2(intensity1) - log2(intensity2), where intensity1 is the intensity of the array studied and 
intensity2 is the intensity of a "pseudo"-array, which has the median values of all arrays. This plot confirmed slight 
variability between arrays. Note that arrays ko1-3 and wt4-6 correspond to female mice, arrays ko4-6 and wt1-3 
correspond to male mice. 
 
In total, 273 probe sets (supplemental table 4) were significantly differentially regulated 
(probe sets with a p-value < 0.05 after multiple testing correction were considered as 
significant). Differentially regulated probe sets with a fold change above 4 (log-ratio >2) are 
summarized in table 10. Two probe sets corresponding to Dbp were highly upregulated with 
a fold change of 28.3 and 12.8, a comparable uregulation of Dbp was already detected in 
kidney (see 3.3.1.1). The non-lysosomal protease cathepsin E, implicated in several 
physiological and pathological processes 292, was 13.6-fold increased in B6 fetuin-A deficient 
mice. Another upregulated probe set was the non-coding H19 fetal liver mRNA with a fold 
change of 7.9. Two probe sets matching period homolog 3 (Per3) were 7.4-fold and 4.2-fold 
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upregulated. Per3 and Dbp are transcription factors under circadian control 293. Renin 1, 
constitutively expressed in the kidney and counter regulating angiotensin, was 4.9-fold 
increased in the liver of B6 fetuin-A deficient mice. Furthermore, regulator of G-protein 
signaling 16 (Rgs 16) showed a 4.2-fold upregulation. Like Per3 and Dbp, Rgs 15 is involved 
in the maintenance of circadian rhythm 294.  
 
 
 
Figure 42. Gene expression in liver of B6 wildtype and knockout mice. 
Volcano plot demonstration of gene expression in liver. Examined mice had B6 genetic background and were 5-
week-old. Differential expression between fetuin-A deficient and wildtype mice is shown as log-ratio on the x-axis, 
negative values represent higher expression in KO mice, positive values represent higher expression in wildtype 
mice. The y-axis encodes the probability for differential regulation calculated by Bayesian statistics in the Limma 
package under Bioconductor. Each dot denotes a probe set, probe sets with highest probability score are 
depicted in blue and probe sets with highest log-ratio are depicted in red, marked probe sets are labeled with the 
appropriate gene name. 
 
The most highly downregulated probe set (fold-change 538.6) represents fetuin-A, which is 
constitutively expressed in the liver. This finding confirmed the knockout of Ahsg. 
Additionally, 3 probe sets matching the serine (or cysteine) peptidase inhibitor, clade A, 
member 4, pseudogene 1 were 7.1-fold, 6.9-fold and 5.7-fold decreased, respectively. 
Downregulation of two probe sets encoding for Dpp4 and showing 5.5-fold and 4.7-fold 
reduction, respectively, resembled the expression pattern in the kidney. Another highly 
downregulated probe set was the transcribed sequence A4630005I04Rik with a fold-change 
of 4.8.  
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Table 10. Differential expression in liver of B6 fetuin-A deficient mice.  
probe set symbol p-value log-ratio 
upregulation    
D site albumin promoter binding protein Dbp < 0.001 -4.823 
cathepsin E Ctse < 0.001 -3.768 
D site albumin promoter binding protein Dbp < 0.001 -3.676 
H19 fetal liver mRNA H19 < 0.001 -2.980 
period homolog 3 (Drosophila) Per3 < 0.001 -2.882 
renin 1 structural Ren1 < 0.001 -2.282 
regulator of G-protein signaling 16 Rgs16 0.005 -2.084 
period homolog 3 (Drosophila) Per3 < 0.001 -2.070 
    
downregulation    
alpha-2-HS-glycoprotein Ahsg < 0.001 9.073 
serine (or cysteine) peptidase inhibitor, clade A, member 4, 
pseudogene 1 Serpina4-ps1 0.005 2.826 
serine (or cysteine) peptidase inhibitor, clade A, member 4, 
pseudogene 1 Serpina4-ps1 0.003 2.787 
serine (or cysteine) peptidase inhibitor, clade A, member 4, 
pseudogene 1 Serpina4-ps1 0.008 2.513 
dipeptidylpeptidase 4 Dpp4 < 0.001 2.454 
RIKEN cDNA A630005I04 gene A630005I04Rik < 0.001 2.254 
dipeptidylpeptidase 4 Dpp4 < 0.001 2.222 
The table shows probe sets, which were significantly (p-value < 0.05) differentially expressed in liver dissected from 
5-week-old B6 wildtype (n=4) and fetuin-A deficient mice (n=6). Bayesian statistic was used for calculation of 
probabilities (p-value) and log-ratio, negative log-ratio encodes upregulation of the particular probe-set in fetuin-A 
deficient mice, positive values denote downregulation. The table shows most highly differentially regulated genes 
with a log-ratio above 2. Note that gene names are given for each probe set, double entries may occur in case of 
genes which are represented by several probe sets encoding different regions or splice variants of the gene. 
 
The most interesting compensatory candidate genes in non-calcifying B6 fetuin-A deficient 
mice should be the ones showing differential expression in B6 Ahsg -/- mice but not in 
calcifying D2 Ahsg -/- mice. Figure 43 shows a heatmap demonstration of the candidate 
genes. The expression values of probe sets are encoded by color. Probe sets with low 
expression value are depicted in dark blue, probe sets with medium expression value are 
depicted in white and high expression is shown in dark red. Assignment of arrays by 
hierarchical clustering showed a pattern reminiscent of kidney arrays (see chapter 3.3.1.1), 
where arrays were clustered according to the fetuin-A genotype in the case of B6 derived 
samples, but not in the case of D2 derived samples. 
The most interesting candidate genes were characterized by their color pattern in the 
heatmap representation and were marked by black boxes. Using this approach, 10 candidate 
probe sets could be identified. Three probe sets matched the transcribed sequence 
4933439C20Rik that were also detected in the kidney. Further candidates were transcribed 
sequence 64307056D22 Rik (two probe sets), response to metastatic cancer 5 (Rmcs5), 
histocompatibility antigen H2-A1, serine peptidase inhibitor, clade A, member 7 (Serpina7) 
and nuclear receptor subfamily 5, group A, member 2 (Nr5a2).  
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Figure 43. Heatmap representation of differentially expressed genes in liver of B6 mice.  
Differential expression in liver of 5-week-old fetuin-A deficient and wildtype mice was calculated using Bayesian 
statistics under Bioconductor. Probe sets shown were significantly (p < 0.05) differentially expressed in B6 mice; 
probe sets, which were altered in kidney of D2 mice (log-ratio > 1), were excluded. Each column corresponds to 
one array; each row represents a probe set. The color encodes the expression intensity of individual probe sets, 
ranging from highest expression values in dark red, medium expression values in white to lowest expression 
values in dark blue. Probe sets, which were altered in B6 knockout animals in comparison to all other genotypes 
are encircled (black boxes) as candidate genes for a compensatory effect. Hierarchical clustering of arrays 
according to the shown subset of genes revealed that B6 genotypes were differentiated by this subset while D2 
genoytpes were nearly randomly distributed. 
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All candidates mentioned before were differentially upregulated in B6 fetuin-A deficient mice, 
while transcribed sequences C730036E19Rik was downregulated. As discussed before, it is 
reasonable to assume that candidate genes for the inhibition of ectopic calcification in B6 
fetuin-A deficient mice are increased not decreased. Thus, 4933439C20Rik was studied 
further as this candidate was detected in both kidney and liver.  
3.3.1.3 Expression Profile of 4933439C20Rik 
The transcribed sequence 4933439C20Rik was differentially upregulated in kidney and liver 
of B6 fetuin-A deficient mice (see chapters 3.3.1.2 and 3.3.1.3), but not in D2 fetuin-A 
deficient mice.  
The transcribed sequence 4933439C20Rik was represented by three probe sets (figures 
44A-C). Two of the probe sets showed an overlap in their sequences (blue label figures 44A, 
B). The probe sets shown in figure 44A and figure 44C were blasted against the NCBI mouse 
genomic and transcript database. The blast of the sequence shown in figure 44A revealed 
consensus with the sequences of phosphatidylserine decarboxylase pseudogene 1 and 
phosphatidylserine decarboxylase pseudogene 2 (figure 44D). The search query covered   
60 % of the phosphatidylserine decarboxylase pseudogene 1 with 96 % identities and 66 % 
of the phosphatidylserine decarboxylase pseudogene 2 with 93 % identities. The blast of the 
probe set shown in figure 43C did not return any hit in the mouse transcript database.  
To confirm the differential regulation of 4933439C20Rik a quantitative PCR was performed. 
The primer sequences are underlined in figures 44A and C. The PCR supported the findings 
of the microarray approach. The two probe sets showed differential upregulation in B6 fetuin-
A deficient mice (figures 44E, F). 
In summary, the comparative microarray approach led to the identification of the transcribed 
sequence 4933439C20Rik as a putative candidate gene for inhibition of calcification in B6 
fetuin-A deficient mice. In liver, further candidates were identified but still need to be verified. 
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Figure 44. Differential expression of 4933439C20Rik.  
A-C. Nucleotide sequences of probe sets corresponding to 4933439C20Rik. The sequence of B is contained in A 
(blue label). D. Blast: The gene sequence of A was searched against the mouse genomic and transcript database 
on NCBI. Two matching transcripts were identified; overlap of hits with the query sequences is demonstrated as 
black box. E-F. Quantitative PCR of the probe set shown in A and C, primer sequences are underlined. Gene 
expression of ribosomal 18s RNA was used as internal correction. Both probe sets were specifically upregulated 
in kidneys of B6 fetuin-A deficient mice but not in D2 fetuin-A deficient mice. * p < 0.05, *** p < 0.001. 
 
3.3.2 Impaired Clearance of Calciprotein-Particles in BMMs Derived from D2 Mice 
Fetuin-A is highly effective in the formation and stabilization of calciprotein-particles (CPPs) 
18, 90-92. In the current thesis, the fate of CPPs in vivo was elucidated (see chapter 3.2) and it 
could be shown that CPP clearance was fast and efficient. Thus, fetuin-A mediated removal 
of mineral debris plays a critical role in prevention of unwanted precipitation of excess 
calcium phosphate and prevention of pathological mineralization. Therefore, effectiveness of 
CPP clearance may contribute to the different calcification phenotypes observed in fetuin-A 
deficient mice on B6 and D2 genetic background. This hypothesis was tested using the well-
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established flow cytometry assays to evaluate CPP binding and endocytosis in bone marrow 
derived macrophages (BMMs) (see chapter 3.2). CPP binding was studied in BMMs derived 
from B6 and D2 fetuin-A deficient and wildtype mice. Binding of CPPs was clearly dependent 
on the mouse strain but not on the fetuin-A genotype (figure 45A).  
 
 
Figure 45. Impaired binding and endocytosis of CPPs in bone marrow macrophages derived from D2 
mice.  
Bone marrow derived macrophages from wildtype (WT) and fetuin-A knockout (KO) mice on B6 and D2 genetic 
background were studied, additionally macrophages derived from the offspring of B6 x D2 fetuin-A KO mice 
(B6D2 KO) breeding were examined. To evaluate binding of CPPs, cells were seeded (500,000 cells per sample) 
and incubated on ice for 45 minutes with 0.05 mg/ml CPPs (A). Endocytosis assays were performed on adherent 
cells (250,000 cells per sample) incubated with indicated concentrations of CPPs with or without serum pre-
treatment at 37°C for 10 minutes (B, C). Scavenger receptor mediated CPP uptake was inhibited by Poly-I pre-
treatment before addition of 0.05 mg/ml CPPs with or without serum pre-treatment (see legend) (C). Cell-
associated fluorescence was measured by flow cytometry. CPP binding and uptake was reduced in BMMs 
derived from D2 and B6D2 KO mice. ** p < 0.01 *** p < 0.001. 
 
 
The cell-associated fluorescence in BMMs derived from B6 mice was 223 and 194, for WT 
and KO cells, respectively in comparison to 66 and 75 in BMMs derived from D2 WT and KO 
mice (WT, p < 0.001 and KO, p < 0.01). Likewise, endocytosis of CPPs was diminished in D2 
BMMs compared to B6 BMMs (figure 45B). Uptake of uncoated CPPs was reduced from 37 
to 22 (p < 0.001) and from 48 to 33 (p < 0.001), when macrophages were incubated either 
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with 0.05 mg/ml or 0.1 mg/ml fetuin-A containing CPPs. As observed before (see chapter 
3.2.9) uptake of serum-coated CPPs was less efficient than endocytosis of uncoated CPPs. 
The comparison of endocytosis of serum-coated CPPs between D2 and B6 BMMs revealed 
the same tendency as for uncoated CPPs but was not statistically significant (figure 45B). In 
addition, CPP endocytosis was studied in BMMs derived from F1 hybrid mice, generated 
from B6 and D2 fetuin-A deficient mice (B6D2 KO). CPP uptake in these macrophages 
resembled the endocytosis of D2 BMMs (figure 45B). 
It was shown that CPP uptake is mediated by scavenger receptors (see chapter 3.2.10). 
Thus, the possibility of an impaired CPP uptake in D2 BMMs as a consequence of decreased 
expression or defects of scavenger receptors was tested. However, pre-incubation of cells 
with the scavenger receptor ligand Poly-I inhibited CPP uptake in all types of BMMs to the 
same extent (figure 45C).  
In conclusion, CPP binding and endocytosis was remarkably decreased in BMMs derived 
from D2 mice. Thus, impaired CPP clearance may play a key role in development of severe 
soft tissue calcification in D2 fetuin-a deficient mice. 
Discussion 
85 
4. Discussion 
4.1 The Pathology of Ectopic Calcification in Fetuin-A Deficient Mice 
Sensitivity of DBA/2 (D2) mice to ectopic calcification is well known. Spontaneous myocardial 
calcification 111, 189, 295 and focal calcification in the tongue 190, 191 was observed starting at day 
20-25 in mice. Thereafter a rapid increase in lesion size was noticed. Ultrastructural analysis 
revealed that calcification foci were mostly found in degenerated mitochondria 296, 297. Large 
lesions in the right ventricular surface were surrounded by fibrous tissue 189, 295. Furthermore, 
it was shown that D2 mice are prone to calcification in response to freeze-thaw injury 112 1999. 
The dramatic calcification phenotype of 2 fetuin-A deficient mice was published by Schäfer et 
al in 2003. Severe soft tissue calcification in 7-9 month old mice affected almost every organ, 
although it was most prominent in skin, kidney, myocardium and testis. This dramatic 
calcification was associated with an increased mortality 56.  
Here, ectopic calcification in D2 fetuin-A deficient mice was examined using TEM, 
immunofluorescence staining, gene expression analysis as well as proteomic analysis. In 
particular early stage calcified lesions were studied in order to reveal the mechanisms 
involved in lesion formation in fetuin-A deficient D2 mice.  
The necropsy of a 42-week-old D2 fetuin-A deficient mice (figure 8) was in full agreement 
with the findings from Schäfer et al 56. However, it could be shown for the first time that 
brown adipose tissue is affected by ectopic calcification. The severity of ectopic calcification 
exceeded those lesions found in D2 wildtype mice by far and thus demonstrated the 
importance of fetuin-A as an inhibitor of ectopic calcification.  
4.1.1 Structure of Calcified Lesions 
At D2 fetuin-A deficient mice older than 3-month calcified lesions were visible 
macroscopically. Lesions appeared as transparent to white spherules in most tissues. In the 
heart a large, diffuse calcified area was observed on the surface of the right ventricle. 
Calcification in the myocardium was similar to the findings in D2 wildtype mice 111, 189, 295-298, 
whereas soft tissue calcification in most major organs was unique to fetuin-A deficient D2 
mice. 
TEM of calcified lesions in brown adipose tissue showed a broad spectrum of lesion 
morphologies. Nonetheless, lesions could be classified in three subtypes: lesions with 
concentric rings of alternating low and high electron density (type 1 lesions), diffuse lesions 
within the microvasculature (type 2 lesions) and electron dense lesions (type 3 lesions). 
Despite their diverse morphologies, early-stage lesions were mostly spherical, occasionally 
other shapes were derived from clustering of initially spherical lesions.  
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The laminated structure of calcified lesion was not unique to brown adipose tissue. Often the 
characteristic tree-aging-ring-like structures appeared even in immunohistological staining, 
e.g. in lung, pancreas and testis of D2 fetuin-A deficient mice 258. Spherical mineral 
structures, containing various kinds of tree-aging-ring-like structures, are a common 
phenomenon throughout phylogeny. Ryall presented a panel of TEM pictures from a wide 
variety of mineral granules in her outstanding review about the future of stone research 299. 
She pointed out that a large diversity in shape, size and morphology exists. In his review on 
calcification seen with the electron microscope 300 Ghadially also reported on laminated 
structures. Such morphologies were found in so-called Michaelis-Gutmann bodies, 
associated with Malakoplakia, a rare inflammatory disease affecting the urinary tract, and in 
tumor associated calcification, where laminated structures derived from collagen fiber 
calcification, named Psammoma bodies were found. Moreover, similar structures were found 
for serum granules 94, previously also described as nanobacteria 98 or nanons 96. Thus, at 
least the appearance of type 1 lesions was in agreement with other well-known mineral 
granulations. However, serum granules as well as nanons are much smaller than all lesions 
observed here. All these granules were of nanometer size and rarely exceeded a size of 0.5 
µm whereas type 1 calcified lesions in brown adipose tissue of D2 fetuin-A deficient mice 
ranged between 6 and 9 µm. Nonetheless, not only the structure of calcified lesions but also 
the proteomic content was in part reminiscent of the serum granules described by Young et 
al. 94. This will be discussed in detail in chapter 4.1.4. 
Mechanisms of mineral formation, in particular the nucleation mechanisms involved in 
laminated mineral structure formation are largely unknown. Thus, at this point it was 
unfeasible to draw a conclusion on the mineral formation mechanism of type 1 lesions in D2 
fetuin-A deficient mice. 
Type 2 lesions were identified within the microvasculature as will be discussed in detail in the 
next chapter (4.1.2). However, the structure of these lesions was completely different when 
compared with the highly organized type 1 lesions. The mineral appeared as fibrous 
precipitate and lesions contained organic material with lower electron density. As those 
lesions without a doubt occurred in the lumen of vessels, it is reasonable to assume that 
these distinct regions of low electron density were proteinaceous or of anuclear cellular 
origin, e.g. erythrocytes or platelets. To the best of my knowledge no comparable ectopic 
calcification phenotype has been described so far. The structure of these lesions might be 
determined by (i) the nucleation mechanism and (ii) the environment. However, the TEM 
observation could not reveal any evidence concerning the starting point of mineral 
precipitation. 
The third subtype of lesions identified in brown adipose tissue of D2 fetuin-A deficient mice 
was amorphous; lesions were electron dense and occasionally associated or surrounded by 
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membranes. These lesions did not show an organized structure and resembled the lesions 
identified in the myocardium of D2 wildtype mice 111, 189, 295, 296, 298. It was proposed that these 
lesions develop from mitochondria calcification 296, 297. Electron dense granules within 
degenerating mitochondria are considered precursors of mitochondria calcification 297, 300. 
Here, type 3 lesions were found in tight proximity of mitochondria, but neither electron dense 
granules nor degenerated mitochondria could be observed. However, brown adipose tissue 
is highly effective in generating body heat and thus extremely rich in mitochondria. Thus, it is 
reasonable to assume that type 3 lesions may be a result of mitochondria calcification. In 
fact, it is likely that type 3 lesions as well as similar calcified lesions in the heart of D2 fetuin-
A deficient mice may not be directly related to the fetuin-A deficiency, but to the pre-
disposition of the D2 strain to calcify. It would be of great interest to examine whether type 3 
calcified lesions also occur in D2 wildtype mice. As brown adipose tissue calcification is 
described here for the first time, it is reasonable to assume that brown adipose tissue has not 
been examined in previous studies on D2 mice. 
In conclusion, a broad spectrum of morphologies of calcified lesions has been detected. This 
was on the one hand dependent on the tissue studied, but on the other hand occurred also 
within one type of tissue, e.g. brown adipose tissue, which was analyzed in TEM. Structural 
diversity of calcified lesions is a common observation and was described in various other 
studies 94, 299, 300. It can be assumed that at least partly the different morphologies may be 
attributed to different mechanisms of lesion formation. For instance type 3 lesions in D2 
fetuin-A deficient mice may be related to mitochondrial calcification characteristic of the D2 
genetic background. As type 1 and type 2 lesions were remarkably different in structure as 
well as in terms of localization, it is likely that a different mechanism of lesion formation was 
involved. However, the mechanisms of ectopic calcification in D2 fetuin-A deficient mice, in 
particular the mechanisms of nucleation, remain to be determined.  
4.1.2 Localization of Calcified Lesions 
The structure of calcified lesions in D2 fetuin-A deficient mice was pleomorphic, and so was 
their localization. Colocalization of calcified lesions with either blood vessels or lymphatic 
ducts was examined using double immunofluorescence staining (figure 9). Calcified lesions 
were frequently observed in close proximity with the endothelial marker CD31, but never with 
lymphatic ducts. Calcified blood vessels were clearly identified as microvasculature by their 
small diameter as well as by lack of auto-fluorescence, which is characteristic of elastic fibers 
in larger arteries. However, even though a colocalization of calcified lesions with 
microvessels could be shown in different tissues as well as in different stages of the 
calcification progress, calcified lesions may still develop outside the microvasculature.  
TEM analysis of calcified lesions was performed to overcome the limitations of immuno-
fluorescence staining. Generally it was observed that there is a rapid increase in number and 
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size of calcified lesions once initiation of calcification has started. This was observed for 
spontaneous calcification in D2 wildtype mice 189 as well as for severe soft tissue calcification 
in D2 fetuin-A deficient mice 264. Therefore, brown adipose tissue (BAT) of a 2 week-old D2 
fetuin-A deficient mice was studied, as a pilot study had suggested that calcification in BAT is 
initiated during the first weeks of life.  
Indeed, a large number of calcified lesions was observed in TEM. Type 2 lesions, localized 
within the microvasculature, confirmed the findings from immunofluorescence. This finding 
was also in agreement with the identification of serum proteins bound to calcified lesions 
(see chapter 3.1.5) and this was probably not restricted to type 2 lesions, because the 
lesions employed for proteomic analysis had been dissected macroscopically without 
distinction of vasculature. However, as discussed before calcified lesions were pleomorphic. 
There was no evidence that type 1 or type 3 lesions were located within the 
microvasculature. In fact, one can hypothesize that type 3 lesions, resembling mitochondria 
calcification in their structure (see chapter 4.1.1), were initially always intracellular, within 
brown adipocytes. This was shown by their proximity to lipid vacuoles and intact 
mitochondria in the 2 week-old D2 fetuin-A deficient mice studied. 
In conclusion, it could be shown for the first time, that calcification in D2 fetuin-A deficient 
mice occurred within the microvasculature. Even though it is not clear how nucleation of 
mineral precipitates commences, the occurrence of micrometer-sized lesions within the 
vasculature reflects once again the important role of fetuin-A as a systemic inhibitor of 
ectopic calcification.  
Structure as well as localization of calcified lesions was extremly variable. In addition to the 
extracellular calcification there was also evidence for intracellular calcification, possibly 
derived from calcifying mitochondria. Thus, even though calcification in D2 fetuin-A deficient 
mice appeared macroscopically uniform it might be driven by distinct mechanisms. Finally, 
the analysis of the mechanisms involved in ectopic mineral formation is severely limited in 
that the observation of early-stage lesions is very rare, because calcification progresses 
rapidly once started. High sensitivity in vivo imaging methods in small rodents may help to 
further delineate the underlying mechanisms of polymorphic calcification.  
4.1.3 Gene Expression Analysis 
4.1.3.1 Differential Gene Expression in Adipose Tissue 
Differential gene expression was studied in brown adipose tissue in the kidney pelvis region 
of 6-week-old D2 fetuin-A deficient and wildtype mice. Soft tissue calcification in this tissue 
was detectable from an age of 3 weeks. Thus, 6-week-old mice should have developed early 
stage soft tissue calcification 264. Histological examination of the tissue showed that 
progression of calcification was associated with development of fibrosis 264. Fibrotic tissue 
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remodeling requires an induction of genes involved in tissue reorganization. The current 
microarray analysis identified a total number of 395 differentially regulated genes, most of 
which were upregulated in KO mice. Probing the differentially expressed probe sets against 
the KEGG data base of biological pathways revealed mostly signaling and remodeling 
processes, namely focal adhesion, ECM-receptor interaction, cell cycle regulation, p53 
signaling pathway, cell adhesion molecules and notch signaling pathway. Among the most 
highly upregulated genes were two members of the small proline-rich protein family, Sprr1a 
and Sprr2a. The function of these proteins is currently unknown, but they have been 
associated with various inflammatory diseases including inflammatory skin diseases 260, 
allergic inflammation 261 and fibrosis 262. Pradervand and colleagues demonstrated a stress-
related induction of Sprr1a in cardiomyocytes and a protective effect against ischemic injury 
263. Thus, increased expression of Sprr1a in calcified brown adipose tissue may be 
secondary to the pro-fibrotic stimulus of calcification. In addition a 17.3-fold increase of OPN 
expression was detected in calcifying brown adipose tissue. OPN is known for its calcification 
inhibitory function and was previously detected at calcification sites in uremic B6 fetuin-A 
deficient mice 114, in histology of D2 fetuin-A deficient mice 258, 301 and in calcified human 
coronary arteries 265, 302. Calcification-associated OPN is secreted by macrophages, which 
commonly accumulate at calcified lesions 258. Various functions of OPN have been proposed. 
In ectopic calcification OPN prevented mineral growth and partially dissolved mineral 
deposits. Steitz and colleagues reported that OPN physiologically blocked crystal growth by 
induction of carbonic anhydrase 2 and thus by acidification of the extracellular milieu 168. This 
finding was confirmed in MGP-deficient mice where genetic ablation of OPN further 
enhanced the calcification phenotype 165. OPN accumulation was however not associated 
with reduced levels of calcification in D2 fetuin-A deficient mice. On the contrary, OPN was 
always associated with calcified tissue, but not with calcification-free tissue. Thus, OPN 
expression seemed to be reactive rather than preventive. Recent publications suggested a 
bifunctional role of OPN. While intact phosphorylated OPN is an effective inhibitor of 
mineralization as previously described, a fragment of OPN derived from thrombin cleavage 
was shown to be pro-inflammatory 170 and to promote ectopic mineralization in aortic 
calcification of LDLR deficient mice 171. Beside its role in calcification OPN was described in 
association with a broad spectrum of immunomodulatory functions. Among others it was 
shown to function as a chemotactic stimulus for macrophage infiltration 162, 303. Thus, OPN 
expression in calcified brown adipose tissue may reflect the recruitment of macrophages and 
leukocytes.  
Another highly upregulated gene in calcified brown adipose tissue was MMP12. Dean et al. 
reported that MMP12 effectively cleaved a group of CXC chemokines and may therefore play 
a key role in regulation of active inflammatory responses by terminating the influx of 
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polymorphonuclear leukocytes 304. In calcified lesions of D2 fetuin-A deficient mice an 
increased MMP12 expression may explain the previously described moderate progress of 
inflammation 264. While macrophage accumulation was observed in most cases, 
polymorphonuclear leukocytes were only detected occasionally. Also macrophage 
enrichment was primarily detected in calcifying tissues containing resident macrophages. 
Possibly MMP12 counteracted the chemotactic function of OPN as well as of serum amyloid 
P, another opsonic protein, which was shown to accumulate at calcified lesions of D2 fetuin-
A deficient mice 301. 
In conclusion, gene expression analysis of brown adipose tissue in a state of early soft tissue 
calcification revealed an activation of genes involved in tissue remodeling and inflammation. 
This was in agreement with earlier findings showing a steady progression of calcification in 
D2 fetuin-A deficient mice. In early stages small globular lesions were occasionally covered 
by macrophages, whereas the surrounding tissue appeared completely normal. With 
increasing age of the D2 fetuin-A deficient mice the lesions progressed and fibrotic 
remodeling was observed 264.  
Ectopic calcification was studied in great detail in association with atherosclerosis and 
vascular calcification. Originally vascular calcification was considered to be a passive 
process, mainly regulated by chemical equilibrium of mineral ions. However, the identification 
of matrix vesicles in calcified vasculature 305-307 and the detection of bone-associated proteins 
such as OPN, MGP and BMP2 in human atherosclerotic plaques 265, 308 changed this view. 
The overexpression of several mineralization-associated transcription factors, namely Msx1, 
Msx2 and Cbfa1, was shown in cultured calcifying vascular smooth muscle cells in vitro 176, 
184 as well as in mouse models 176, 179 and calcified human arterial biopsies 177 in vivo. Ever 
since vascular calcification is considered an active biological process including an 
osteochondrocytic transdifferentiation of vascular smooth muscle cells. A similar mechanism 
was suggested for valvular calcification 309, yet the principle of osteogenic differentiation 
remains controversial. Anger and colleagues published a DNA microarray analysis reporting 
the gene expression profile of human calcified aortic valves. In comparison with non-calcified 
control samples they found elevated inflammatory markers but no upregulation of 
osteoblastic markers 310. Recently Villa-Bellosta and colleagues showed that the deposition 
of calcium phosphate was passive and the osteogenic differentiation of VSMCs happened 
after the initial calcification 311. A recent DNA microarray study compared mesenchymal cell 
derived osteoblasts with calcifying VSMCs and likewise showed that CVC predominantly 
retained their VSMC profile and only partially overlapped with the osteoblastic gene 
expression profile 312. The DNA microarray analysis presented here also suggested that 
calcification in fetuin-A deficient mice does not involve osteochondrogenic conversion of 
cells. As discussed before no osteogenic genes were upregulated in these mice. 
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Furthermore, the pathway analysis did not reveal any pathway associated with bone or 
cartilage formation within the significant differentially regulated genes. Thus the underlying 
mechanism of soft tissue calcification in D2 fetuin-A deficient mice may be distinct from the 
one of vascular calcification. 
4.1.3.2 Gene Expression Analysis of Fetuin-A Deficient Kidney 
Differential gene expression in kidneys of 5-week-old D2 fetuin-A deficient and wildtype mice 
was studied to identify genes involved in precipitation of calcium phosphate as well as in 
lesion formation. The analysis revealed only 12 differentially regulated genes. The 
expression of 5 genes was increased in fetuin-A deficient kidneys whereas 7 genes were 
downregulated. The upregulation of angiotensin I converting enzyme (petidyl-dipeptidase) 2 
(Ace2), a key factor of the renin-angiotensin system, may point to alterations in the mineral 
balance of fetuin-A deficient mice. This is in agreement with all previous findings. It was 
shown that fetuin-A is effective in stabilizing calcium phosphate by forming transient soluble 
calciprotein particles 18, 90-92, 313, which enable the clearing of excess calcium phosphate from 
the circulation (see chapter 3.2). Thus, lack of fetuin-A in D2 fetuin-A deficient mice may 
cause changes in the mineral homeostasis, finally leading to progressive soft tissue 
calcification. It was shown that calcified lesions were detectable from an age of 2 weeks in 
most tissues but remarkably later in kidneys (slight calcification was observed in 1-month-old 
mice) 264. Therefore, in the 5-week-old mice analyzed ectopic calcification might have been 
initiated. Nevertheless, none of the differentially regulated genes in kidney was directly 
related to mineralization. Furthermore, no genes involved in tissue remodelling as seen in 
calcified adipose tissue were differentially regulated. This reflected that kidneys of 5-week-
old mice were indeed not yet calcified severly.  
As discussed before, osteochondrocytic transdifferentiation of vascular smooth muscle cells 
was proposed by serveral groups as the underlying mechanism of vascular calcification. 
Some recent publications suggest a passive process that does not primarily involve 
osteochondrocytic transdifferentiation. The absence of any differentially regulated genes 
related to mineralization or osteogenic differentiation in kidney likewise suggests that 
calcification in D2 fetuin-A deficient mice is not osteogenic. Osteochondrogenic gene 
expression may happen at later stages of calcification, but kidneys of 5-week-old D2 fetuin-A 
deficient mice showed neither calcification nor osteochondrogenic cell conversion.  
4.1.3.3 Gene Expression Profile of the Liver 
The liver gene expression in D2 fetuin-A deficient mice was studied for three reasons. First, 
in adult mice fetuin-A is constitutively expressed in the liver. Thus, fetuin-A deficiency may 
cause alterations in the gene expression pattern. Such changes may influence the 
calcification phenotype. In this case they would be exclusively detected in calcifying D2 
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fetuin-A deficient mice, but not in resistant B6 fetuin-A deficient mice. Secondly, it is 
reasonable to assume that lack of fetuin-A, a major plasma protein caused changes in gene 
expression independent of the calcification phenotype. These effects should be detectable 
on both genetic backgrounds. The third reason to study the liver gene expression is the key 
function of liver in metabolism. Massive defects in peripherical organs afflicted by ectopic 
calcification should be reflected in a modified gene expression pattern in the liver.  
In fact genome-wide expression analysis identified 142 significantly differentially regulated 
genes in the liver of D2 fetuin-A deficient mice. Strikingly, three genes of the phase II 
metabolic pathway including the sulfotransferase family members Sult3A1, Sult2a2 and 
Sult1e1 were dramatically upregulated in fetuin-A deficient liver. Remarkably, these genes 
were not upregulated in non-calcifying fetuin-A deficient mice on B6 genetic background (see 
chapter 3.3.2). Thus, increased expression of the sulfotransferases may be related to the 
phenotype of massive soft tissue calcification in D2 fetuin-A deficient mice. The correlation of 
these metabolic changes and ectopic mineralization remains to be clarified.  
Increased expression of the acute-phase reactants 271 and apolipoproteins 314 serum amyloid 
A1 (SAA-1) and serum amyloid A2 (SAA-2) may be caused by inflammatory stimuli. In 5-
week-old D2 fetuin-A deficient mice several organs exhibited calcified lesions, occasionally 
associated with macrophages as well as granulocytes 264. Even though inflammation was 
moderate in calcified D2 fetuin-A deficient mice it is reasonable to assume that a mild acute-
phase response was initiated. Typically the expression of serum amyloid proteins rises up to 
1000-fold during the acute phase of inflammation 271. Here a comparatively slight increase of 
7.4- and 6-fold for SAA-2 and SAA-1, respectively, was observed. The mild if any induction of 
acute phase reactants is underscored by the absence of differential expression of other 
major acute phase reactants like C-reactive protein.  
The most highly upregulated probe sets were invariably identified in D2 fetuin-A deficient 
mice but not in B6 fetuin-A deficient mice. Therefore, the upregulation was likely related to 
the calcification phenotype, even though none of these proteins were directly related to 
mineralization or tissue remodelling.  
As expected fetuin-A was the most highly downregulated gene. Few other probe sets were 
more than 10-fold decreased in D2 fetuin-A deficient mice. Most of these genes could also 
be detected in B6 fetuin-A deficient mice, suggesting that the downregulation was associated 
with gene regulatory effects caused by the knockout of fetuin-A but not by the calcification 
phenotype. 
 
In conclusion, gene expression analysis confirmed that ectopic calcification in D2 fetuin-A 
deficient mice was associated with fibrotic tissue remodelling. Differentially regulated genes 
related to osteochondrogenic mineral formation could be identified neither in fetuin-A 
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deficient kidneys before initiation of calcification nor in calcified adipose tissue nor in liver. 
These findings pointed to dystrophic rather than osteochondrogenic mineralization and lesion 
formation. However, the failure of the gene expression analysis to identify genes related to 
calcification may also be attributed to technical reasons. RNA was extracted from whole 
organ samples. Particularly, kidney and liver are heterogeneous tissues, which may lead to 
large variability between replicates. Furthermore, the number of replicates in the current 
gene expression analysis was low, the wildtype control groups comprised only 3-4 mice. 
Previously Pavlidis and colleagues studied the effect of replication on gene expression 
microarray experiments and came to the conclusion that at least 5 biological replicates are 
needed to obtain stable results 315. Thus, the current microarray approach may not be 
sufficient to identify all alterations in gene expression with high reproducibility. Thus, further 
validation should be sought for any given candidate gene using independent gene 
expression measurements. 
4.1.4 Proteomic Analysis 
Protein content in calcified lesions was studied by comparison of the protein expression in 
intact, calcification-free tissue and in calcified lesions of mice suffering from severe ectopic 
calcification. Using this approach, differentially expressed proteins could be identified. Most 
detected proteins were serum proteins, including serum albumin, apolipoprotein A1 (ApoA1), 
hemoglobin subunit beta-1, fibrinogen beta chain, serum amyloid P (SAP), Ig kappa chain C 
region and complement component 9 (C9). The identification of serum proteins in calcified 
lesions suggests that precipitation of calcium phosphate happened in the presence of serum 
and thus extracellularly. This hypothesis is supported by results of Young and colleagues 
who studied serum granulations derived from human or bovine serum mixed with calcium, 
phosphate or both 93, 94, 316. The granules contained various serum proteins, with serum 
albumin, ApoA1 and hemoglobin fetal subunit beta, as well as components of the 
complement systems comprising the most abundant proteins 94. The striking similarity in 
protein content of serum granules and calcified lesions studied here suggest similar 
mechanisms of mineral formation, preferentially in the presence of serum. An earlier study of 
proteins contained in fetuin-mineral complexes isolated from serum of etidronate-treated rats 
further confirmed this hypothesis. Price et al. detected matrix Gla protein, secreted 
phosphoprotein 24, SAP, prothrombin, platelet factor 4 and occasionally hemoglobin along 
with fetuin-A in fetuin-mineral complexes 89. At this time it is not clear whether the protein 
composition in calcified lesion merely reflected the relative abundance of proteins in the 
given environment as previously discussed by Young et al. 94, or if there was a selective 
enrichment of the identified proteins. In the case of SAP both may be true. SAP was shown 
to have opsonic properties 227 and binds to a broad spectrum of pathogen-related 
substances, e.g. lipopolysaccharide 317. Furthermore, SAP accumulats in atherosclerotic 
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plaques 318, 319. Thus, it is reasonable to assume that SAP accumulation in pathological 
calcification (i) reflects its abundance in serum and (ii) that SAP binds to mineral debris due 
to its opsonic binding capacity.  
The non-serum protein, carbonic anhydrase 3 (Ca3), an intracellular protein, was identified in 
calcified lesions isolated from skin of D2 fetuin-A deficient mice. Carbonic anhydrases 
catalyze the conversion of carbon dioxide and water to bicarbonate and protons. Their main 
function is to maintain the acid/base balance in tissue. Earlier work from our laboratory 
showed that calcified skin lesions of D2 fetuin-A deficient mice contained a mixed mineral of 
calcium phosphate and calcium carbonate liberating copious amounts of carbon dioxide 
when treated with acid. The detection of Ca3 in the skin, but not in other tissues suggests 
that the mixed calcium phosphate/carbonate mineral, which was likewise formed in the skin 
but not in other tissues, might be formed by the local induction of Ca3 in response to lack of 
fetuin-A. Alternatively, Ca3 induction might be an adaptive response following calcification, 
but not leading towards calcification. It is well known that carbonic anhydrases play a critical 
role in bone resorption 320. Carbonic anhydrase 2 deficiency is linked to the development of 
osteopetrosis 321. However, Kim et al showed that Ca3 was dispensable in mice living under 
standard laboratory husbandary conditions 322. Taking all these findings into account, it 
remains unclear whether Ca3 enrichment in calcified lesion was linked to a mineral 
resorption activity, or if it was a result of a disbalance in acid/base homeostasis in the 
environment of calcified lesions. So far there is no evidence for either osteoclast 
accumulation or bone resorption activities at calcified lesions in D2 fetuin-A deficient mice. 
Gene expression analysis as well as histological observation of calcified tissue failed to 
detect such activities. The analysis of osteoclast specific tartrate-resistant acid phosphatase 
(TRAP) should be included in further studies to clarify the role of osteoclasts and bone 
resorption in ectopic calcification in fetuin-A deficient mice. 
Several proteins differentially expressed in calcified lesions could be identified in the current 
proteomic analysis. Nevertheless, further studies on the protein content of ectopic 
calcifications in D2 fetuin-A deficient mice are needed. The comparison of protein patterns in 
tissue extracts was restricted to proteins, which could be stained with Coomassie blue 
protein stain. Moreover, differential expression was hardly detectable in protein-rich tissues, 
e.g. heart. Another limitation of the method used was the extraction protocol; EDTA 
treatment of samples might not be sufficient to detach proteins strongly bound to the 
hydroxyapatite mineral. To overcome this, further studies should adapt extraction procedures 
used for bone and teeth proteins. 
4.1.5 Summary 
It was previously known that D2 fetuin-A deficient mice develop spontaneous soft tissue 
calcification 56. In the current thesis the pathology of ectopic calcification was studied in great 
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detail. For the first time it could be shown that calcification affects brown adipose tissue. 
Ultrastructural analysis of calcified lesions revealed a broad variety in microarchitecture of 
lesions. Two important findings were made. First, calcified lesions could be detected within 
the microvasculature. This was obvious in TEM, in immunofluorescence staining, and was 
further confirmed by the detection of serum proteins as part of the protein matrix of lesions. A 
second subtype of lesions was found intracelluarly in tight proximity to mitochondria, 
probably reflecting mitochondria calcification. Thus, different mechanisms of calcification 
contributed to the severe soft tissue calcification. Gene expression analysis of calcified tissue 
showed that the mineral formation process did not involve an active transdifferentiation 
towards bone or cartilage cells as was found in vascular calcification. Once calcified lesions 
had formed, changes in both local gene expression patterns as well as in systemic gene 
expression were activated. This conclusion is based on the upregulation of several genes 
involved in tissue remodelling in calcified brown adipose tissue, as well as the differential 
expression of several liver specific genes.  
 
4.2 Clearance of Calciprotein Particles 
Soluble colloidal protein-mineral complexes are now considered natural byproducts of 
general mineral homeostasis. They are variously called calciprotein particles (CPPs) in 
analogy to lipoprotein particles 55 or mineralo-protein complexes 94. To prevent local 
deposition of such granules, especially in conditions with excess calcium and phosphate in 
the body, a clearance mechanism is required mediating CPP recycling or disposal by 
dissolution, degradation or storage. It was shown that the plasma protein fetuin-A plays a 
critical role in the formation and stabilization of such protein-mineral complexes 18, 55. 
Accordingly, fetuin-A deficient mice develop widespread ectopic calcification 56. Here 
clearance and disposal of in vitro generated fetuin-A containing CPPs was studied in mice, 
and a receptor responsible for macrophage uptake of CPPs was identified. 
4.2.1 In Vivo Clearance of CPPs 
4.2.1.1 Clearance from Circulation is Fast and Efficient 
Several studies have investigated the clearance of fetuin-A monomer, and especially of its 
desialylated form, asialofetuin. Endocytosis of fetuin-A monomer was found to be mediated 
by annexins expressed on the cell surface 123, 285. Asialofetuin, like many asiologlycoproteins, 
is rapidly cleared from the circulation by the hepatic asialoglycoprotein receptor ASGP-R 121, 
323, 324. To study the role of fetuin-A in the clearance of CPPs, the clearance of fetuin-A 
monomer, its desialylated form asialofetuin, serum albumin and fetuin-A containing CPPs 
were compared in vivo. The asialofetuin monomer was cleared from circulation within 
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minutes confirming the highly efficient ASGP-R mediated endocytosis of this protein (figure 
20). The kinetics observed in vivo demonstrated slow clearance for monomeric albumin (t1/2 
~ 4 h) and fetuin-A (t1/2 ~ 2.5 h), and faster clearance for asialofetuin (t1/2 ~ 43 min.). In the 
case of albumin and fetuin-A monomer most likely a mixture of clearance and tissue 
redistribution/sequestration from blood was observed as albumin and fetuin-A monomer did 
not accumulate in particular organs judged from tissue blots (figure 25) and fluorescent 
tissue sections (figure 21, 27). In contrast, accumulation of asialofetuin monomer was 
detected in liver tissue (not shown) the major site of ASGP-R expression. This finding 
confirmed the well-established activity of the ASGP-R 121 and thus validated the experimental 
approach. Employing CPPs a fast clearance (t1/2 ~ 4 min) in spleen and liver was observed 
(figure 21, 27) pointing to an efficient clearing mechanism. 
4.2.1.2 CPPs are Taken Up by Macrophages 
Immunofluorescence staining revealed that CPPs accumulate in macrophages of the 
reticulo-endothelial system (RES), namely hepatic Kupffer cells and splenic MARCO-positive 
marginal zone macrophages (MZMs) (figures 21, 27). These cells are known to be involved 
in the clearance of aged blood cells 325 and particulate matter 326. In contrast, liver sinusoid 
endothelial cells and hepatocytes, the prime sites of ASGP-R expression, did neither 
accumulate fetuin-A monomer nor fetuin-A containing CPPs (figure 21). Thus the particulate 
form of fetuin-A bound to CPPs invoked a clearance mechanism that overcame the putative 
clearance of fetuin-A monomer and the well established ASGP-R mediated endocytosis of 
asialofetuin-A monomer. An equal tissue distribution was found for polysterene beads in size 
reminiscent to CPPs (figures 22, 28). This finding was in full agreement with an earlier study 
on the biodistribution of polystyrene particles, where particles were found predominantly in 
liver and spleen 221. 
In addition to the CPP accumulation observed in liver and spleen, aggregated forms of CPPs 
were detected in the lung (figure 29). These aggregates clearly exceeded the size of CPPs 
found in Kupffer cells and MZMs and probably were located within the microvasculature. 
Lung capillaries have been considered a predilection sites for microparticulate depositions 
because of their small diameter 327. Accordingly, in D2 fetuin-A deficient mice, where soft 
tissue calcification occurred in the microvasculature to some extend (see chapter 3.1), the 
lung was one of the most calcification-prone organs.  
Tissue distribution of CPPs, CPP aggregates as well as of polystyrene particles suggests 
that particle size may determine the targeting of particles. It was previously shown in beagle 
dogs that organ distribution of microspheres depended on particle size. Whereas 3 µm 
particles were found predominantly in liver and spleen, an increasing size targeted particles 
to the lung 220. Beside organ distribution also the cell type of target tissues may depend on 
particle size. Jansen and colleagues showed that particulate preparations of formaldehyde-
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treated albumin were taken up by Kupffer cells in the liver, while considerably smaller 
monomeric preparations accumulated predominantly in liver endothelial cells 328. 
4.2.2 Identification of a CPP Receptor In Vitro 
4.2.2.1 Receptor Mediated Endocytosis of CPPs but not of Fetuin-A Monomer 
Endocytosis of fetuin-A monomer and CPPs was studied in RAW 246.7 macrophages in vitro 
(figure 30). RAW cell endocytosis of labeled fetuin-A followed linear non-saturable kintics 
suggesting a fluid-phase uptake (pinocytosis) rather than a receptor-mediated uptake. This is 
in full agreement with findings of Chen et al. 123 who showed that uptake of Cy5-labeled 
fetuin-A in vascular smooth muscle cells could not be inhibited by excess unlabeled fetuin-A, 
suggesting fluid phase uptake.  
Compared to pinocytosis of fetuin-A monomer, uptake of a similar amount of fetuin-A 
contained in CPPs by RAW 246.7 macrophages was strongly enhanced. The inhibition of 
uptake by inhibition of actin polymerization with Cytochalsin D suggested that CPP uptake is 
an active process. Furthermore, CPP uptake in BMMs was dose-dependent saturable 
suggesting a receptor-mediated uptake mechanism. In conclusion, the in vitro assays 
collectively confirmed the findings in vivo suggesting that fetuin-A containing CPPs, but not 
monomeric fetuin-A are taken up in a receptor-mediated manner by macrophages.  
4.2.2.2 Scavenger Receptor-A is Involved in CPP Clearance 
Using a cell culture assay, blocking reagents and macrophages from clearance receptor 
deficient mice, it could be shown that macrophage uptake of CPPs is receptor mediated, and 
that in particular scavenger receptor AI/II is essential for CPP endocytosis. This was in 
agreement with a previous study showing that uptake of polystyrene nanospheres, 50 nm in 
size, coated with fetuin-A into cultured rat Kupffer cells could be partially inhibited by 
polyinosinic acid, as well as by anti-class A scavenger receptor antibodies. Moreover, similar 
results were obtained in liver perfusion studies in rats 80. Collectively these results and the in 
vivo clearance presented in this study demonstrate that Kupffer cells and MZMs, both 
expressing SR-AI/II 329, most likely cleared CPPs through SR-AI/II in vivo. 
However, the specific architecture of the RES constituting a mechanical microfilter must 
direct CPP clearance to Kupffer cells and MZM macrophages (see 4.2.1.2), since SR-A 
expression alone is insufficient for CPP clearance. For instance, SR-AI/II positive liver 
endothelial cells 329, 330 failed to take up CPPs (see 4.2.1.2). Similarly, particulate 
preparations of formaldehyde-treated albumin were taken up via scavenger receptors of 
Kupffer cells, but not by endothelial cells 328. Furthermore, splenic red pulp macrophages are 
SR-AI/II positive 329, but did not accumulate CPPs. At least in part this may be explained by 
the blood flow in spleen; arterial blood passes into the marginal sinus, from where it flows 
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through the marginal zone into the red pulp 331. Thus, MZMs may capture CPPs before they 
reach the red pulp. However, not all arterial blood takes this route. Some arterial branches 
end directly in the red pulp 331. In conclusion, specific architecture of the RES as well as 
particle size (see chapter 4.2.1.2) likely contribute in targeting CPPs to specific SR-AI/II 
positive cells. 
Regarding the ligand responsible for SR-AI/II binding the data suggest that additional serum 
proteins other than fetuin-A might confer high affinity CPP binding and clearance by 
macrophages, while fetuin-A is mainly responsible for the stabilization of CPPs. It is currently 
unknown which serum proteins contribute to the clearance of CPPs and fetuin-A stabilized 
mineral debris. A situation similar to the “clearance synapse” identified for the clearance of 
apoptotic cells containing many, yet circumscriptive factors 332 can be anticipated. The 
identification of albumin as a major contributor in mineralo-protein complexes 89, 90, 94, 96, 
suggests that albumin and the albumin receptor GP60 333 may contribute to CPP clearance 
as well. Apolipoprotein A1 (ApoA1), a known SR-AI/II ligand, likewise is a candidate ligand 
334, which was previously identified in mineralo-protein complexes 94 as well as in calcified 
lesions of fetuin-A deficient mice (see chapter 3.1.5).  
4.2.2.3 Contribution of Additional Receptors and Uptake Routes 
CPP uptake in SR-AI/II deficient macrophages was significantly reduced. However, some 
CPP endocytosis was still detectable. Participation of SR-AI/II in CPP uptake suggested an 
uptake route similar to that of modified lipoprotein particles. Therefore, it was reasonable to 
assume that other receptors involved in endocytosis of modified lipoproteins may also 
contribute to CPP uptake. In the current study, the focus was on CD36 whereas MARCO 
another member of the scavenger receptor family involved in endocytosis of acLDL was not 
examined. However, the lack of MARCO expression on Kupffer cells 335 suggests that 
MARCO might not be essential for CPP clearance in vivo. Furthermore, CPP uptake in CD36 
deficient macrophages was not altered excluding a participation of this class B scavenger 
receptor as well. Thus, endocytosis pathways distinct from scavenger receptor mediated 
uptake routes might be involved in CPP endocytosis. 
Several groups have previously reported an opsonic activity of fetuin-A enhancing the 
phagocytosis of E.coli and S.aureus by human neutrophils 53, increasing uptake of DNA or 
latex particles in mouse peritoneal macrophages 76 and neutrophils 77 and accelerated 
phagocytosis of fetuin-A opsonized polystyrene particles 78. Thus, we investigated the uptake 
route of two well known opsonic plasma proteins, namely serum amyloid P (SAP) and C-
reactive protein (CRP) 226, 336. The endocytosis of both, SAP or CRP opsonized particles 
could be strongly reduced by inhibition of the Fcγ receptor pathway, e.g. through spleen 
tyrosin kinase (SYK) and phosphatidylinositol-3-kinase (PI3K) function. Transfection of non-
phagocytic cells with distinct subtypes of the Fcγ receptor (FcγR) resulted in a gain of 
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function in that transfected cells could efficiently endocytose the opsonized particles 226, 337, 
338. In the current work the inhibition of uptake using inhibitors of SYK and PI3K showed 
inconclusive results. While inhibition of PI3K resulted in a slight non-significant decrease in 
CPP uptake, SYK inhibition caused a strong reduction of CPP endocytosis. However, cell 
viability following SYK inhibition was also much reduced. To clarify the role of FcγR-mediated 
endocytosis of CPPs, FcγR-deficient BMMs were tested. This experiment clearly showed that 
FcγR was not involved in CPP uptake and thus uptake of fetuin-A opsonized particles or of 
fetuin-A containing CPPs for that matter did not resemble the endocytosis of SAP, CRP or 
immunoglobulin opsonized particles and pathogens.  
Furthermore, dectin-1, which is also associated with SYK activity, was apparently not 
involved in CPP endocytosis judged by the comparison of CPP uptake in dectin-1 KO BMMs 
in comparison to WT BMMs. However, dectin-1 expression on BMMs is weak 339, 340. 
Therefore, a contribution of dectin-1 in CPP endocytosis could not be excluded with 
confidence using the current approach. 
Annexins A2, A5, and A6 have been reported to mediate fetuin-A endocytosis 123, 285. Here, 
endocytosis of CPPs was not affected by annexin A5 or annexin A6 deficiency. This result 
once again confirmed the finding that fetuin-A in a particulate form, such as fetuin-A 
containing CPP is cleared differently from fetuin-A monomer. Thus, the CPP clearance 
mechanism is specific for fetuin-A-mineral complexes and therefore highly efficient in 
preventing pathological deposition of mineral debris without touching general fetuin-A 
metabolism. 
In conclusion, in the current thesis no additional receptors involved in CPP endocytosis could 
be identified. On the one hand this might be due to a specific CPP uptake exclusively by 
SRA-I/II. Yet, minor endocytosis of CPPs was observed in SR-AI/II-deficient BMMs and there 
was evidence that SYK, which is not associated with scavenger receptors, is involved in CPP 
uptake. The failure to detect additional receptors might be attributed to technical reasons. 
Subpopulations of macrophages show a high level of heterogeneity in their surface receptors 
209. Therefore, the current approach using BMM is restricted to receptors expressed by this 
macrophage subtype and may not completely represent CPP uptake in Kupffer cells and 
MZMs in vivo. 
4.2.2.4 Does a Galectin-Fetuin Interaction Influence CPP Uptake? 
Fetuin-A is a highly glycosylated protein 15. Accordingly, it is reasonable to assume that an 
interaction with proteins of the galectin family might influence endocytosis of fetuin-A 
containing CPPs or fetuin-A monomer. Importantly, in macrophages it was shown that 
galectin-1 inhibited phagocytosis via FcγR 255, while galectin-3 was effective in enhancing 
clearance of apoptotic neutrophils 256. However, the presence or absence of galectin-1 and 
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galectin-3 did not affect the uptake of fetuin-A monomer or CPPs. This is in agreement with 
the fact that CPPs prepared from asialofetuin showed identical tissue distribution and kinetics 
in organ accumulation as fetuin-A containing CPPs (supplemental figure 1).  
4.2.3 Interference with Lipid Metabolism and Atherosclerosis 
The data shows that SR-AI/II is responsible for the major part of endocytosis of CPPs. The 
finding that SR-AI/II, a well-known scavenger receptor for LDL particles 216 and lipid debris, 
likewise participates in the clearance of CPPs and therefore of mineral debris, may help to 
explain why atherosclerotic plaque frequently calcifies especially in patients with perturbed 
mineral homeostasis. Several studies in humans showed that fetuin-A colocalizes with 
atherosclerotic plaque in calcifying atherosclerosis 341-343. In mice the combined deficiencies 
for fetuin-A and apolipoprotein E caused an exacerbated phenotype of calcifying 
atherosclerosis 115 further supporting a combined role for the clearance of lipids and mineral 
debris in the pathogenesis of atherosclerosis. Thus, the stimulation of SR-AI/II function in 
clearing macrophages may be of therapeutic value in calcifying atherosclerosis. 
4.2.4 Summary 
The deposition of mineral precipitates in the vasculature and in soft tissues is a common 
pathological event especially in dialysis patients 344. Even under physiological conditions, 
blood is considered a metastable aqueous calcium-phosphate system sustaining mineral 
precipitation once crystals are nucleated. Thus, a mechanism is required to safeguard 
against the disposal of mineral nuclei from circulation to prevent pathological calcification. It 
was shown that fetuin-A plays a critical role in the formation and stabilization of protein-
mineral complexes CPPs 18, 55.  
Here it could be shown for the first time that fetuin-A containing CPPs were removed from 
circulation fast and efficiently. SR-AI/II dependent CPP uptake by hepatic Kupffer cells and 
splenic MZMs therefore prevented pathological deposition of mineral debris. Thus, CPPs 
interfered with the endocytosis of modified lipoprotein particles, demonstrating a protective 
role of fetuin-A in atherosclerosis.  
4.3 Prevention of Ectopic Calcification in B6 Fetuin-A Deficient Mice 
D2 fetuin-A deficient mice suffer from severe soft tissue calcification (see chapter 3.1 and 56). 
In contrast, B6 fetuin-A deficient mice on a high phosphate diet developed extraosseous 
calcification under uremic conditions, but were resistant to spontaneous calcification 56, 114. 
These findings suggest that B6 mice posses protective mechanisms preventing pathological 
dystrophic calcification. 
The sensitivity to ectopic calcification of certain mouse strains was previously described. 
Using a quantitative trait locus (QTL) analysis, a major locus named Dyscalc1 was identified 
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193, 195, 345. Subsequent ultra-fine mapping approaches led to the identification of ATP-binding 
cassette sub-family C member 6 (Abbc6) as a putative causative gene 197, 198. Indeed, Abbc6 
mutation or deficiency was associated with pseudoxanthoma elasticum (PXE), a disorder of 
connective tissue linked to ectopic calcification in humans 203 and mice 201, respectively. 
However, a mechanism explaining the linkage of Abbc6 and soft tissue calcification has not 
been described so far. In these studies, dystrophic calcification was commonly induced by 
myocardial cell death as a consequence of a freeze-thaw injury 195-198, 346. Even though a 
stable calcification phenotype could be induced, calcification was restricted to the 
myocardium, whereas pathological mineralization in fetuin-A deficient D2 mice affected 
almost all major organs (see chapter 3.1 and 56). Consequently, fetuin-A deficient mice 
should be particularly suitable for the detection of genes involved in the formation as well as 
the prevention of dystrophic calcification. 
4.3.1 Differential Gene Expression in B6 Fetuin-A Deficient Mice 
First, a DNA microarray approach was applied to detect candidate genes. Differential gene 
expression in kidney and liver of fetuin-A deficient mice on B6 and D2 genetic background 
was compared. In B6 mice fetuin-A deficiency is most apparent in bone as previously 
described in fetuin-A deficient mice on a mixed 129Sv X C57BL/6 genetic background 40. In 
B6 mice femora were severely stunted and growth plates showed increased mineralization 
55. Apart from that, B6 fetuin-A deficient mice had no obvious alterations in phenotype. 
Nevertheless, a number of genes were differentially expressed in kidney and liver of B6 KO 
mice. One of the candidate genes, the enzyme 24-OHase, has a known function in 
mineralization biology. 24-OHase is responsible for the catabolic breakdown of 1,25-
dihydroxyvitamin D, the active form of vitamin D 127. Mice deficient in 24-OHase developed 
abnormal mineralization, which is explained by increased serum calcium levels of active 
vitamin D 290. Here, 24-OHase was differentially upregulated in the kidney of female B6 
fetuin-A deficient mice. In D2 mice, expression of 24-OHase was also high in two KO mice 
(one female and one male), whereas expression in all other D2 mice was lower but still 
increased in comparison to B6 WT and male KO mice. Thus, the role of 24-OHase in 
pathologic calcification of fetuin-A deficient mice suggests further studies on the vitamin D 
status. 
Genes whose expression patterns corresponded to the calcification phenotype of fetuin-A 
deficient mice were identified in a heatmap representation. Genes, which were differentially 
upregulated in non calcifying B6 fetuin-A deficient, while their expression remained constant 
in fetuin-A deficient calcifying D2 mice were of particular interest. Those genes may be 
compensating fetuin-A deficiency and preventing ectopic calcification in B6 fetuin-A deficient 
mice. Kidneys of D2 fetuin-A deficient mice are affected by soft tissue calcification. Thus, in 
kidneys of calcification resistant fetuin-A deficient B6 mice local mechanisms might be 
Discussion 
102 
differentially upregulated to inhibit mineral deposition. In contrast, the liver of fetuin-A 
deficient B6 mice might express genes preventing ectopic calcification on a systemic level. 
However, no genes involved in mineralization biology could be detected by this approach. 
Instead, a transcribed sequence, mapped with high identity to phosphatidylserine 
decarboxylase pseudogene 1 and phosphatidylserine decarboxylase pseudogene 2 using 
NCBI nucleotide blast, could be identified in both organs. The differential expression of the 
transcripts was confirmed by quantitative PCR. Thus, differential expression of this transcript 
may be involved in inhibition of ectopic calcification in B6 mice. However, identification of a 
corresponding gene product as well as biological significant function is missing.  
Interestingly, Abcc6, previously identified as a causative gene for dystrophic calcification (see 
above), was not differentially regulated. After identifying Abcc6 as a major causal gene, 
Meng and colleagues demonstrated up to 100-fold higher expression of Abbc6 in liver, heart 
and kidney of B6 mice in comparison to calcification susceptible C3H or D2 mice 199. This 
finding could not be reproduced by the whole genome expression study presented here. 
However, a more recent study identified a splice variant of the Abcc6 gene in C3H as well as 
in D2 mice, leading to a truncated protein and consequently to a protein deficiency 200. 
Taking this finding into account, it is reasonable to assume that a difference in Abcc6 
expression might not be detectable on RNA level. Thus, to clarify the role of Abcc6 in fetuin-
A deficient mice, differential expression should be investigated on the protein level or at least 
on the level of specific exons. 
In conclusion, the current DNA microarray analysis did not identify genes with an obvious 
function in calcification prevention in B6 mice. As discussed before (see chapter 4.1.3) this 
might be attributed to technical reasons and the number of replicates might have been 
insufficient to obtain valid, reproducible results. Furthermore, the time points and tissues 
studied might have been suboptimal. Although ectopic calcification in fetuin-A deficient D2 
mice was already detected in 2-week-old mice, the initiation of calcification varied between 
organs; in addition, variability of initiation was observed in different animals 264. Remarkably, 
calcification in kidney was detected only occasionally in young mice, which was attributed to 
high expression of the calcification inhibitor osteopontin in kidney tubules 166, 264. Thus, if one 
assumes that predominantly local mechanisms might prevent calcification in fetuin-A 
deficient B6 mice, it is reasonable to assume that such mechanisms might not have been 
initiated in kidneys of 5-week-old mice. 
4.3.2 Impaired Clearance of Calciprotein-Particles in BMMs Derived from D2 Mice 
In the current thesis, it could be shown that fetuin-A plays a critical role in clearance of 
mineral debris in vivo (see chapter 3.2). Even under physiological conditions, blood is 
considered a metastable aqueous calcium-phosphate system sustaining mineral precipitation 
once crystals are nucleated. William Neuman aptly stated that we all suffer “Lot’s wife’s 
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problem” the imminent danger of turning into a pillar of salt 125. Thus, a mechanism protecting 
against the disposal of mineral nuclei to prevent pathological calcification is of high 
importance. Consequently, efficiency in clearance of mineral particles from circulation might 
contribute to the different phenotypes of B6 and D2 fetuin-A deficient mice. Indeed, CPP 
clearance by BMMs derived from D2 mice was less efficient than by BMMs derived from B6 
mice. Having shown that CPP clearance was predominantly mediated by scavenger receptor 
AI/II (see chapter 3.2), it was tested whether impaired CPP clearance in D2 BMMs is likewise 
due to a decreased expression of SR-AI/II. Inhibition of SR-AI/II using the SR antagonist 
polyinosinic acid further reduced uptake of CPPs in D2 BMMs. However, inhibition of CPP 
endocytosis in both B6 and D2 BMMs reached about a 25 % reduction only for uncoated 
CPPs and a 50 % reduction when serum-coated CPPs were applied. Therefore, using this 
assay differences in SR-A expression might be difficult to detect. On the other hand, a 
complete absence of SR-AI/II in D2 BMMs could thus be excluded. Further analysis of SR-
AI/II expression on the protein level might prove difficult, because a polymorphism in B6 mice 
prevents detection of SR-AI/II using the popular monoclonal antibody clone 2F8 347. 
The analysis of endocytosis of particular matter distinct from CPPs might be of interest to 
obtain further information of causes for an impaired CPP uptake in D2 BMMs. Furthermore, it 
might be interesting to evaluate whether impaired CPP clearance is restricted to BMMs or if it 
is a common phenomenon in different macrophage subtypes in D2 vs. B6 mice. Finally, CPP 
clearance should be studied in D2 mice in vivo. 
4.3.3 Summary 
This part of the thesis aimed to identify molecular mechanisms determining the different 
calcification phenotypes of fetuin-A deficient B6 and D2 mice. So far, no candidate genes 
involved in mineralization mechanisms could be identified on the gene expression level. 
However, it is reasonable to assume that mechanisms distinct from differential gene 
expression in the tissues and at the particular time studied might contribute to calcification 
resistance and calcification susceptibility, respectively. Here, for the first time a significant 
difference in clearance of mineral particles was detected in vitro. This difference needs yet to 
be validated in vivo.  
Finally, it may be assumed that a combination of several effects may result in the calcification 
susceptibility of certain mouse strains. In addition to the clearance efficiency reported here, 
the concentration of calcification inhibitors may be of importance. For instance, it was 
described recently that dietary magnesium was sufficient to inhibit connective tissue 
calcification in Abcc6 deficient mice 153, 154. It was previously shown that serum magnesium 
levels were considerably lower in D2 mice compared to B6 mice 56, 348 suggesting a 
correlation of serum magnesium levels and the calcification phenotype of D2 mice.  
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4.4 Perspectives 
Fetuin-A is effective in formation and stabilization of soluble protein mineral particles (CPPs). 
In the current thesis it could be shown that CPPs are rapidly removed from the circulation in 
vivo. Endocytosis of CPPs was mediated by macrophages of liver and spleen in a SR-AI/II 
dependent manner. Protein analysis suggested a rapid degradation of fetuin-A. However, 
using these methods no information on the fate of internalized calcium phosphate was 
obtained. Several studies suggested a pro-inflammatory effect of hydroxyapatite 233, 234, 236, 
237. Thus, future work should include the elucidation of the inflammatory potential of CPPs.  
Furthermore, it should be studied whether the mineral content of CPPs is resolved and 
restored to the calcium phosphate pool, or if the endocytosed mineral remains in the 
macrophages. In vascular calcification, an increased calcium accumulation in vascular 
smooth muscle cells mediates cell death associated with the release of calcification-prone 
apoptotic bodies 185. Therefore, it is reasonable to assume that high doses of intracellular 
calcium in macrophages may likewise lead to cell death and consequently to mineral 
deposition.  
In the current study, accumulation of intravenously injected CPPs was detected in spleen 
and liver. It was not analyzed whether CPPs were also cleared directly by blood monocytes. 
This might be of interest, because recently circulating calcifying cells were identified, which 
had a high potential to induce calcification 349. The origin of these cells is unknown, but it was 
shown that they derived from myeloid precursors. Therefore, one could hypothesize that 
these cells might have developed from monocytes, which have taken up CPPs or mineral 
debris. To answer this question it should be examined whether uptake of CPPs induces 
expression of osteogenic markers, which is characteristic for circulating calcifying cells. 
Another part of the current thesis was to study mechanisms of ectopic calcification in fetuin-A 
deficient mice. Gene expression analysis pointed to a passive chemical process of mineral 
precipitation distinct from the active cell-mediated mineralization triggering vascular 
calcification. For instance low serum magnesium levels, which were detected in D2 mice 56, 
348 may contribute to calcification. As dietary magnesium supplementation was shown to be 
of therapeutic value in high phosphate induced aortic calcification 152 and connective tissue 
calcification in a mouse model of pseudoxanthoma elasticum (PXE) 153, 154, it should be 
tested if dietary magnesium is likewise of therapeutic value in calcifying D2 fetuin-A deficient 
mice. Furthermore, studies on the uptake of CPPs by macrophages of calcifying D2 mice in 
comparison to BMM derived from non-calcifying B6 mice revealed an impaired endocytosis 
of CPPs in D2 mice. Defective or rather ineffective clearance of mineral debris might 
therefore be another risk factor for calcification in D2 mice. The relevance of CPP clearance 
for ectopic calcification may be elucidated by studying CPP clearance in D2 mice in vivo. If 
macrophage uptake of CPPs is crucial to prevent calcification, D2 mice should have 
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prolonged circulation of CPPs in serum compared to B6 mice. Furthermore, extended CPP 
accumulation may lead to aggregation and subsequently to deposition of mineral debris.  
In conclusion, an important role of fetuin-A in the clearance of mineral debris was identified in 
vivo. The finding that SR-AI/II, a well-known scavenger receptor for LDL particles and lipid 
debris 216, likewise participates in the clearance of CPPs and mineral debris points to a 
combined role for the clearance of lipids and mineral debris in the pathogenesis of 
atherosclerosis. Thus, the stimulation of SR-AI/II function in macrophages may be of 
therapeutic value in calcification diseases, in particular in calcifying atherosclerosis. 
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24-OHase   25-hydroxyvitamin D-24-hydroxylase 
Abbc6   ATP-binding cassette sub-family C member 6 
Ace2   angiotensin 1 converting enzyme 2 
acLDL   acetylated low density lipoprotein 
Ahsg   α2-Heremans-Schmid-glycoprotein 
ApoA1   apolipoprotein A1 
ApoE   apolipoprotein E 
AsF    asialofetuin 
ASGP-R   asialoglycoprotein receptor 
B6    C57BL/6N mouse strain  
B6D2   offspring (F1) of C57BL/6N x DBA/2N matings 
BAT    brown adipose tissue 
bp   base pairs 
BCP   basic calcium phosphate 
BMM    bone marrow derived macrophage 
BMP   bone morphogenic protein 
BSA    bovine serum albumin 
C9    complement component 9 
Ca3    carbonic anhydrase 3 
Cbfa1   core-binding factor subunit alpha-1 
CDS    coding sequences 
CKD   chronic kidney disease 
cM   centi Morgan 
CPP    calciprotein particle 
CR   complement receptor 
CTDL   C-type lectin carbohydrate-binding domain 
CUA   calcific uremic arteriolopathy 
Cyp24a1   cytochrome P450, family 24, subfamily a, polypeptide 1 
D   domain 
D2    DBA/2N mouse strain 
Dbp    D site albumin promoter binding protein 
DC    dendritic cells  
Dpp4    dipeptidyltransferase 4 
EDTA   ethylenediaminetetraacetic acid 
EMP-3   epithelial membrane protein 3 
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ESRD   end-stage renal disease 
FBS   fetal bovine serum 
FcγR    Fcγ receptor 
FETUB  fetuin-B 
FGF-23  fibroblast growth factor 23 
Gapdh   Glycerinaldehyd-3-phosphat-dehydrogenase 
Glt25d2   glycosyltransferase 25 domain containing 2 
Gpi   glycosylphosphatidylinositol 
HAP   hydroxyapatite 
HL   hepatic lectin 
Hrc   histidine rich calcium binding protein 
HRG   histidine rich gycoprotein 
IgG   immunoglobulin G 
Il-1β   interleukin-1beta 
i.v.   intravenous 
Kb   kilo bases 
KEGG   Kyoto encyclopedia of genes and genomes 
KNG   kininogen 
KO   knockout 
LAMP    lysosomal-associated membrane protein  
LCM   L929 cell conditioned medium 
LDL   low density lipoprotein 
log10p   logarithm to base 10 
LOX-1   lectin-like oxidized low density lipoprotein receptor 1 
LPS   lipopolysaccharide 
Mal   myelin and lymphocyte protein, T-cell differentiation protein 
MARCO   macrophage receptor with collagenous structure 
Mbp   mega base pairs 
M-CSF  macrophage colony-stimulating factor 
MetS   metabolic syndrome 
MGP    matrix gla protein 
MMM    marginal metallophilic macrophages 
Mmp12   macrophage-specific metalloelastase 12 
MOMA-1  antibody recognizing marginal metallophilic macrophages in the mouse 
   spleen 
MPS   mononuclear phagocyte system 
MS    mass spectrometry 
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MZ    marginal zone 
MZM    marginal zone macrophage 
NCBI    national center for biotechnology information 
NFκB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NK   natural killer 
ns   not significant 
OPN    osteopontin 
PAMP   pathogen-associated molecular pattern 
PBMC   peripheral blood mononuclear cell 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
Per3   period homolog 3 
PEPT2   peptide transporter 2 
PI3K    phosphoinositole-3-kinase 
Poly-I    polyinosinic acid 
POT    proton oligopetide transporter 
PP   pyrophosphat 
pp63   phosphorylated N-glycoprotein 
PRR   pattern recognition receptor 
PTH   parathyroid hormone 
PXE    pseudoxanthoma elasticum 
QTL    quantitative trait locus 
RES    reticuloendothelial system 
RP    red pulp 
Runx2   runt-related transcription factor 2 
SAP    serum-amyloid P 
SDS    sodium dodecyl sulfate 
SDS-PAGE   SDS polyacrylamid gel electrophoresis 
Slc15a2   solute carrier family 15, member 2 
SOP   standard operation procedure 
Spp1   secreted phosphoprotein 1, equivalent to OPN 
Sprr    small proline rich 
SR-A    scavenger receptor A 
SRCR   scavenger receptor cysteine-rich domain 
SYK    spleen tyrosin kinase 
TEM    transmission electron microscopy 
TGF-β   transforming growth factor-beta 
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TLR   toll-like receptor 
Tmprss2  transmembrane protease, serine 2 
TNF   tumor necrosis factor 
TRAP   tatrate-resitant acid phosphatase 
Tris   Tris base (2-Amino-2-hydroxymethyl-propane-1,3-diol) 
VSMC   vascular smooth muscle cell 
WP    white pulp 
WT    wildtype 
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Supplemental Figures 
 
 
Supplemental Figure 1. Organ distribution and kinetics of fetuin-A and asialofetiun containing CPPs.  
Mice were injected with CPPs i.v., sacrificed 10, 30, 60 and 180 minutes afterwards and organs were harvested. 
The tissue protein extracts were analyzed by SDS-PAGE and the content of the fluorescence-label in the tissues 
was evaluated by densitometry. The values shown were quantified relative to an internal standard of 10 ng 
labeled fetuin-A co-separated on each gel. The protein content is given as the absolute protein amount per 100 
mg fresh organ weight. The dotted lines indicate the mean signal of all organs after the subtraction of the brain 
values considered as negative control because of the blood-brain barrier and excluding bone because of the 
considerably lower values. Fetuin-A (F-A) containing CPPs (A) and asialofetuin containing CPPs (B) showed the 
same organ distribution. Compared to the average protein content of all organs increased levels of labeled protein 
were found in liver and spleen. (At least three animals per group were investigated at each time point). 
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Supplemental Tables 
Supplemental Table 1. Differential expression in adipose tissue of D2 fetuin-A deficient mice.  
probe set p-value  log-ratio  
upregulation   
RIKEN cDNA 1110032A04 gene 0.004 -6.977 
small proline-rich protein 1A 0.005 -6.021 
small proline-rich protein 2A 0.005 -5.495 
small proline-rich protein 2A 0.009 -4.683 
RIKEN cDNA 1110032A04 gene 0.003 -4.369 
myelin and lymphocyte protein, T-cell differentiation protein 0.001 -4.316 
matrix metallopeptidase 12 0.001 -4.315 
transmembrane protease, serine 2 0.008 -4.157 
secreted phosphoprotein 1 0.024 -4.116 
uroplakin 3A 0.014 -3.949 
lymphocyte antigen 6 complex, locus D 0.002 -3.845 
sorting nexin 31 0.008 -3.728 
forkhead box A1 0.001 -3.628 
myelin protein zero 0.001 -3.525 
Purkinje cell protein 4 0.001 -3.493 
prostate stem cell antigen 0.008 -3.436 
carnitine palmitoyltransferase 1b, muscle 0.006 -3.390 
WAP four-disulfide core domain 2 0.022 -3.351 
cadherin 1 0.007 -3.256 
claudin 4 0.002 -3.185 
pyridoxal-dependent decarboxylase domain containing 1 < 0.001 -3.159 
myelin basic protein 0.001 -3.148 
forkhead box Q1 0.001 -3.137 
involucrin 0.005 -3.078 
transmembrane protease, serine 2 0.016 -3.063 
FXYD domain-containing ion transport regulator 3 0.001 -3.056 
keratin 18 0.002 -3.046 
chloride channel calcium activated 2 0.001 -2.976 
small proline-rich protein 2F 0.001 -2.969 
myelin basic protein 0.001 -2.943 
gasdermin C2 0.028 -2.917 
chloride channel calcium activated 2 0.010 -2.904 
regulator of G-protein signaling 1 0.043 -2.862 
grainyhead-like 2 (Drosophila) 0.001 -2.799 
transmembrane protease, serine 2 0.008 -2.798 
ring finger protein 128 0.020 -2.792 
myelin basic protein 0.003 -2.785 
otopetrin 1 0.043 -2.784 
keratin 20 0.001 -2.775 
ring finger protein 128 0.011 -2.772 
GATA binding protein 3 < 0.001 -2.743 
myelin basic protein 0.001 -2.702 
cytochrome c oxidase, subunit VIIa 1 0.030 -2.699 
myelin basic protein 0.003 -2.654 
keratin 7 0.027 -2.652 
uroplakin 1A 0.010 -2.623 
sonic hedgehog 0.012 -2.619 
epiphycan 0.001 -2.600 
pyruvate dehydrogenase kinase, isoenzyme 4 0.005 -2.597 
calponin 1 0.005 -2.535 
RIKEN cDNA 1600029D21 gene 0.047 -2.506 
keratin 5 0.001 -2.504 
steroid 5 alpha-reductase 1 0.002 -2.504 
forkhead box Q1 0.005 -2.497 
SH3-binding domain glutamic acid-rich protein 0.007 -2.492 
SH3-domain GRB2-like 2 0.001 -2.454 
RIKEN cDNA 1600029D21 gene 0.006 -2.451 
myosin, heavy polypeptide 11, smooth muscle 0.003 -2.416 
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aquaporin 3 0.009 -2.409 
SH3-domain GRB2-like 2 0.001 -2.406 
PERP, TP53 apoptosis effector 0.029 -2.340 
shisa homolog 3 (Xenopus laevis) 0.001 -2.324 
aquaporin 3 0.010 -2.311 
aquaporin 3 0.008 -2.290 
interleukin 1 receptor antagonist 0.033 -2.255 
RIKEN cDNA 2200001I15 gene 0.007 -2.222 
cathepsin E 0.001 -2.203 
tetraspanin 8 0.011 -2.185 
claudin 7 0.005 -2.178 
interferon regulatory factor 6 0.044 -2.177 
apolipoprotein D 0.005 -2.159 
transmembrane protein 30B 0.012 -2.158 
myelin basic protein 0.005 -2.140 
vesicle amine transport protein 1 homolog-like (T. californica) 0.001 -2.137 
serine protease inhibitor, Kunitz type 1 0.033 -2.132 
myocardin 0.010 -2.110 
regulating synaptic membrane exocytosis 1 0.003 -2.087 
steroid 5 alpha-reductase 1 0.002 -2.070 
actin, gamma 2, smooth muscle, enteric 0.009 -2.057 
claudin 23 0.005 -2.044 
flavin containing monooxygenase 5 0.013 -2.030 
cell death-inducing DNA fragmentation factor, alpha subunit-like effector A 0.009 -2.022 
deiodinase, iodothyronine, type II 0.022 -2.015 
RIKEN cDNA 4930550L11 gene 0.006 -2.011 
integrin alpha X 0.030 -1.985 
myelin and lymphocyte protein, T-cell differentiation protein 0.011 -1.971 
estrogen-related receptor gamma 0.044 -1.941 
keratin 8 0.014 -1.936 
ATPase, H+ transporting, lysosomal V0 subunit D2 0.047 -1.934 
thrombospondin 4 0.003 -1.927 
oncoprotein induced transcript 1 0.001 -1.916 
ladinin 0.050 -1.882 
myosin, light polypeptide kinase 0.046 -1.879 
Kruppel-like factor 5 0.001 -1.873 
acyl-CoA synthetase short-chain family member 1 0.010 -1.872 
RAB27b, member RAS oncogene family 0.007 -1.866 
tropomyosin 2, beta 0.006 -1.855 
prominin 2 0.005 -1.845 
grainyhead-like 3 (Drosophila) 0.013 -1.843 
uroplakin 2 0.011 -1.835 
carboxypeptidase X 2 (M14 family) 0.028 -1.809 
chloride channel calcium activated 1 0.003 -1.805 
solute carrier family 14 (urea transporter), member 1 0.008 -1.792 
transformation related protein 63 0.004 -1.790 
keratin 8 0.017 -1.787 
CDP-diacylglycerol synthase 1 0.005 -1.786 
transgelin 0.007 -1.782 
tumor-associated calcium signal transducer 2 0.011 -1.770 
CAP, adenylate cyclase-associated protein, 2 (yeast) 0.009 -1.755 
Purkinje cell protein 4-like 1 0.037 -1.725 
potassium channel tetramerisation domain containing 1 0.008 -1.719 
actin, alpha 2, smooth muscle, aorta 0.003 -1.706 
syndecan 1 0.010 -1.704 
aldehyde dehydrogenase family 3, subfamily A1 0.009 -1.681 
serine protease inhibitor, Kunitz type 2 0.009 -1.667 
corneodesmosin 0.041 -1.663 
chemokine (C-X-C motif) ligand 14 0.010 -1.660 
mast cell protease 2 0.028 -1.657 
RIKEN cDNA 2310076L09 gene 0.013 -1.638 
predicted gene, 100043005 0.030 -1.633 
oligodendrocyte transcription factor 1 0.038 -1.620 
Ly6/Plaur domain containing 3 0.023 -1.614 
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keratin 8 0.024 -1.603 
RIKEN cDNA A330049M08 gene 0.010 -1.599 
tenascin C 0.030 -1.589 
chemokine (C-C motif) ligand 3 0.047 -1.582 
tropomyosin 2, beta 0.007 -1.564 
RAB27b, member RAS oncogene family 0.031 -1.545 
neurotrophic tyrosine kinase, receptor, type 3 0.047 -1.538 
regulator of G-protein signaling 2 0.029 -1.535 
serine incorporator 2 0.005 -1.530 
mast cell protease 4 0.013 -1.522 
myosin, light polypeptide kinase 0.003 -1.517 
syndecan 1 0.047 -1.517 
myosin, light polypeptide kinase 0.003 -1.509 
stratifin 0.013 -1.497 
chemokine (C-X-C motif) ligand 14 0.046 -1.488 
SH3 domain binding glutamic acid-rich protein like 2 0.005 -1.482 
RIKEN cDNA 2310076L09 gene 0.022 -1.471 
RIKEN cDNA 6330546B05 gene 0.020 -1.468 
estrogen-related receptor gamma 0.025 -1.462 
shisa homolog 3 (Xenopus laevis) 0.016 -1.460 
periaxin 0.008 -1.458 
SH3-domain GRB2-like 2 0.005 -1.455 
cortexin 1 0.003 -1.447 
RNA binding motif protein 24 0.021 -1.427 
syndecan 1 0.008 -1.425 
potassium intermediate/small conductance calcium-activated channel, subfamily N, 
member 4 0.011 -1.416 
myosin, light polypeptide 9, regulatory 0.008 -1.408 
RNA binding motif protein 4B 0.016 -1.389 
chymase 1, mast cell 0.008 -1.384 
cyclin-dependent kinase inhibitor 1A (P21) 0.020 -1.383 
RNA binding motif protein 35A 0.033 -1.370 
eyes absent 4 homolog (Drosophila) 0.041 -1.350 
matrix Gla protein 0.047 -1.345 
cadherin 2 0.036 -1.340 
V-set and immunoglobulin domain containing 2 0.007 -1.339 
smoothelin 0.008 -1.337 
oxysterol binding protein-like 3 0.004 -1.336 
carboxypeptidase A3, mast cell 0.028 -1.334 
enabled homolog (Drosophila) 0.017 -1.333 
filamin binding LIM protein 1 0.047 -1.325 
melanoregulin 0.024 -1.321 
RAB27b, member RAS oncogene family 0.032 -1.319 
transmembrane protease, serine 13 0.017 -1.318 
peripheral myelin protein 2 0.047 -1.311 
RNA binding motif protein 35b 0.033 -1.308 
CDP-diacylglycerol synthase 1 0.015 -1.304 
regulating synaptic membrane exocytosis 1 0.024 -1.300 
syndecan 1 0.010 -1.296 
T-box 2 0.010 -1.286 
fatty acid 2-hydroxylase 0.008 -1.278 
synaptopodin 2 0.008 -1.271 
L1 cell adhesion molecule 0.022 -1.264 
Jun-B oncogene 0.030 -1.264 
growth arrest and DNA-damage-inducible 45 gamma 0.047 -1.262 
acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) 0.028 -1.259 
potassium voltage-gated channel, shaker-related subfamily, member 1 0.027 -1.257 
steroid 5 alpha-reductase 1 0.008 -1.247 
uroplakin 1B 0.033 -1.234 
proteolipid protein (myelin) 1 0.030 -1.233 
ankyrin repeat domain 9 0.008 -1.231 
CCAAT/enhancer binding protein (C/EBP), beta 0.004 -1.229 
acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) 0.030 -1.221 
RIKEN cDNA 2810432L12 gene 0.019 -1.204 
S100 protein, beta polypeptide, neural 0.022 -1.204 
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metallothionein 1 0.022 -1.192 
beta-site APP-cleaving enzyme 2 0.030 -1.188 
KH domain containing, RNA binding, signal transduction associated 3 0.040 -1.188 
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 0.015 -1.182 
tripartite motif-containing 29 0.008 -1.173 
secreted frizzled-related protein 1 0.008 -1.173 
CCAAT/enhancer binding protein (C/EBP), beta 0.007 -1.163 
expressed sequence AA986860 0.028 -1.159 
glutathione S-transferase, mu 1 0.004 -1.154 
expressed sequence AI452195 0.022 -1.148 
serine protease inhibitor, Kunitz type 2 0.016 -1.132 
solute carrier family 14 (urea transporter), member 1 0.022 -1.131 
pleckstrin homology domain containing, family B (evectins) member 1 0.048 -1.129 
glutathione S-transferase, mu 1 0.006 -1.122 
acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) 0.024 -1.114 
dickkopf homolog 2 (Xenopus laevis) 0.010 -1.094 
inhibitor of DNA binding 4 0.020 -1.090 
NIPA-like domain containing 2 0.018 -1.079 
calpain 13 0.008 -1.074 
cell division cycle associated 2 0.007 -1.069 
PCTAIRE-motif protein kinase 3 0.008 -1.069 
cytochrome c oxidase, subunit VIIIb 0.044 -1.061 
DNA segment, Chr 14, ERATO Doi 449, expressed 0.009 -1.059 
potassium intermediate/small conductance calcium-activated channel, subfamily N, 
member 4 0.043 -1.057 
neuropilin 2 0.048 -1.053 
protein tyrosine phosphatase, receptor type, F 0.047 -1.052 
potassium voltage-gated channel, shaker-related subfamily, member 1 0.024 -1.048 
phosphoglucomutase 5 0.010 -1.047 
major facilitator superfamily domain containing 4 0.047 -1.046 
RAB25, member RAS oncogene family 0.049 -1.041 
chloride channel calcium activated 1 0.024 -1.026 
glutathione S-transferase, mu 1 0.010 -1.013 
transmembrane protein 20 0.033 -1.010 
double homeobox B-like 0.036 -0.999 
protein kinase N1 0.022 -0.997 
adrenergic receptor, beta 2 0.048 -0.997 
high mobility group AT-hook 1 0.040 -0.989 
testis derived transcript 0.044 -0.989 
protein phosphatase 1, regulatory (inhibitor) subunit 12A 0.049 -0.988 
similar to apolipoprotein D 0.022 -0.985 
CD24a antigen 0.041 -0.984 
transmembrane protein 40 0.043 -0.961 
transformation related protein 53 inducible protein 11 0.021 -0.954 
desmin 0.047 -0.949 
solute carrier family 6 (neurotransmitter transporter, creatine), member 8 0.016 -0.944 
glutathione S-transferase, alpha 4 0.015 -0.940 
latent transforming growth factor beta binding protein 2 0.022 -0.937 
protein phosphatase 1, regulatory (inhibitor) subunit 12A 0.048 -0.935 
transmembrane channel-like gene family 4 0.041 -0.934 
calpain 5 0.048 -0.932 
ADP-ribosylation factor-like 4C 0.044 -0.931 
placenta specific 9 0.023 -0.908 
cDNA sequence X99384 0.049 -0.903 
RIKEN cDNA 9230104K21 gene 0.043 -0.892 
dystonin 0.012 -0.886 
cyclin J-like 0.047 -0.873 
EMI domain containing 1 0.026 -0.872 
protein kinase C, eta 0.042 -0.869 
pleckstrin homology domain containing, family H (with MyTH4 domain) member 1 0.035 -0.849 
calpain 1 0.048 -0.834 
pyridoxal-dependent decarboxylase domain containing 1 0.022 -0.831 
huntingtin interacting protein 1 related 0.048 -0.820 
integrin beta 4 0.026 -0.817 
E26 avian leukemia oncogene 2, 3' domain 0.044 -0.815 
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cysteine rich protein 2 0.033 -0.805 
MARVEL (membrane-associating) domain containing 1 0.038 -0.795 
serine (or cysteine) peptidase inhibitor, clade B, member 5 0.047 -0.790 
secreted frizzled-related protein 1 0.046 -0.733 
beta-site APP-cleaving enzyme 2 0.043 -0.714 
tsukushin 0.046 -0.701 
huntingtin interacting protein 1 related 0.047 -0.683 
guanine nucleotide binding protein, alpha 12 0.049 -0.674 
   
downregulation   
pyridoxal-dependent decarboxylase domain containing 1 < 0.001 4.111 
cytochrome b reductase 1 < 0.001 3.119 
penta-EF hand domain containing 1 < 0.001 3.108 
basonuclin 1 0.004 2.587 
glycoprotein m6a 0.005 2.483 
mesothelin 0.008 2.460 
glycoprotein m6a 0.023 2.355 
fibroblast growth factor 1 0.007 2.091 
plakophilin 2 0.028 2.011 
ISL1 transcription factor, LIM/homeodomain 0.019 1.954 
catechol-O-methyltransferase 1 0.002 1.874 
suprabasin 0.047 1.818 
R-spondin homolog (Xenopus laevis) 0.014 1.781 
ribosomal protein L17 0.001 1.778 
dermokine 0.028 1.757 
mucin 16 0.001 1.755 
gremlin 2 homolog, cysteine knot superfamily (Xenopus laevis) 0.010 1.702 
chordin-like 1 0.001 1.659 
fibroblast growth factor 1 0.011 1.624 
oligonucleotide/oligosaccharide-binding fold containing 2A 0.003 1.604 
uroplakin 3B 0.011 1.565 
uroplakin 3B 0.011 1.552 
spectrin beta 3 0.021 1.544 
orosomucoid 2 0.008 1.505 
epidermal growth factor-containing fibulin-like extracellular matrix protein 1 0.046 1.499 
chordin-like 1 0.003 1.487 
dipeptidylpeptidase 4 0.007 1.480 
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 0.024 1.475 
chordin-like 1 0.009 1.469 
phosphorylase kinase gamma 1 0.024 1.423 
secretory leukocyte peptidase inhibitor 0.015 1.417 
rhophilin, Rho GTPase binding protein 2 0.027 1.406 
succinate receptor 1 0.030 1.405 
dipeptidylpeptidase 4 0.003 1.400 
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 0.028 1.379 
solute carrier family 39 (metal ion transporter), member 8 0.013 1.355 
immunoglobulin-like domain containing receptor 2 0.049 1.349 
G protein-coupled receptor 34 0.049 1.347 
solute carrier family 39 (metal ion transporter), member 8 0.043 1.340 
kelch-like 2, Mayven (Drosophila) 0.023 1.337 
macrophage activation 2 like 0.024 1.312 
T-cell specific GTPase 0.048 1.305 
estrogen receptor 1 (alpha) 0.025 1.299 
GULP, engulfment adaptor PTB domain containing 1 0.021 1.299 
dipeptidylpeptidase 4 0.028 1.279 
stanniocalcin 2 0.010 1.278 
kelch-like 2, Mayven (Drosophila) 0.016 1.277 
complement component 2 (within H-2S) 0.006 1.273 
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 0.044 1.270 
RIKEN cDNA 9330159F19 gene 0.022 1.262 
GULP, engulfment adaptor PTB domain containing 1 0.007 1.260 
Na+/K+ transporting ATPase interacting 4 0.047 1.230 
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 0.036 1.195 
coiled-coil domain containing 80 0.042 1.192 
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cache domain containing 1 0.007 1.183 
complement component 2 (within H-2S) 0.008 1.166 
oligonucleotide/oligosaccharide-binding fold containing 2A 0.005 1.141 
orosomucoid 1 0.030 1.136 
solute carrier family 16 (monocarboxylic acid transporters), member 7 0.035 1.131 
insulin-like growth factor 1 0.028 1.123 
complement component 2 (within H-2S) 0.008 1.114 
intersectin 1 (SH3 domain protein 1A) 0.048 1.114 
avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog 0.039 1.112 
androgen receptor 0.009 1.106 
histone cluster 1, H4h 0.030 1.101 
GULP, engulfment adaptor PTB domain containing 1 0.038 1.100 
macrophage galactose N-acetyl-galactosamine specific lectin 2 0.030 1.087 
chemokine (C-X-C motif) ligand 9 0.049 1.085 
fibroblast growth factor binding protein 1 0.026 1.084 
homeo box C8 0.016 1.084 
immunoglobulin-like domain containing receptor 2 0.026 1.083 
ATP-binding cassette, sub-family D (ALD), member 2 0.011 1.062 
activin A receptor, type IC 0.047 1.058 
ATP-binding cassette, sub-family D (ALD), member 2 0.006 1.055 
somatostatin receptor 4 0.024 1.054 
insulin-like growth factor 1 0.047 1.051 
predicted gene, 100039706 0.021 1.047 
guanine nucleotide binding protein (G protein), alpha inhibiting 1 0.005 1.042 
RIKEN cDNA 2610019F03 gene 0.029 1.040 
RAB30, member RAS oncogene family 0.045 1.039 
RIKEN cDNA 1110059G02 gene 0.019 1.021 
ISL1 transcription factor, LIM/homeodomain 0.030 1.017 
oligonucleotide/oligosaccharide-binding fold containing 2A 0.021 1.012 
synaptopodin 2 0.049 1.010 
suppressor of cytokine signaling 2 0.047 0.987 
zinc finger protein 503 0.019 0.986 
ubiquitin specific peptidase 15 0.047 0.981 
hect domain and RLD 5 0.047 0.973 
SLIT and NTRK-like family, member 4 0.049 0.964 
Rho GTPase activating protein 29 0.010 0.964 
RAS p21 protein activator 2 0.047 0.961 
histone cluster 1, H2bc 0.028 0.955 
growth hormone receptor 0.017 0.953 
RIKEN cDNA 1110059G02 gene 0.038 0.947 
dopachrome tautomerase 0.022 0.932 
DnaJ (Hsp40) homolog, subfamily A, member 1 0.037 0.929 
X-box binding protein 1 0.025 0.926 
growth hormone receptor 0.011 0.922 
oligonucleotide/oligosaccharide-binding fold containing 2A 0.024 0.920 
ubiquitin specific peptidase 15 0.019 0.914 
cytochrome P450, family 2, subfamily s, polypeptide 1 0.038 0.912 
cache domain containing 1 0.027 0.903 
activin A receptor, type IC 0.028 0.903 
RIKEN cDNA 9030425E11 gene 0.022 0.902 
polycystic kidney disease 2-like 2 0.028 0.896 
butyrylcholinesterase 0.011 0.886 
RIKEN cDNA 1110059G02 gene 0.025 0.877 
guanine nucleotide binding protein (G protein), alpha inhibiting 1 0.022 0.877 
solute carrier family 9 (sodium/hydrogen exchanger), member 6 0.030 0.874 
exonuclease 3'-5' domain-like 1 0.041 0.866 
integrin beta 1 binding protein 1 0.027 0.865 
RIKEN cDNA 9330159F19 gene 0.044 0.856 
guanine nucleotide binding protein (G protein), alpha inhibiting 1 0.026 0.853 
eukaryotic translation initiation factor 4E binding protein 1 0.028 0.850 
ring finger protein 41 0.016 0.840 
predicted gene, 100042856 0.044 0.837 
butyrylcholinesterase 0.025 0.836 
DNA segment, Chr 3, ERATO Doi 751, expressed 0.047 0.827 
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phosphoribosyl pyrophosphate synthetase 1 0.028 0.827 
androgen receptor 0.024 0.822 
hypothetical protein LOC621549 0.049 0.820 
F-box protein 4 0.043 0.807 
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 0.022 0.805 
3-ketodihydrosphingosine reductase 0.035 0.804 
fibronectin type III and SPRY domain containing 2 0.027 0.804 
RAD51-like 1 (S. cerevisiae) 0.047 0.794 
cDNA sequence BC034902 0.049 0.787 
phosphoribosyl pyrophosphate synthetase 1 0.030 0.785 
ATP-binding cassette, sub-family D (ALD), member 2 0.039 0.763 
X-box binding protein 1 0.046 0.747 
asparagine synthetase 0.042 0.740 
estrogen receptor 1 (alpha) 0.046 0.711 
X-box binding protein 1 0.047 0.691 
DNA segment, Chr 3, ERATO Doi 751, expressed 0.047 0.689 
amylase 1, salivary 0.049 0.685 
histone cluster 1, H1e 0.047 0.681 
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 0.050 0.662 
The table shows probe sets, which were significantly (p-value < 0.05) differentially expressed in adipose tissue 
dissected from 6-week-old DBA/2 wildtype (n=4) and fetuin-A deficient mice (n=6). Bayesian statistics was used 
for calculation of probabilities (p-value) and log-ratio, negative log-ratio encode upregulation of the particular 
probe-set in fetuin-A deficient mice, positive values denote downregulation. Note that gene names are given for 
each probe set, double entries may occur in case of genes which are represented by several probe sets encoding 
different regions or splice variants of the gene. 
 
 
Supplemental Table 2. Differential expression in liver from fetuin-A deficient D2 mice.  
probe set p-value log-ratio 
upregulation   
sulfotransferase family 3A, member 1 0.012 -6.695 
RIKEN cDNA C730007P19 gene 0.032 -5.665 
sulfotransferase family 1E, member 1 0.009 -4.002 
lipocalin 2 0.004 -3.820 
serum amyloid A 2 0.042 -2.890 
solute carrier family 15 (H+/peptide transporter), member 2 < 0.001 -2.817 
ribonucleotide reductase M2 0.005 -2.810 
DNA segment, Chr 17, human D6S56E 5 0.024 -2.744 
baculoviral IAP repeat-containing 5 0.014 -2.721 
cyclin B2 0.038 -2.670 
serum amyloid A 1 0.043 -2.575 
pyridoxal-dependent decarboxylase domain containing 1 < 0.001 -2.551 
cDNA sequence AB056442 0.008 -2.517 
minichromosome maintenance deficient 6 (MIS5 homolog, S. pombe) (S. cerevisiae) 0.007 -2.516 
minichromosome maintenance deficient 6 (MIS5 homolog, S. pombe) (S. cerevisiae) 0.016 -2.474 
regulator of calcineurin 2 0.002 -2.470 
ribonucleotide reductase M2 0.017 -2.411 
SPARC related modular calcium binding 2 0.004 -2.247 
PDZ binding kinase 0.046 -2.204 
SPARC related modular calcium binding 2 0.008 -2.148 
cell division cycle associated 8 0.025 -2.131 
CD36 antigen 0.015 -2.059 
minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) 0.013 -2.043 
histone cluster 1, H2ae 0.016 -2.039 
cell division cycle associated 3 0.046 -2.011 
suppressor of cytokine signaling 2 0.019 -1.988 
cytochrome P450, family 17, subfamily a, polypeptide 1 0.008 -1.953 
aldo-keto reductase family 1, member C18 0.032 -1.897 
stathmin 1 0.041 -1.887 
aldo-keto reductase family 1, member B7 0.002 -1.830 
hypothetical protein LOC215866 0.038 -1.742 
cDNA sequence AB056442 0.032 -1.682 
transcription factor 19 0.019 -1.639 
insulin-like growth factor binding protein 1 0.007 -1.601 
solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), 0.004 -1.600 
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member 4 
basic helix-loop-helix domain containing, class B9 0.015 -1.591 
neuregulin 4 0.027 -1.560 
nicotinamide N-methyltransferase 0.024 -1.559 
RAD51-like 1 (S. cerevisiae) 0.043 -1.478 
solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), 
member 4 0.002 -1.455 
solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), 
member 4 0.002 -1.450 
MAD2 mitotic arrest deficient-like 1 (yeast) 0.019 -1.448 
family with sequence similarity 19, member A2 0.013 -1.401 
fibrinogen-like protein 1 0.043 -1.367 
stearoyl-Coenzyme A desaturase 2 0.032 -1.358 
DNA primase, p49 subunit 0.016 -1.334 
pituitary tumor-transforming gene 1 0.004 -1.324 
ribosomal protein S4, Y-linked 2 0.013 -1.323 
centromere protein A 0.045 -1.320 
RIKEN cDNA 2610305J24 gene 0.043 -1.288 
nucleolar and spindle associated protein 1 0.044 -1.281 
transmembrane protein 48 0.012 -1.253 
CDC28 protein kinase 1b 0.008 -1.218 
growth factor receptor bound protein 10 0.038 -1.207 
S100 calcium binding protein A8 (calgranulin A) 0.037 -1.190 
proliferating cell nuclear antigen 0.046 -1.182 
pantothenate kinase 2 (Hallervorden-Spatz syndrome) 0.010 -1.178 
S100 calcium binding protein A9 (calgranulin B) 0.045 -1.177 
thyroid hormone receptor interactor 13 0.019 -1.168 
transmembrane protein 98 0.003 -1.167 
RIKEN cDNA 2700094K13 gene 0.038 -1.127 
solute carrier family 41, member 2 0.037 -1.126 
prostaglandin reductase 1 0.018 -1.118 
uracil DNA glycosylase 0.007 -1.108 
ligase I, DNA, ATP-dependent 0.045 -1.094 
neuregulin 4 0.038 -1.073 
RIKEN cDNA D630004K10 gene 0.037 -1.044 
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 0.033 -1.038 
carbonic anhydrase 2 0.019 -1.034 
six transmembrane epithelial antigen of prostate 2 0.041 -1.031 
geminin 0.032 -0.988 
thioredoxin 2 0.034 -0.987 
deoxythymidylate kinase 0.041 -0.973 
insulin-like growth factor 2 mRNA binding protein 3 0.038 -0.939 
peroxisome proliferator activated receptor gamma 0.027 -0.915 
lectin, galactose binding, soluble 1 0.046 -0.911 
GINS complex subunit 1 (Psf1 homolog) 0.044 -0.807 
retinol binding protein 1, cellular 0.032 -0.779 
protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b 0.046 -0.770 
   
downregulation   
alpha-2-HS-glycoprotein < 0.001 8.631 
pyridoxal-dependent decarboxylase domain containing 1 < 0.001 4.762 
cytochrome P450, family 4, subfamily a, polypeptide 12a 0.041 4.635 
solute carrier organic anion transporter family, member 1a1 0.017 3.712 
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 0.016 3.522 
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 5 0.008 3.275 
kidney androgen regulated protein 0.001 3.193 
RIKEN cDNA 2610016E04 gene 0.011 3.181 
GRAM domain containing 3 < 0.001 2.651 
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 0.002 2.593 
cytochrome P450, family 7, subfamily b, polypeptide 1 0.001 2.252 
cytochrome P450, family 7, subfamily b, polypeptide 1 0.002 2.244 
GRAM domain containing 3 < 0.001 2.190 
major urinary protein 3 0.001 2.125 
NADPH oxidase 4 0.006 2.039 
neurotrophic tyrosine kinase, receptor, type 2 0.001 1.997 
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ribosomal protein L17 < 0.001 1.927 
aminolevulinic acid synthase 2, erythroid 0.019 1.886 
UDP glycosyltransferases 3 family, polypeptide A1 0.001 1.863 
RIKEN cDNA 9130221J18 gene 0.014 1.813 
glutathione peroxidase 3 0.001 1.771 
4short chain dehydrogenase/reductase family 9C, member 7 < 0.001 1.705 
uromodulin 0.001 1.631 
4short chain dehydrogenase/reductase family 9C, member 7 < 0.001 1.595 
complement component 6 0.010 1.533 
serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1 0.041 1.518 
UDP glycosyltransferases 3 family, polypeptide A1 0.009 1.488 
polypyrimidine tract binding protein 1 0.005 1.468 
guanine nucleotide binding protein, alpha 14 0.003 1.430 
predicted gene, OTTMUSG00000007486 0.009 1.397 
N-myc downstream regulated gene 1 0.008 1.382 
RIKEN cDNA 2810416A17 gene 0.041 1.359 
aldehyde oxidase 3 0.002 1.344 
cleavage and polyadenylation specific factor 6 0.043 1.332 
RIKEN cDNA 2310043N10 gene 0.007 1.316 
catechol-O-methyltransferase 1 0.002 1.235 
radical S-adenosyl methionine domain containing 2 0.045 1.223 
interferon regulatory factor 2 binding protein 2 0.007 1.216 
serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1 0.019 1.208 
predicted gene, ENSMUSG00000074917 0.002 1.201 
elastase 1, pancreatic 0.009 1.164 
splA/ryanodine receptor domain and SOCS box containing 4 0.006 1.080 
cytoplasmic polyadenylation element binding protein 2 0.046 1.077 
guanine nucleotide binding protein, alpha 14 0.002 1.054 
major urinary protein 3 0.041 1.046 
meningioma 1 0.012 1.043 
frizzled homolog 5 (Drosophila) 0.007 1.012 
glucokinase 0.013 1.007 
avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog 0.017 1.007 
UDP glucuronosyltransferase 2 family, polypeptide B5 0.016 0.976 
glucokinase 0.043 0.931 
cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog, Drosophila) 0.046 0.931 
RIKEN cDNA 6430527G18 gene 0.046 0.928 
fetuin beta 0.013 0.883 
glyoxalase 1 0.013 0.875 
deleted in lymphocytic leukemia, 2 0.019 0.861 
histocompatibility 2, K1, K region 0.021 0.836 
neurotrophic tyrosine kinase, receptor, type 2 0.041 0.825 
interferon regulatory factor 2 0.045 0.820 
2'-5' oligoadenylate synthetase-like 1 0.046 0.812 
gelsolin 0.043 0.780 
histocompatibility 2, D region 0.029 0.760 
Ras association (RalGDS/AF-6) domain family member 3 0.043 0.751 
The table shows probe sets, which were significant (p-value < 0.05) differentially expressed in liver dissected from 
5-weeks-old DBA/2 wildtype (n=3) and fetuin-A deficient mice (n=5). Bayesian statistics was used for calculation 
of probabilities (p-value) and log-ratio, negative log-ratio encode upregulation of the particular probe-set in fetuin-
A deficient mice, positive values denote downregulation. Note that gene names are given for each probe set, 
double entries may occur in case of genes which are represented by several probe sets encoding different 
regions or splice variants of the gene. 
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Supplemental Table 3. Differential expression in kidney of B6 fetuin-A deficient mice.  
probe set p-value log-ratio 
upregulation   
D site albumin promoter binding protein < 0.001 -3.169 
cytochrome P450, family 24, subfamily a, polypeptide 1 0.003 -2.987 
D site albumin promoter binding protein < 0.001 -2.890 
RIKEN cDNA 4933439C20 gene 0.001 -2.366 
RIKEN cDNA 4933439C20 gene < 0.001 -2.010 
RIKEN cDNA 4933439C20 gene < 0.001 -1.979 
cytochrome P450, family 24, subfamily a, polypeptide 1 0.030 -1.796 
peptidase M20 domain containing 1 < 0.001 -1.688 
solute carrier family 7, (cationic amino acid transporter, y+ system) member 
13 < 0.001 -1.679 
period homolog 3 (Drosophila) < 0.001 -1.634 
peptidase M20 domain containing 1 < 0.001 -1.531 
camello-like 3 < 0.001 -1.494 
period homolog 2 (Drosophila) 0.003 -1.174 
period homolog 3 (Drosophila) 0.002 -1.120 
nuclear receptor subfamily 1, group D, member 2 0.006 -1.096 
similar to Zinc finger BED domain containing protein 4 0.004 -1.014 
nuclear receptor subfamily 1, group D, member 2 0.013 -0.943 
cytoplasmic polyadenylation element binding protein 3 0.001 -0.936 
uridine phosphorylase 2 0.016 -0.870 
thyrotroph embryonic factor 0.010 -0.833 
cytoplasmic polyadenylation element binding protein 3 0.034 -0.818 
period homolog 3 (Drosophila) 0.018 -0.789 
cytoplasmic polyadenylation element binding protein 3 0.030 -0.775 
camello-like 3 0.030 -0.757 
   
downregulation   
aldo-keto reductase family 1, member C14 < 0.001 2.928 
aldo-keto reductase family 1, member C18 0.001 2.519 
alpha-2-HS-glycoprotein < 0.001 2.466 
lymphocyte antigen 6 complex, locus F < 0.001 2.387 
RIKEN cDNA 9130221J18 gene 0.001 2.017 
suppressor of cytokine signaling 2 0.008 1.972 
solute carrier family 22 (organic anion transporter), member 7 < 0.001 1.968 
nuclear factor, interleukin 3, regulated < 0.001 1.938 
major urinary protein 3 0.010 1.852 
RIKEN cDNA 1110069O07 gene < 0.001 1.755 
major urinary protein 1 0.027 1.700 
dipeptidylpeptidase 4 < 0.001 1.696 
neuronal PAS domain protein 2 < 0.001 1.673 
dipeptidylpeptidase 4 < 0.001 1.654 
suppressor of cytokine signaling 2 0.017 1.626 
phosphatidylinositol-specific phospholipase C, X domain containing 2 0.002 1.582 
dipeptidylpeptidase 4 < 0.001 1.517 
RIKEN cDNA 1110069O07 gene < 0.001 1.505 
RIKEN cDNA A630005I04 gene < 0.001 1.481 
solute carrier family 9 (sodium/hydrogen exchanger), member 8 0.001 1.467 
phosphatidylinositol-specific phospholipase C, X domain containing 2 0.013 1.412 
complement component 8, alpha polypeptide 0.002 1.349 
3-hydroxy-3-methylglutaryl-Coenzyme A reductase 0.042 1.320 
solute carrier family 10, member 2 0.017 1.277 
myosin VA 0.017 1.228 
carbonic anhydrase 8 0.001 1.224 
sorting nexin 29 0.001 1.222 
solute carrier family 16 (monocarboxylic acid transporters), member 1 < 0.001 1.210 
solute carrier family 17 (sodium phosphate), member 2 0.045 1.114 
SH3-domain binding protein 2 0.044 1.081 
yippee-like 2 (Drosophila) 0.015 1.051 
RIKEN cDNA 2200001I15 gene 0.001 1.038 
Rho-related BTB domain containing 1 0.040 1.033 
aryl hydrocarbon receptor nuclear translocator-like 0.008 1.020 
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ATP-binding cassette, sub-family C (CFTR/MRP), member 3 0.010 1.000 
RIKEN cDNA 1300002K09 gene 0.008 0.987 
RIKEN cDNA 5730559C18 gene 0.027 0.986 
forkhead box Q1 0.050 0.951 
SEC16 homolog B (S. cerevisiae) 0.021 0.928 
family with sequence similarity 107, member A 0.009 0.920 
arylsulfatase G 0.009 0.919 
family with sequence similarity 129, member A 0.010 0.919 
RIKEN cDNA 1700112E06 gene 0.013 0.874 
transmembrane protein 68 0.028 0.869 
family with sequence similarity 107, member A 0.030 0.862 
histidine decarboxylase 0.016 0.860 
guanylate binding protein 3 0.028 0.859 
solute carrier family 17 (sodium phosphate), member 3 0.042 0.776 
family with sequence similarity 129, member A 0.025 0.763 
glycosyltransferase 25 domain containing 2 0.036 0.718 
The table shows probe sets, which were significant (p-value < 0.05) differentially expressed in kidney dissected 
from 5-week-old B6 wildtype (n=4) and fetuin-A deficient mice (n=6). Bayesian statistics was used for calculation 
of probabilities (p-value) and log-ratio, negative log-ratio encode upregulation of the particular probe-set in fetuin-
A deficient mice, positive values denote downregulation. Note that gene names are given for each probe set, 
double entries may occur in case of genes which are represented by several probe sets encoding different 
regions or splice variants of the gene. 
 
 
Supplemental Table 4. Differential expression in liver of B6 fetuin-A deficient mice.  
probe sets p-value log-ratio 
upregulation   
D site albumin promoter binding protein < 0.001 -4.823 
cathepsin E < 0.001 -3.768 
D site albumin promoter binding protein < 0.001 -3.676 
H19 fetal liver mRNA < 0.001 -2.980 
period homolog 3 (Drosophila) < 0.001 -2.882 
renin 1 structural < 0.001 -2.282 
regulator of G-protein signaling 16 0.005 -2.084 
period homolog 3 (Drosophila) < 0.001 -2.070 
uridine phosphorylase 2 < 0.001 -1.914 
RIKEN cDNA 4933439C20 gene < 0.001 -1.840 
uridine phosphorylase 2 < 0.001 -1.819 
ubiquitin specific peptidase 2 < 0.001 -1.791 
period homolog 3 (Drosophila) < 0.001 -1.612 
cytochrome P450, family 3, subfamily a, polypeptide 16 0.003 -1.565 
thyroid hormone responsive SPOT14 homolog (Rattus) 0.023 -1.485 
nuclear receptor subfamily 1, group D, member 2 < 0.001 -1.471 
thyrotroph embryonic factor < 0.001 -1.440 
regulator of G-protein signaling 16 0.001 -1.435 
C-type lectin domain family 2, member h 0.002 -1.413 
thyroid hormone responsive SPOT14 homolog (Rattus) 0.032 -1.409 
ring finger protein 170 0.002 -1.399 
tribbles homolog 3 (Drosophila) 0.002 -1.354 
tribbles homolog 3 (Drosophila) 0.001 -1.330 
serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 7 0.010 -1.326 
regulator of G-protein signaling 16 0.020 -1.246 
nuclear receptor subfamily 5, group A, member 2 0.002 -1.225 
period homolog 2 (Drosophila) 0.004 -1.198 
pigeon homolog (Drosophila) < 0.001 -1.165 
gene model 129, (NCBI) < 0.001 -1.155 
nuclear receptor subfamily 1, group D, member 1 0.001 -1.131 
nuclear receptor subfamily 1, group D, member 2 < 0.001 -1.119 
cytochrome P450, family 2, subfamily c, polypeptide 55 0.014 -1.116 
nuclear factor, erythroid derived 2 0.001 -1.109 
RIKEN cDNA 4933439C20 gene < 0.001 -1.085 
ATPase, H+ transporting, lysosomal V0 subunit D2 0.024 -1.084 
basic helix-loop-helix family, member e40 0.039 -1.075 
RIKEN cDNA 4933439C20 gene < 0.001 -1.068 
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BTB and CNC homology 2 0.015 -1.068 
PHD finger protein 17 0.011 -1.067 
response to metastatic cancers 5 0.019 -1.024 
BTB and CNC homology 2 0.005 -1.021 
thyrotroph embryonic factor 0.010 -1.006 
growth arrest and DNA-damage-inducible 45 alpha 0.001 -0.998 
cytochrome P450, family 2, subfamily b, polypeptide 13 0.015 -0.993 
ubiquitin specific peptidase 2 0.001 -0.991 
thyrotroph embryonic factor 0.001 -0.988 
SH3-binding kinase 1 0.001 -0.983 
histocompatibility 2, class II antigen A, alpha 0.046 -0.964 
transglutaminase 1, K polypeptide 0.011 -0.956 
peroxisome proliferative activated receptor, gamma, coactivator 1 beta 0.001 -0.951 
aldehyde dehydrogenase 1 family, member L1 0.018 -0.949 
C-type lectin domain family 2, member h 0.006 -0.944 
solute carrier family 16 (monocarboxylic acid transporters), member 5 0.012 -0.932 
glutathione S-transferase, mu 3 0.044 -0.927 
histocompatibility 2, class II antigen A, alpha 0.018 -0.927 
ATPase, H+ transporting, lysosomal V0 subunit D2 0.010 -0.918 
X-linked lymphocyte-regulated 3A 0.022 -0.918 
RIKEN cDNA 6430706D22 gene 0.001 -0.912 
collagen, type IV, alpha 5 0.009 -0.895 
occludin 0.011 -0.870 
tensin like C1 domain-containing phosphatase < 0.001 -0.870 
family with sequence similarity 134, member B 0.010 -0.867 
serine peptidase inhibitor, Kazal type 3 0.034 -0.865 
histocompatibility 2, class II antigen A, beta 1 0.034 -0.863 
cytochrome P450, family 2, subfamily g, polypeptide 1 0.046 -0.861 
CD24a antigen 0.009 -0.857 
PHD finger protein 17 0.001 -0.857 
glucosaminyl (N-acetyl) transferase 2, I-branching enzyme 0.005 -0.855 
brain expressed gene 1 0.024 -0.854 
peptidase M20 domain containing 1 0.002 -0.849 
C-type lectin domain family 2, member h 0.009 -0.847 
cyclin-dependent kinase inhibitor 3 0.024 -0.840 
uridine phosphorylase 2 0.029 -0.838 
oligodendrocyte transcription factor 1 0.007 -0.838 
CD24a antigen 0.049 -0.836 
X-linked myotubular myopathy gene 1 0.018 -0.835 
family with sequence similarity 134, member B 0.028 -0.833 
guanine nucleotide binding protein, alpha transducing 1 0.037 -0.832 
CD74 antigen (invariant polypeptide of major histocompatibility complex, class 
II antigen-associated) 0.030 -0.826 
ataxin 1 0.001 -0.820 
tumor necrosis factor receptor superfamily, member 19 < 0.001 -0.811 
cytochrome P450, family 26, subfamily b, polypeptide 1 0.039 -0.806 
period homolog 3 (Drosophila) 0.010 -0.804 
protease, serine, 8 (prostasin) 0.014 -0.802 
ankyrin 3, epithelial 0.016 -0.800 
RIKEN cDNA 6430706D22 gene 0.006 -0.787 
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 0.036 -0.785 
mitogen-activated protein kinase kinase 6 0.015 -0.782 
gremlin 2 homolog, cysteine knot superfamily (Xenopus laevis) 0.010 -0.776 
doublecortin-like kinase 3 0.047 -0.762 
retinoic acid receptor, beta 0.025 -0.744 
ankyrin 3, epithelial 0.046 -0.744 
cDNA sequence BC048546 0.001 -0.741 
Ngfi-A binding protein 2 0.037 -0.740 
peptidase M20 domain containing 1 0.016 -0.730 
erythroid differentiation regulator 1 0.030 -0.728 
WEE 1 homolog 1 (S. pombe) 0.016 -0.728 
Ras association (RalGDS/AF-6) domain family member 5 0.010 -0.719 
DNA segment, human D4S114 0.035 -0.709 
BCL2 modifying factor 0.023 -0.709 
DNA segment, human D4S114 0.038 -0.708 
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very low density lipoprotein receptor 0.022 -0.705 
frizzled homolog 8 (Drosophila) 0.003 -0.704 
period homolog 2 (Drosophila) 0.018 -0.703 
myeloid cell leukemia sequence 1 0.031 -0.702 
cryptochrome 2 (photolyase-like) 0.012 -0.700 
RIKEN cDNA A930033H14 gene 0.029 -0.697 
G protein-coupled receptor 146 0.002 -0.691 
serum/glucocorticoid regulated kinase 2 0.007 -0.689 
MAP kinase-interacting serine/threonine kinase 2 0.027 -0.685 
zinc finger, FYVE domain containing 21 0.044 -0.677 
RIKEN cDNA 2900026A02 gene 0.030 -0.666 
CD24a antigen 0.046 -0.663 
chemokine (C-X-C motif) ligand 1 0.042 -0.660 
LIM domain containing 2 0.010 -0.659 
G protein-coupled receptor 146 0.015 -0.655 
MHC class I like protein GS10 0.037 -0.648 
cytochrome P450, family 2, subfamily a, polypeptide 5 0.030 -0.642 
transmembrane protein 146 0.030 -0.631 
solute carrier family 20, member 1 0.018 -0.628 
WEE 1 homolog 1 (S. pombe) 0.033 -0.618 
very low density lipoprotein receptor 0.037 -0.617 
dehydrogenase E1 and transketolase domain containing 1 0.012 -0.615 
SRY-box containing gene 7 0.017 -0.612 
folliculin 0.009 -0.607 
immunoglobulin-like domain containing receptor 2 0.022 -0.592 
immunoglobulin-like domain containing receptor 2 0.022 -0.590 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 59 0.016 -0.589 
cytohesin 1 0.028 -0.565 
von Willebrand factor C and EGF domains 0.040 -0.562 
G protein-coupled receptor 146 0.049 -0.556 
NAD(P)H dehydrogenase, quinone 1 0.040 -0.556 
transcription factor Dp 2 0.031 -0.554 
RIKEN cDNA 1810013L24 gene 0.014 -0.551 
family with sequence similarity 81, member A 0.020 -0.548 
spinster homolog 2 (Drosophila) 0.044 -0.544 
annexin A13 0.027 -0.544 
metastasis suppressor 1 0.033 -0.537 
oxysterol binding protein-like 3 0.026 -0.530 
serine (or cysteine) peptidase inhibitor, clade A, member 6 0.040 -0.530 
frizzled homolog 8 (Drosophila) 0.024 -0.524 
solute carrier family 38, member 3 0.030 -0.520 
C-type lectin domain family 16, member A 0.023 -0.518 
nuclear prelamin A recognition factor 0.022 -0.515 
RIKEN cDNA 2610204M08 gene 0.037 -0.512 
RIKEN cDNA 5730409N24 gene 0.050 -0.496 
chromodomain helicase DNA binding protein 1-like 0.047 -0.490 
metastasis suppressor 1 0.040 -0.489 
zinc finger protein 217 0.044 -0.489 
sirtuin 5 (silent mating type information regulation 2 homolog) 5 (S. cerevisiae) 0.041 -0.483 
solute carrier family 39 (zinc transporter), member 14 0.047 -0.478 
olfactomedin 1 0.045 -0.468 
   
downregulation   
alpha-2-HS-glycoprotein < 0.001 9.073 
serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1 0.005 2.826 
serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1 0.003 2.787 
serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1 0.008 2.513 
dipeptidylpeptidase 4 < 0.001 2.454 
RIKEN cDNA A630005I04 gene < 0.001 2.254 
dipeptidylpeptidase 4 < 0.001 2.222 
caseinolytic peptidase X (E.coli) < 0.001 1.968 
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 0.020 1.886 
carbonic anhydrase 8 < 0.001 1.819 
nuclear factor, interleukin 3, regulated < 0.001 1.798 
Supplement 
156 
aryl hydrocarbon receptor nuclear translocator-like < 0.001 1.723 
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 5 0.011 1.715 
solute carrier organic anion transporter family, member 1a1 0.004 1.698 
choline kinase alpha < 0.001 1.697 
choline kinase alpha < 0.001 1.694 
RIKEN cDNA C730036E19 gene < 0.001 1.636 
dipeptidylpeptidase 4 < 0.001 1.624 
heat shock protein 1 < 0.001 1.565 
solute carrier organic anion transporter family, member 1a1 0.006 1.562 
pyruvate dehydrogenase kinase, isoenzyme 4 < 0.001 1.543 
5,10-methylenetetrahydrofolate reductase < 0.001 1.530 
solute carrier family 25, member 30 0.020 1.505 
DNA segment, Chr 9, Wayne State University 90, expressed 0.019 1.495 
ceruloplasmin < 0.001 1.485 
solute carrier family 25, member 30 0.013 1.470 
solute carrier family 25, member 30 0.014 1.452 
cyclin-dependent kinase inhibitor 1A (P21) < 0.001 1.429 
heat shock protein 1 < 0.001 1.314 
LON peptidase N-terminal domain and ring finger 3 0.002 1.292 
neuronal PAS domain protein 2 < 0.001 1.289 
RIKEN cDNA 2610016E04 gene 0.016 1.269 
carbonic anhydrase 8 < 0.001 1.247 
regulatory factor X, 4 (influences HLA class II expression) 0.001 1.223 
N-myc downstream regulated gene 1 < 0.001 1.219 
AT hook containing transcription factor 1 < 0.001 1.206 
acyl-CoA thioesterase 2 < 0.001 1.187 
acyl-CoA thioesterase 1 < 0.001 1.177 
choline kinase alpha < 0.001 1.167 
N-myc downstream regulated gene 1 < 0.001 1.164 
cytochrome P450, family 4, subfamily a, polypeptide 12a 0.040 1.151 
transmembrane protein 68 < 0.001 1.147 
RIKEN cDNA 1110067D22 gene 0.001 1.120 
E2F transcription factor 8 0.009 1.094 
fetuin beta < 0.001 1.065 
RIKEN cDNA 1110067D22 gene < 0.001 1.023 
development and differentiation enhancing factor 2 < 0.001 1.021 
caseinolytic peptidase X (E.coli) < 0.001 0.998 
RIKEN cDNA 6430573F11 gene 0.003 0.991 
sulfotransferase family 5A, member 1 0.001 0.984 
N-myc downstream regulated gene 1 < 0.001 0.942 
cryptochrome 1 (photolyase-like) 0.007 0.941 
insulin induced gene 2 < 0.001 0.931 
solute carrier family 45, member 3 0.005 0.917 
insulin induced gene 2 < 0.001 0.908 
insulin induced gene 2 < 0.001 0.905 
N-myc downstream regulated gene 1 0.001 0.895 
S100 calcium binding protein A10 (calpactin) < 0.001 0.890 
predicted gene, 100040465 0.002 0.881 
solute carrier family 45, member 3 0.011 0.857 
3'-phosphoadenosine 5'-phosphosulfate synthase 1 0.001 0.856 
SKI-like 0.001 0.852 
circadian locomoter output cycles kaput < 0.001 0.844 
RAB30, member RAS oncogene family 0.025 0.828 
neural precursor cell expressed, developmentally down-regulated gene 4-like 0.006 0.826 
neuron navigator 1 0.002 0.821 
protein phosphatase 1, regulatory (inhibitor) subunit 3B 0.014 0.819 
solute carrier family 30, member 10 0.001 0.816 
predicted gene, OTTMUSG00000007486 0.033 0.802 
arginine vasopressin receptor 1A 0.020 0.779 
LON peptidase N-terminal domain and ring finger 3 0.002 0.777 
arginine vasopressin receptor 1A 0.018 0.776 
apolipoprotein A-IV 0.004 0.762 
trans-golgi network protein 0.004 0.741 
cAMP responsive element modulator 0.040 0.741 
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RIKEN cDNA C730049O14 gene 0.010 0.735 
predicted gene, 100039344 0.009 0.734 
N-myc downstream regulated gene 1 0.003 0.730 
RIKEN cDNA 9030425P06 gene 0.021 0.726 
DNA methyltransferase 3B 0.004 0.726 
cysteine-rich hydrophobic domain 1 0.017 0.724 
ADP-ribosylation factor-like 4A 0.009 0.723 
proline-rich nuclear receptor coactivator 1 0.002 0.714 
lysyl oxidase-like 4 0.016 0.712 
serine (or cysteine) peptidase inhibitor, clade A, member 3K 0.029 0.709 
AT hook containing transcription factor 1 0.011 0.705 
trans-golgi network protein 0.009 0.695 
ring finger protein 125 0.023 0.688 
major urinary protein 5 0.018 0.685 
RIKEN cDNA C730029A08 gene 0.022 0.681 
ADP-ribosylation factor-like 4A 0.046 0.675 
hydroxysteroid dehydrogenase like 2 0.026 0.674 
retinol saturase (all trans retinol 13,14 reductase) 0.028 0.662 
nuclear receptor subfamily 0, group B, member 2 0.040 0.662 
leucine-rich repeat, immunoglobulin-like and transmembrane domains 1 0.013 0.658 
apolipoprotein A-IV 0.010 0.645 
leucine rich repeat and fibronectin type III domain containing 3 0.009 0.642 
solute carrier family 30, member 10 0.003 0.637 
RAB interacting factor 0.016 0.625 
steroid 5 alpha-reductase 1 0.014 0.624 
SET binding factor 2 0.018 0.621 
trans-golgi network protein 0.009 0.619 
ring finger protein 144A 0.007 0.612 
retinol saturase (all trans retinol 13,14 reductase) 0.015 0.612 
trans-golgi network protein 0.010 0.603 
carnitine acetyltransferase 0.028 0.602 
adipose differentiation related protein 0.013 0.601 
expressed sequence AI117581 0.045 0.597 
SCO cytochrome oxidase deficient homolog 2 (yeast) 0.010 0.581 
4short chain dehydrogenase/reductase family 9C, member 7 0.026 0.579 
defensin related cryptdin, related sequence 7 0.027 0.561 
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 0.030 0.551 
AT hook containing transcription factor 1 0.047 0.550 
progestin and adipoQ receptor family member IX 0.048 0.546 
DNA segment, Chr 5, Wayne State University 178, expressed 0.044 0.542 
leptin receptor overlapping transcript-like 1 0.014 0.540 
USP6 N-terminal like 0.037 0.540 
mitogen-activated protein kinase kinase kinase 7 interacting protein 2 0.036 0.510 
deltex 4 homolog (Drosophila) 0.031 0.504 
hydroxysteroid dehydrogenase like 2 0.048 0.499 
melanoregulin 0.034 0.497 
The table shows probe sets, which were significant (p-value < 0.05) differentially expressed in liver dissected from 
5-week-old B6 wildtype (n=4) and fetuin-A deficient mice (n=6). Bayesian statistics was used for calculation of 
probabilities (p-value) and log-ratio, negative log-ratio encode upregulation of the particular probe-set in fetuin-A 
deficient mice, positive values denote downregulation. Note that gene names are given for each probe set, double 
entries may occur in case of genes which are represented by several probe sets encoding different regions or 
splice variants of the gene. 
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Supplemental Protocols 
SOP Purification of Fetuin-A 
 
Column    Superdex 200 16/60  
     (run with a ÄKTA purifier system) 
 
Fetuin-A    Sigma Cat. No. F-2379 
 
Eluent     PBS (Biochrom Cat. No. L-182): 
     NaCL   8.00 g/l 
     KCL   0.20 g/l 
     Na2HPO4 1.15 g/l 
     KH2PO4 0.20 g/l 
 
Flow rate     1 ml/min 
 
Fraction size    3 ml 
 
Concentration of fetuin-A  20 mg/ml  
 
Volume    5 ml 
 
 
Fractions   monomeric fetuin-A  21-27 
    dimeric fetuin-A  18-20 
   aggregrates   14-17 
 
 
After chromatography fetuin-A is concentrated using Centriprep YM-30 (Millipore              
Cat. No. 4307). 
 
Extinction Coefficient Fetuin-A: E1% = 4.1 (278 nm) 350; E1% = 4.5 (27) 351 
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SOP Formation of CPPs 
 
Stock solutions: 
 purified fetuin-A  
 (SOP purification of fetuin-A)  > 2mg/ml 
 CaCl2      100 mM 
 Na2HPO4    60 mM 
 Tris-Cl pH 7,4    0,5 M 
 NaCl     5 M 
 PBS (Biochrom Cat. No. L-182) 
 
Materials: 
 Centrisart 1, cut-off 300kDa, Sartorius Cat. No. 13279 
 Water bath 37°C 
 Centrifuge 4°C 
 
Experimental procedure: 
produce 1 ml reaction mixtures each; a rapid and complete mixture of all compounds is 
crucial for CPP formation; when more CPPs are needed several 1 ml reaction mixtures have 
to be prepared 
 
prepare a reaction mixtures with final concentrations: 
 
purified fetuin-A  1 mg/ml 
Na2HPO4   6 mM 
Tris PH 7,4   50 mM 
NaCl    140 mM   vortex and add 
 
CaCl2     10 mM    vortex immediately 10s 
 
incubate:  - 1 h at 37 °C (water bath) 
  - 10 min on ice 
  - combine all reaction mixtures 
 
 
Concentration of CPPs: 
 
all reagents and disposables have to be pre-cooled ! 
 
  - pipette CPPs in centrisarts, fill-up centrisarts with PBS to 2.5ml  
  - centrifugation 15 min, 4 °C, 1500 x g 
  - collect the filtrate in a falcon tube and fill-up again with PBS 
  - centrifugation 15 min, 4 °C, 1500 x g 
  - collect the filtrate in a falcon tube 
  - centrifugation 15 min, 4 °C, 1500 x g 
  - collect the filtrate in a falcon tube, determine the final volume of the CPP 
  solution (the final volume depend on the number of CPP reaction mixtures 
  started-with, approx. 1 ml for 6 x 1 ml, approx. 0.3 ml for 2 x 1 ml) 
  - determine the protein content in both, the CPP and the filtrate 
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